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Huntington's disease (HD) is caused by the expansion of a CAG repeat in the huntingtin 
(HTT) gene The R6/2 transgenic mouse model exhibits a rapid onset of Huntington's 
disease-like phenotypes including neurodegeneration and aggregation of mutant 
huntingtin protein (mHTT). Neural progenitor cells (NPCs) are a pool of cells with stem 
cell-like properties and are responsible for self-renewal and differentiation into the cells 
of the central nervous system and mature brain. 
In this thesis, NPC lines were established from cells extracted from foetal R6/2 and 
wildtype mouse embryos and cultured in optimised culture media. NPCs were 
successfully maintained in a mitotic state as monolayer cultures for multiple passages 
without effects to karyotype or CAG repeat length. Cultures were differentiated by 
removal of growth factors, into mixed neurons and glia populations that expressed 
proteins indicative of mature cell types; neurons showed evidence of synaptophysin 
expression at junctions between cell neurites, suggesting synaptic functionality and 
formation of rudimentary neural networks. After differentiation, mHTT aggregation was 
detectable using immunohistochemistry from 14 days of differentiation in 5% of R6/2 
cell nuclei, rising to 20% by 28 days, recapitulating an HD-like phenotype found in vivo. 
Detection of detergent insoluble mHTT-aggregated protein was also validated via 
western blotting. Super high resolution cell imaging showed aggregation of mHTT is also 
present in the cytoplasm. 
High-content imaging analysis system was performed using the Operetta system to 
explore morphological differences between WT and R6/2 cultures, as well as within the 
subset of cells with detectable aggregation. R6/2 nuclei were found to be larger than those 
of WT cells. Novel compounds known to affect protein aggregation were applied to the 
cell lines to assess their potential use in screening for approaches to modulation mHTT 
aggregation. The cells developed in this thesis are a novel and useful complement to the 
R6/2 mouse; phenotypes observed in vivo can be interrogated at the molecular level in 
terms of how mHTT protein misfolding and aggregation occur and how this affects 
cellular function.  
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Anatomy  
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MGE Medial ganglionic eminence 
STR Striatum 
SVZ Sub-ventricular zone 
Antibodies  
BLBP Brain-lipid-binding protein 
DAPI 4',6-diamidino-2-phenylindole DNA stain 
DCX Doublecortin 
GABA Gamma-aminobutyric acid 
GAD67 Glutamic acid decarboxylase 
GFAP Glial fibrillary acidic protein 
GLAST Glutamate aspartate transporter 
Ki67 Ki-67 protein encoded by the MKI67 gene 
MAP2 Microtubule-associated protein 2 
Nestin Neuroectodermal stem cell marker 
NeuN Neuronal nuclei, FOX-3 
P62 SQSTM1 
S100b S100 calcium-binding protein B 
S830 Polyclonal sheep antibody S830 






µM/nM Micromolar/nanomolar mass 
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Chapter 1 Introduction 
1.1 Introduction to Huntington’s disease 
Huntington’s disease (HD) is an autosomal dominant disease, caused by the expansion of 
a polyglutamine (CAG) repeat in the huntingtin gene (HTT) which in turn translates to 
alterations in the ubiquitous protein huntingtin (HTT) (HDCRG, 1993), resulting in a 
mutated pathogenic form that underlies the disease. HD typically clinically presents in 
middle-aged adults in the prime of their life with particular ferocity in the brain; the 
motor, cognitive and behavioural problems make it a devastating condition to both 
patients and their families. 
The most common and well-documented type of motor problems seen in HD is chorea, 
which are rapid ‘dance-like’ movements involving all the muscles of the trunk, face and 
extremities. As well as chorea, patients can suffer from bradykinesia, a slowness to 
initiate voluntary movements; hypokinesia, the partial or complete loss of muscle 
movement; and dystonia, abnormal muscle tone resulting in muscular spasm. Cognitive 
problems often present as a slowness of thought, which progresses to difficulty to 
maintain attention and difficulties with memory (Lawrence et al., 1998). Sleep 
disturbances are often reported with a delayed onset to sleep and longer duration of time 
spent asleep (Morton, 2013). All these symptoms increase over time as the disease 
becomes more severe, slowly making reliance on care a necessity. Eventually, the final 
stages of the disease lead to a patient becoming completely bedridden, incontinent and 
mute. HD is the most common monogenetic neurological disorder in the developed world 
(Evans et al., 2013, Fisher and Hayden, 2014, Morrison et al., 2011), yet therapeutic 
interventions have been extremely hard to develop. 
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1.2 Genetics 
HD was named after George Huntingtin who made the first thorough medical description 
of the symptoms of HD in 1872 (Huntington, 1872), although other less prominent 
descriptions can been found as early as 1841 (Bates et al., 2014). During the subsequent 
decades, reports of HD were made in medical texts around the world in almost all 
continents (Marsden, 1975). In terms of neuropathology, the experts of the time argued 
widely about how the disease manifested in the brain. Considering the modern day 
findings around the differences that can been seen between patients with the same CAG 
repeat lengths (Waldvogel et al., 2012), this disagreement is not surprising. In the 1920s, 
it was finally agreed upon that the brain changes were principally degenerative and 
atrophic, with the caudate nucleus most obviously affected, despite an overall generalised 
brain shrinkage. Because of the autosomal dominant aspect and age of onset of HD, 
patients have been found in concentrated locations as the result of a single ancestor with 
the disease who produced decedents over many generations who carry the mutant gene. 
One such population in Venezuela was crucial to the success of the work of the HD 
foundation and Huntington’s disease collaborative research group to isolate and map the 
huntingtin gene (HTT), which was achieved in 1993. Mapping HTT was a major step in 
accurately diagnosing and describing HD. HTT is found on the short arm of chromosome 
4 and contains 67 exons, which encode for a protein of around 350 kDa. The HD 
collaborative group of researchers observed that sufferers had an expansion in a CAG 
repeat within the first exon of HTT, in at least one allele (HDCRG, 1993). CAG codon 
repeat lengths in the range of between 9 and 35 are considered normal and not connected 
with HD. Repeat lengths over 35 are generally associated with development of HD; 
repeats in the range of up to 39 are rare and are estimated to make up only around 3% of 
sufferers (Huntington Study Group and Dorsey, 2012), while those over 39 are considered 
pathogenic. An inverse correlation exists between CAG repeat length and age of onset, 
26 
with patients with longer repeats generally presenting with symptoms at younger ages 
(Wexler et al., 2004, Langbehn et al., 2004, Langbehn et al., 2010). Indeed, those with 
extreme repeat lengths can present with a juvenile form of HD before the age of 20 years 
(Quarrell, 2009). In these cases, the pathological features of the disease can present 
differently to the adult form (Vonsattel et al., 2011). Due to the somatic instability of the 
CAG repeat in HD, the repeat can lengthen over time, particularly in the brain (Wheeler 
et al., 1999, Kennedy and Shelbourne, 2000, Kennedy et al., 2003). Evidence is varied to 
how this instability occurs and how it relates to the overall pathology; it is thought to 
mainly take place during DNA repair and replication (McMurray, 2010). 
 
1.3 Normal HTT 
In mammals, HTT is expressed ubiquitously throughout the body, with the highest levels 
found in central nervous system (CNS), neurons, and the testes (Strong et al., 1993, 
Landwehrmeyer et al., 1995, Sharp et al., 1995). HTT is a large protein of 3144 amino 
acid residues and is mainly found in the cytoplasm and dendritic processes, as well as at 
the axon terminals of neurons, although to a lesser extent (Trottier et al., 1995, Ferrante 
et al., 1997, Sharp et al., 1995). Within these cell compartments, HTT is associated with 
the Golgi apparatus and endoplasmic reticulum (DiFiglia et al., 1995, Hilditch-Maguire 
et al., 2000). In some cells, HTT is also found in the nucleus (Hoogeveen et al., 1993, 
Kegel et al., 2002). Within the cell the function of HTT is varied and changes depending 
on stage of mammalian life studied. HTT intereacts with a number of other proteins. 
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1.4 HTT in Development 
In development, HTT is expressed early in the post-fertilisation stages (Dragatsis et al., 
1998). A targeted disruption of the protein function at this stage in mice or production of 
nullizygous mice (Htt-/-) halts development and is lethal between embryonic day 8.5 and 
10.5 (Duyao et al., 1995, Nasir et al., 1995, Dragatsis et al., 1998, Zeitlin et al., 1995) 
indicating the importance of HTT at this developmental stage. This time point is roughly 
just after the start of neural tube development and CNS formation. At this stage, HTT is 
involved in control of neuroepithelial cell-cell interaction by regulation of cell adhesion 
pathways (Lo Sardo et al., 2012). Later in CNS development, HTT is known to control 
mitotic spindle orientation during cortical neurogenesis (Godin et al., 2010). Indeed, HTT 
is specifically needed for the development of cortical and striatal neurons (Reiner et al., 
2001). 
Evidence exists for HTT having an anti-apoptotic function. In striatal derived cells, 
overexpression of HTT is protective against lethal stresses such as deprivation of serum 
or introduction of 3-nitropropionic, a mitochondrial toxin (Rigamonti et al., 2000, 
Rigamonti et al., 2001). Postnatal inactivation of the Htt gene in mice resulted in apoptotic 
cells in the cortex, striatum, and hippocampus, and a reduction in axonal processes 
(Dragatsis et al., 2000). HTT blocks the creation and function of the apoptosome complex 
and activation of caspase-3 and caspase-9 (Rigamonti et al., 2000, Rigamonti et al., 2001), 
which could be the mechanism by which it moderates apoptotic cell death (Zhang et al., 
2006). 
Within neurons, HTT is partially important for normal function. HTT stimulates the 
production of brain-derived neurotrophic factor (BDNF), which is important to neuronal 
function and survival (Zuccato et al., 2001). BDNF levels are directly lowered in cortical 
neurons of mice heterozygous for Htt (Zuccato et al., 2003). HTT in the cytoplasm is 
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found enriched in compartments containing vesicle-associated proteins (Velier et al., 
1998). In the axon, where HTT interacts with motor proteins such as HAP1 
(Gunawardena 2005, 15642849), it is vital for the transport of mitochondria (Trushina et 
al., 2004) and BDNF (Gauthier et al., 2004). At the synapse, HTT interacts with vesicle 
proteins that are vital for exocytosis and endocytosis (Smith et al., 2005), linking HTT to 
the normal synaptic activity of neurons. In the presence of longer CAG repeats in HD, 
this transport function can become impaired (Smith et al., 2005). 
 
1.5 Neuropathology 
HD induces pathology throughout the body. Heart disease affects around a third of HD 
patients (Lanska et al., 1988), and muscle wasting (Farrer and Meaney, 1985) and bone 
loss (Goodman and Barker, 2011) are common HD phenotypes. However, it is within the 
brain that HD has most pronounced effects. The most striking pathology in the human 
brain occurs in the caudate nucleus and putamen, which compose the striatum (Figure 
1-1). That said, other areas of the basal ganglia, particularly areas that receive striatal 
projections such as the global pallidus and substantia nigra, are also highly affected. The 
cortex is consistently substantially affected but few brain regions are spared in severely 
degenerated brains. Although the areas of the striatum and cortex are most classically 
associated with HD neurodegeneration, the speed and extent of cell loss can be variable, 
even in patients with the same CAG repeat length (Hadzi et al., 2012, Pillai et al., 2012). 
Indeed, the same pattern is true for the clinical manifestation of the disease. HD is a single 
gene disease with a measurable pathological CAG repeat expansion, yet symptoms can 
present as a mixture of deficits in mood, cognition, and motor ability. This variation is 
most eloquently displayed by twin studies where onset can differ by many years 
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(Georgiou et al., 1999, Friedman et al., 2005). This said, eventually a similar pattern of 
neurodegeneration eventually occurs in all patients. 
Within the striatum, the most highly effected cell population are the medium spiny 
neurons that make up 90-95% of neurons in this region (Kemp and Powell, 1971, Holt et 
al., 1997). The loss of these GABAergic inhibitory neurons leads to the dysfunction in 
motor functions commonly observed in HD (Marshall et al., 1983). The particular 
vulnerability of medium spiny neurons is unclear because the exact mechanisms that 
cause cell death in Huntington’s disease remain unclear. With the aggregation of mHTT 
being a concentration dependent process, it could be due to an endogenously higher 
steady state of the protein accelerating the process in this cell population. Particular 
processes within these cells might also altered by the presence of mHTT and could lead 
to damaging processes such as transcriptional dysregulation, excitotoxicity, oxidative 
stress and detrimental changes to neurotransmitters. Cells from other areas such as the 
cortex, which project to the medium spiny neurons, could be compromised and so have 
reduced delivery of pro-survival factors such as BDNF. A combination of these processes 
most probably causes the selective vulnerability of the medium spiny neuron population 
rather than a specific effect of mHTT on these cells. 
The neurons making up the rest of the striatum are also affected but to a lesser extent, 
especially at the earlier stage (Ferrante et al., 1987, Hedreen et al., 1991). It is known that 
a population of large cholinergic neurons are consistently lost as the disease progresses 
(Cicchetti and Parent, 1996), while other populations are almost always spared (Ferrante 
et al., 1987, Cicchetti et al., 2000). Why certain neuronal populations have an increased 
vulnerability in HD is still not fully understood, however it might be related to their 
function and the neurotransmission-associated mechanisms they undergo. 
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Like the striatum, the cerebral cortex is a structure comprising many different regions and 
cell types affected in HD. Grossly, overall volume loss is seen in the cerebral cortex, with 
cortical thinning and increased cellular density as well as neuronal cell loss (de la Monte 
et al., 1988, Hedreen et al., 1991, Rajkowska et al., 1998). The earliest gross studies on 
the cortex found total cortical volume loss to be in line with total brain volume loss 
(around 19% reduction in total volume) and to correlate with both striatal atrophy and 
CAG repeat number (Halliday et al., 1998). Cortical thinning occurs early in the disease 
and is greatest in the sensorimotor cortex at all stages of the disease (Rosas et al., 2002), 
however other cortical areas also show varying degrees of thinning (Rosas et al., 2008). 
The degree of increased cell density and cell loss is different between each cortical layer. 
The cortical pyramidal projection found in layers III, V, and VI suffer the largest 
degeneration and happen to be those that primarily project to the striatum (Hedreen et al., 
1991, Cudkowicz and Kowall, 1990). Despite the connection between the two structures, 
the degeneration that happens is thought to be a parallel rather than a downstream process 
(Hedreen et al., 1991, Cudkowicz and Kowall, 1990). Unlike in the striatum, the 
interneurons of the cortex are relatively less affected by cell death. Some loss of inhibition 
has been observed in the frontal cortex but little in other regions (Beal, 1994). This loss 
of inhibition could lead to excitotoxicity in other neurons as well as the regions they 
project to (Cepeda et al., 2007, Fusco et al., 1999). 
The mechanism by which the mutated form of HTT (mHTT) leads to cell death is still 
not fully understood. The CAG repeat of HTT exon 1 is thought to interact with a number 
of other genes. Genome-wide expression studies using post-mortem tissue have found 
large numbers of altered RNAs (Hodges et al., 2006). This finding has been backed up 
with similar evidence using HD mouse models (Luthi-Carter et al., 2000). This evidence 
leads to a complex picture, which implicates a number of possible dysfunctions, including 
transcriptional dysregulation, excitotoxicity, alteration to neurotransmitters, and vesical 
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transport and disruption of morphogens such as BDNF (Cattaneo et al., 2001, Morton et 
al., 2001, Zuccato and Cattaneo, 2007, Rosas et al., 2008). 
 
 
Figure 1-1. Pathological effects of HD on the brain. Coronal sections through the human brain 
of (A) a normal control left cerebral hemisphere of a 35-year-old male, and (B) an advanced HD 
case. Sections cut at the level of the striatum and the nucleus accumbens. Shrinkage of the caudate 
nucleus and putamen (arrows) is apparent in the HD case. Reduction of the cerebral cortex is also 
evident. HD=Huntington disease; CN=caudate nucleus; P=putamen. Adapted from Bates et al., 





1.6 The HTT protein and its structure 
The translated product of the HTT gene is the HTT protein, which is made up of several 
domains with distinct functions. At the N-terminus is a short 17 amino acid sequence 
termed N17, which is followed by the polyQ stretch that becomes elongated in HD. The 
protein contains multiple HEAT (Huntingtin, Elongator factor 3, the regulatory A subunit 
of protein phosphatase 2A, and TOR1) repeats (Andrade and Bork, 1995). These repeats 
produce a series of ordered domains interspersed with intrinsically disordered segments. 
HTT is thought to contain 16 HEAT repeats grouped into 3 clusters (Tartari et al., 2008) 
which interact with other proteins. Some HEAT sequences, known as karyopherins, are 
also involved in trafficking of other proteins through the nuclear pore complex (Conti et 
al., 2006). Between the clusters of HEAT repeats are disordered segments of unknown 
function, in which post-translational modifications have been identified 
HTT is dynamically mobile across the nuclear membrane, a process enabled by its HEAT 
repeats (Truant et al., 2006, Truant et al., 2007). N17, the first 17 amino acids of exon 1 
of HTT that precede the polyQ region, interacts with the nuclear pore protein translocated 
promotor region (TPR), which allows for protein export from the nucleus. Disruption of 
these amino acids can cause HTT to accumulate in the nucleus (Cornett et al., 2005). HTT 
can shuttle between the cytoplasm and nucleus (Truant et al., 2007), which is enabled by 
the presence of both nuclear localisation signal (Desmond et al., 2012) and nuclear export 
signals (Xia et al., 2003, Zheng et al., 2013). 
1.6.1 Post-translational modifications 
HTT is known to undergo many post-translational modifications, including 
phosphorylation, ubiquitination, acetylation, and SUMOylation, which can influence its 
cellular location and stability (Warby et al., 2008). Most of these post-translational 
modifications are found within four regions, described as the PEST domains, because of 
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their enrichment in proline (P), glutamate (E), serine (S), and threonine (T) (Warby et al., 
2008). The first PEST domain of HTT contains the N17, the polyQ tract and is a site of 
phosphorylation, ubiquitination, and SUMOylation. In the presence of an expanded 
polyQ, the ubiquitination and SUMOylation processes, which normally act on the lysines 
within HTT, are impaired (Steffan et al., 2004). This modification has been linked to 
nuclear phenotypes such as to changes DNA repair, nuclear export, endocytosis and 
enzymatic activity, (Jackson and Durocher, 2013) as well as changes at the synapse (Haas 
and Broadie, 2008). 
Phosphorylation also plays an important role in HD. HTT has multiple phosphorylation 
sites, including threonine 3, the levels of which are reduced to an increasing extent with 
longer polyQ repeats in striatal neurons (Aiken et al., 2009). Other sites at serine 13, and 
possibly serine 16, promote the ubiquitin–proteasome system (UPS) and autophagy 
pathways when phosphorylated (Thompson et al., 2009). This process is reduced in the 
presence of a longer polyQ and could inhibit the clearance of mHTT from cells 
(Thompson et al., 2009). Furthermore, phosphorylation of serine 421 of HTT has been 
implicated in a number of disease phenotypes (Warby et al., 2005). In the HD brain, the 
level of phosphorylation at serine 421 is lowest in areas with the highest levels of cell 
death suggesting a neuroprotective role (Warby et al., 2005), which could be related to 
excitotoxicity (Metzler 2010, 20980587). This same phosphorylation site is also 




Figure 1-2. Processing of Huntingtin. The HTT gene is transcribed and processed to mRNA, 
which normally encodes the full length huntingtin protein (label 1), however, it can be aberrantly 
spliced into mRNA encoding only exon1 when the gene contains an expanded CAG repeat (label 
2). Translation of full-length mRNAs generates the full-length huntingtin protein (label 3), 
whereas translation of aberrantly spliced mRNAs generates the HTT exon1 protein fragment N17 
(label 4). Proteolytic cleavage sites (arrows) facilitated by recognition sequences in the disordered 
segments generate a group of products, including HTT exon1-like fragments (label 5). These 
fragments have important roles in triggering of Huntington disease when they contain expanded 
polyQ segments by mechanisms that are yet to be clarified. HTT=huntingtin. Figure adapted from 
Bates et al 2016 and reproduced under copyright agreement with Nature Publishing Group, 
License Number: 3925870186664.  
 
1.6.2 HTT proteolysis. 
Proteolytic cleavage of mHTT into smaller fragments could be a key step in the HD 
pathological mechanism (Goldberg et al., 1996, Graham et al., 2006). The HTT protein 
is cleaved by a number of different proteases. Caspases were the first enzymes shown to 
cleave HTT (Goldberg et al., 1996) before the observation that the protein is also cleaved 
by calpains (Kim et al., 2001) as well as aspartyle proteases (Kim et al., 2006). 
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Caspase cleavage of HTT is carried out by caspase-3 at amino acids 513 and 552, by 
caspase-6 at amino acid 586 as well as by caspase-2 at amino acid 552 (Wellington et al., 
1998, Hermel et al., 2004). Evidence suggests that the caspases show no preference 
between cleavage of HTT and its mutated form, however the cleavage of mHTT results 
in fragments containing the longer polyQ. This observation combined with evidence that 
cellular toxicity increases in cells with huntingtin fragments (Martindale et al., 1998, 
Cooper et al., 1998) led to the toxic fragment hypothesis, in which the presence of the 
fragments promotes further caspase activity and cleavage resulting in a pathogenic 
feedforward cycle (Wellington and Hayden, 2000, Albrecht et al., 2007). 
 
1.7 mHTT in HD brains and aggregation 
Protein aggregation is a hallmark of several neurodegenerative diseases and in many of 
these the association between aggregation and cell death is still not understood. In HD 
mHTT misfolds, fragments at the N-terminus and accumulates in aggregated inclusions 
(DiFiglia et al., 1997). Aggregates can be found in a range of sizes with the largest thought 
to contain millions of protein molecules (DiFiglia et al., 1997, Sahl et al., 2012). 
Aggregates increase in size with disease progression and so have been suggested to be 
toxic, leading to the neurodegeneration seen in HD. The aggregating nature of mHTT 
might be related to its structure, and the larger polyQ region could promote a “poly-
zipper”-like effect (Perutz et al., 1994). This hypothesis is based on anatomic models of 
the polyQ adopting -sheets formed of -strands held in place by hydrogen bonds. X-ray 
crystallography has shown that the HTT polyQ can also form other formations such as -
helix, extended loops, and random coils (Kim et al., 2009). 
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The aggregation process starts from HTT monomers which can self assemble into larger 
fibrils when their polyQ region is larger than 32 repeats (Scherzinger et al., 1999). The 
presence of these fribils is a catalyst for other mHTT monomers to aggregate. These 
fibrils together form beta-sheet formations. 
It is widely agreed that the fragmentation of HTT is a key early step in HD pathology. 
HTT fragments have been discovered in HD post-mortem brains (DiFiglia et al., 1997, 
Lunkes et al., 2002) and mouse models before evidence of aggregation can be detected 
(Kim et al., 2006, Ratovitski et al., 2007, Landles et al., 2010). The fact that only 
antibodies raised against the N-terminus detect nuclear inclusions in human patient brains 
(DiFiglia et al., 1997, Schilling et al., 2007) and that N-terminal fragments aggregate 
more readily in vitro (Davies et al., 1997) implies that these fragments could underlie 
pathology. Many of the fragments found in HD mouse models can be mapped to various 
proteolysis cleavage sites along the protein (Landles et al., 2010). 
The smallest of these fragments is an N-terminal fragment of around 100 amino acids. 
Because this N-terminal fragment is encoded by exon 1 of HTT it has thus been termed 
exon 1 HTT. This fragment contains the most N-terminal segment, N-17, the polyQ 
segment that is expanded when encoded by a larger CAG repeat, and a proline-rich 
domain (PRD). The exon 1 HTT fragments are formed in mouse models via the 
translation of aberrantly spliced mRNA transcript expressing Htt (Sathasivam et al., 
2013) or HTT (Mangiarini et al., 1996). This transcript is also found in fibroblast lines 
from HD patients, along with HD post-mortem tissue (Gipson et al., 2013). The splicing 
process is regulated by SRSF6 splicing factor, which binds to the 5’ end of the Htt gene 
with an expanded CAG repeat, and can facilitate translation of a partially spliced 
transcript (Sathasivam et al., 2013). 
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This exon 1 HTT fragment can be involved in the formation of a variety of aggregated 
structures, especially when elongated with a longer polyQ (Benn et al., 2005, Arrasate et 
al., 2004, Davies et al., 1997, DiFiglia et al., 1997) (Figure 1-3).  Indeed, this aggregation 
could begin from small oligomers of between 4–15 HTT exon 1 monomers that are driven 
by the ability of the N-17 to self-associate and assemble into alpha–helical clusters 
(Jayaraman et al., 2012, Ossato et al., 2010). These oligomers can grow in size as non-β-
oligomers and then become rearranged to β-sheet-rich polyQ amyloid fibrils in a process 
that increases in the presence of a longer polyQ (Scherzinger et al., Jayaraman et al., 2012, 
Bhattacharyya et al., 2005). In HD, the length of the polyQ is correlated with the onset of 
disease and severity (Bhattacharyya et al., 2005) once over the pathogenic threshold of 
37Q. The process of amyloid fibrillation can still occur below the 37Q threshold 
(Sivanandam et al., 2011, Lee et al., 2012a, Ansaloni et al., 2014) but there is no evidence 
that this occurs in physiological concentrations. As the poly Q expands the HTT becomes 
more prone to aggregate. The length of the polyQ determines the stiffness of the HTT 
fibril. Increased polyQ length results in a stiffer and smoother structure which allows for 
more bonds with other HTT sheets and so are more readily able to aggregate (Ruggeri et 
al., 2016).  
The kinetics of mHTT aggregation are proportional to its concentration. Higher 
concentrations make the correct orientation of the fibrils required for aggregation 
formation more likely (Thakur et al., 2009, Jayaraman et al., 2012). The concentration 
will depend on many factors including the quantity and length of fragments, somatic 
instability, PMTs, and proteolysis within each cell. Increases in these factors are thought 
to result in more aggregation events (Scherzinger et al., 1999, Bhattacharyya et al., 2005). 
As such, the concentration factor could be behind why neurons are more readily affected 
in HD brains compared with glial cells; neurons express higher levels of HTT 
(Landwehrmeyer et al., 1995). Additionally, increasing evidence shows the potential of 
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non-cell autonomous HTT transmission from other cells (Frost and Diamond, 2010, 
Babcock and Ganetzky, 2015). It has long been known that mammalian cells can import 
amyloid polyQ fibrils (Yang et al., 2002) and that this process can recruit other polyQ 
proteins in the cells into aggregates and even result in cell death (Yang et al., 2002, Ren 
et al., 2009). Evidence suggests that this process can also take place in HD (Cicchetti et 
al., 2014, Pecho-Vrieseling et al., 2014). 
 
Figure 1-3. HTT pathology within the cell. The Huntintin gene is translated into the full length 
HTT protein, or HTT exon 1 fragments via spliced RNA when an expanded CAG repeat is present 
(label 1). The full length protein is cleaved via proteolysis to generate additional fragments (label 
2). These fragments can enter the nucleus (label 3) and are retained inside through self-
association, oligomerization and aggregation which in turn results in the formation of inclusions 
that cause transcriptional dysregulation through the sequestration of other proteins and by 
additional incompletely defined mechanisms (label 4). The fragments also oligomerise and 
aggregate in the cytoplasm (label 5). This aggregation is intensified through the disease-
associated impairment of the proteostasis network, which in turn leads to global cellular 
impairments (label 6). All together, the presence of mHTT results in global cellular impairments, 
including synaptic dysfunction, mitochondrial toxicity, and a decreased rate of axonal transport 
(label 7). HTT=hungtingtin; PRD=proline rich domain; Ub=ubiquitin. Figure from Bates et al 


























































The mechanisms driving the complex and numerous cellular pathologies of HD and the 
role that mHTT aggregation plays within the context of the disease are still not fully 
understood. 
 
1.8 Animal models 
Manipulation of the mouse genome to model HD has conventionally been achieved using 
two approaches: creation of transgenic animals (Mangiarini et al., 1996) or by 
manipulation of the Htt locus that encodes the murine HTT protein (Barnes et al., 1994, 
Lin et al., 1994). 
The original transgenic models of HD were created by implantation of DNA containing 
fragments of the human HTT gene into a single cell mouse embryo (Mangiarini et al., 
1996). Subsequently, other transgenic models were made using whole genomic sequences 
of the human HTT gene in the form of either a bacterial artificial chromosome (BAC) 
(Gray et al., 2008) or yeast artificial chromosome (YAC) (Hodgson et al., 1999, Slow et 
al., 2003). 
The complementary method of editing the murine Htt can be used to alter gene sequences 
to produce knock-in models or to knock-out the gene, and so prevent its expression 
altogether. These knock-out models of HTT are embryonically lethal (Duyao et al., 1995, 
Nasir et al., 1995, Dragatsis et al., 1998, Zeitlin et al., 1995). Knock-in models replace 
the normal 7 glutamines in mouse Htt with an expanded tract on one or both alleles 
(Levine et al., 1999, Shelbourne et al., 1999). Expansion of the Htt repeat length to a 
pathogenic range more accurately reproduces the genetics of the human disease compared 
with those represented by transgenic models, However, such models also generally have 
a slower onset of pathology. In all HD mice, a longer CAG repeat length, beyond the 
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range observed in humans, is needed to produce a model with measurable phenotypes 
within a 2-year laboratory mouse life span (Levine et al., 1999, Shelbourne et al., 1999). 
The R6 transgenic mouse models, created by our research group, develop an early disease 
phenotype followed by a rapid pathological disease advancement (Mangiarini et al., 
1996). Of these mouse models, the R6/2 model has become the most commonly used in 
HD research. The R6/2 mouse was created with fragments of the human HTT gene 
containing exon 1 with around 150 CAG repeats. The R6 models are models of the 
missplicing that occurs in HD, which produces the exon 1 HTT (Sathasivam et al., 2013). 
Phenotypically, R6/2 mice rapidly develop many of the HD-like symptoms found within 
the human disease and die around 16 weeks of age. Impairments in cognition (Lione et 
al., 1999), motor ability (Carter et al., 1999), and a decrease in brain volume (Zhang et 
al., 2010a, Rattray et al., 2013) are observed. HD-like behavioural phenotypes can be 
detected from 4 weeks of age in some novel activity analyses (Hickey et al., 2005). 
Rotorod and grip strength tests show deficits by 8 weeks and increase progressively until 
death (Carter et al., 1999, Rattray et al., 2013). Alterations in the electrophysiology in the 
corticostriatal pathway (Cepeda et al., 2003) and deficits to hippocampal synaptic 
plasticity (Murphy et al., 2000) underlie some of these symptoms. HTT aggregates also 
appear early within the brain, before the onset of many other phenotypes (Davies et al., 
1997). Many studies have shown the presence of inclusions in R6/2 mice between 3-4 
weeks of age (Davies et al., 1997, Li et al., 1999a, Morton et al., 2000, Meade et al., 2002) 
while others have shown they can be detected even earlier, in p1 neonates (Stack et al., 
2005) although at low concentrations. Similar to in the human HD brain, this aggregation 
is a useful phenotype to monitor the disease. 
Data for whether the R6/2 mouse model replicates the neurodegeneration seen in the 
human HD are conflicting. A stereological analysis by Stack and colleagues in 2005 
found a 25% reduction in striatal neurons in 12 week old R6/2 mice compared with their 
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WT littermates (Stack et al., 2005). However, analysis performed in our lab found little 
cell death in R6/2 mice compared with their WT littermates at 16 weeks of age in either 
the striatum or the cortex (Rattray et al., 2013). Lack of cell death was apparent, despite 
a widespread inclusion phenotype and dramatic progressive reduction of brain volume 
and of cortical thickness measured using MRI. Many other groups have also found low 
levels of cell death in the brains of R6/2 mice (Davies et al., 1997, Zhang et al., 2010a). 
The CAG repeat in the R6 lines is unstable (Mangiarini et al., 1996) and so independent 
colonies can have varied CAG repeat sizes. The length of CAG repeat influences disease 
onset, progression, and survival time with a longer repeat accelerating the disease 
(Menalled et al., 2009, Morton et al., 2009). However, when this repeat becomes very 
long, over 330 repeats, phenotypes become milder and onset is delayed (Morton et al., 
2009), which is important to consider when using R6/2 mice. 
Despite varied approached to modelling HD in mice, no single HD mouse model 
recapitulates all aspects of human HD disease progression—most likely due to the 
fundamental genetic differences between rodents and humans. 
Other than mice, additional animal models of HD have been created. These include 
transgenic rats (von Horsten et al., 2003), as well as models using larger mammals such 
as sheep (Jacobsen et al., 2010), pigs (Yang et al., 2002), and the rhesus macaque 
nonhuman primate (Yang et al., 2008). These models have been useful to study effects of 
mHTT on larger brains more similar to the human CNS. Because these larger models 
have longer lifespans than the laboratory mouse, shorter CAG repeats closer to those 
commonly seen in human HD patients can be used. Even so these repeats are still 
artificially extreme so that it is possible to study the disease in a reasonable time frame. 
Cognitive and memory deficit phenotypes were seen in the rats with 53Q (Brooks et al., 
2009), while the larger models have developmental abnormities (Jacobsen et al., 2010, 
Chiang et al., 2012) and many of the105Q pigs and 84Q monkeys die soon after birth 
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(Yang et al., 2010, Yang et al., 2008). The 73Q sheep model, under the human HTT 
promotor, shows reduction of striatal DARPP-32 (dopamine- and cAMP-regulated 
neuronal phosphoprotein) staining by 7 months (Jacobsen et al., 2010). These models will 
be useful to study the disease over longer lifespans than the laboratory mouse yet still do 
not fulfil all the needs required to understand the disease process. 
Animals provide excellent models of how HD affects the brain and body as a system, 
dissecting molecular mechanisms in an animal model is a slow and challenging. An 
alternative is to transfer the underlying processes and tissue to study in vitro. To be able 
to study the process of HD pathology in a cell would be hugely beneficial to understand 
the disease mechanism and the ideal approach to do this would be to establish human HD 
cultures that exhibit measurable phenotypes within a reasonable time-frame for 
experimentation. 
 
1.9 Human tissue research 
The use of human HD post-mortem tissue has long been the most accurate way to 
distinguish HD neuropathology. However, in general, such tissue only really gives 
information on the late-stage processes of the disease and not those that underlie 
pathology (Sterneckert et al., 2014). Beyond this, studying HD in vitro had been limited 
to extractable cell pools such as blood or spinal fluid. Despite huge leaps being made 
during the last decades in stem-cell science, a reliable cell model of HD for therapeutic 
development remains elusive. 
1.9.1 Immortalised human cell lines. 
A traditional way to maintain neural cells in vitro was to artificially immortalise them. 
Immortalised neuronal cells lines, such as human SH-SY5Y, as well as murine mouse 
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N2a, rat PC-12m lines, can be transfected with different polyQ-expanded huntingtin 
constructs to model HD (Scotter et al., 2010, Cisbani and Cicchetti, 2012, Zemskov et al., 
2003). One study using an immortalised line transfected with polyQ constructs of 150Q 
showed mHTT localisation in the nucleus, as well as changes to cell morphology, gene 
expression, and decreased viability (Li et al., 1999a). The process of immortalisation 
might impact the cells and introduce unpredictable variables, including genetic mutations 
and karyotype instability, and therefore such cell lines might not be ideal to model HD. 
Besides neuronal cells, mHtt has also be transfected into non-neuronal cells (Cisbani and 
Cicchetti, 2012) including HeLa cells (Iwata et al., 2005, Majumder et al., 2006, 
Raychaudhuri et al., 2008) human embryonic kidney cell-line 293T (HEK293T) (Sancho 
et al., 2011, Iwata et al., 2005, Cooper et al., 1998) as well as monkey kidney cell lines 
(COS-7) (Ossato et al., 2010, Ho et al., 2001) with various phenotypes. Despite much 
potential, candidate compounds in drug screens using these models have yet to translate 
to larger HD models or in clinical trials (Bard et al., 2014). This failing could be down to 
the levels of HTT differing from physiological levels in such lines, as well as the potential 
effects of immortalisation. 
1.9.2 Human stem cells. 
Advances in cell culture knowledge and techniques have allowed non-immortalised cells 
to be used. Embryonic stem cell (ESC) technology has created a resource of human cells 
that can be isolated and cultured long-term (Thomson et al., 1998). Such advances led to 
the creation of several HD ESC lines capable of differentiation into mature adult cell 
types and tissues (Verlinsky et al., 2005, Niclis et al., 2009, Bradley et al., 2011, Lu and 
Palacino, 2013). These lines, once differentiated into neural cells, exhibited HD-like 
phenotype such as CAG repeat length instability, mitochondrial abnormalities, and 
abnormal neurotransmitter responses. However, use of such embryonic human tissue has 
always been hampered by ethical concerns raised by of the destruction of a human 
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blastocyst during the process of ESC creation rendering the availability of new lines 
limited. 
Advancements in stem cell technology include the promising upheaval in the stem cell 
dogma by the possibility of new sources of stem cells using induced pluripotent stem cell 
(iPSC) technology (Takahashi et al., 2007, Takahashi and Yamanaka, 2006). This 
technology can allow for the production of stable progenitor cell lines derived from 
almost any adult human tissue (Zhou et al., 2012). This process bypasses the need for 
embryonic tissue by essentially converting adult cells back into ESC-like iPSCs using 
four transcription factors responsible for an embryonic phenotype (Takahashi et al., 
2007). Stable lines formed in this way can be created from human HD patients. 
Researchers using this approach have produced HD iPSC lines that replicate certain HD 
phenotypes (An et al., 2012, Cheng et al., 2013, HD iPSC Consortium, 2012, Chae et al., 
2012, Jeon et al., 2012, Camnasio et al., 2012). 
The first iPSC line from an HD patient were created by Park et al (2008) who attempted 
to make lines from fibroblasts taken from patients with various diseases (Park et al., 
2008). The patient from whom the fibroblasts were taken for the HD lines had an allele 
with 72 CAG repeats, suggesting a juvenile form of HD. Despite this highly extended 
CAG repeat, gene expression analysis of the iPSC lines by the researchers identified no 
pathological phenotypes (Park et al., 2008). 
This juvenile HD iPSC line was subsequently used by other groups to investigate possible 
phenotypes that Park and colleagues did not investigate in their initial study. A range of 
phenotypes were exposed that differed from iPSCs derived from healthy people, 
including an increased caspase activity upon growth factor removal (Zhang et al., 2010b), 
and high susceptibility to oxidative stress followed by apoptotic cell death (Chae et al., 
2012), when in a NSC state. The cells could be differentiated into GABAergic neurons 
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and survive transplantation into rat brains. An aggregation phenotype was not present 
within these neurons unless the cultures were treated with the proteasome inhibitor MG-
132 (Jeon et al., 2012). The levels of this aggregation were reduced by treatment with an 
microRNA, miR-196a, which has similar effects in HD-mouse models (Cheng et al., 
2013). 
An and colleagues identified additional pathological phenotypes in the juvenile HD iPSC 
cell line, including increased apoptosis, decreased BDNF expression, and altered caspase 
activity (An et al., 2012). Subsequently, these authors used homologous recombination 
in the HD iPSCs to reduce the expanded allele of the HTT gene from 76 CAG repeats to 
21 repeats. This reduction in CAG repeat length reversed the pathological phenotypes 
they had previously seen with these lines (An et al., 2012). 
A collaboration of labs formed the HD iPSC consortium to generate 14 iPSC lines from 
seven individuals. These lines were created with CAG repeats of 21, 33, 60, 109, and 180, 
to represent the range from healthy controls through to CAG repeats that would cause 
severe pathology. Once differentiated to NSCs, gene expression was analysed by 
microarray and cluster-based analysis. This analysis revealed that the control lines with 
CAG repeats of 21 and 33 differed from those with pathogenic repeat lengths. The 
differentiated NSCs and derived neurons with longer repeats exhibited problems with cell 
adhesion and decreased adenosine triphosphate (ATP) production, increased caspase-3 
activation, increased cell death after prolonged culture or BDNF withdrawal, and 
increased vulnerability to stress and toxicity. These HD-like phenotypes correlated with 
CAG repeat number and became more severe with longer CAG repeats (HD iPSC 
Consortium, 2012). 
Ideal HD cell models for screening purposes would limit genetic background variance 
while also representing multiple CAG repeat lengths (An et al., 2012). This ideal has been 
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made more realistic with advances in genome engineering using zinc finger nucleases and 
transcription activator-like effector nucleases (TALENS) (Baker, 2012, Alberts, 2012). 
Subsequently, use of clustered regularly interspaced short palindromic repeats (CRISPR) 
has dramatically cut the time and cost of gene editing (Jinek et al., 2012, Segal and 
Meckler, 2013). CRISPR uses a bacterial nuclease to cut specific sites in DNA. The 
nuclease is directed to the site by a guide RNA, which recognises 18–21 base pairs in the 
DNA, allowing unique sites in the genome to be targeted (Bassett et al., 2013). CRISPR 
is therefore an ideal system for making a library of varying length CAG repeat models 
for HD. 
Researchers modelling other neurodegenerative diseases have made gains in 
understanding using iPSCs. For example, in amyotrophic lateral sclerosis research, 
subtypes of motor neurons can now be created from patient iPSCs to model relevant 
pathologies in ways that were not possible with ESCs derived neurons (Sances et al., 
2016, Richard and Maragakis, 2015). This suggests with time similar breakthroughs 
could be made within the HD research field. 
A limitation of iPSC technology is the time needed to create and differentiate these 
patient-specific lines, which is currently extensive. Reliable methods of neuronal 
differentiation within reasonable turnaround times still need to be optimised. Artificial 
genetic alteration of these lines has also been problematic because of the difficulty of 
homologous recombination into endogenous alleles (Han et al., 2011), although the 
advances in editing with technologies like CRISPR could alleviate this. If and when these 
hurdles can be overcome, iPSC cells will be vital in the future of HD research. 
Until the technologies using human tissue and cells can be improved further, the use of 
cells from non-human models remains an important approach for the study of certain HD 
phenotypes and to compliment and dissect findings made with in vivo models. 
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1.10 Mouse stem cell models 
Use of mouse models of HD that exhibit measurable HD-like phenotypes is a useful 
approach for translational in vitro research. Isolation of cells from the R6/2 HD model 
would allow for the study of HD-like phenotypes that underlie the disease at a cellular 
level. The technique applied to obtain cells to culture and when during the mouse life 
span such techniques are applied are important considerations when assessing what aspect 
of HD is to be studied. With the emergence of iPSC technology, this pool of potential 
cells has been expanded greatly yet, as already discussed, this new technology has its 
limitations. Techniques that had fallen out of general use have been newly revitalised, 
mainly due to advancements in the understanding of the growth and maintenance 
conditions required to produce stable lines. 
Mouse ESCs and NSCs both offer a source of cells with great promise to the HD research 
field, especially due to their intrinsic properties to produce a range of cell types. ESCs, in 
theory, permit the creation of all cell types; however, differentiation protocols can be 
complex, as is their required growth on feeder layers (Reubinoff et al., 2000, Thomson et 
al., 1998) or artificial substrates (Nakagawa et al., 2014, Xu et al., 2001). 
NSCs on the other hand are a population of multipotent cells found in the developing 
brain and adult CNS. NSCs are mitotic and are capable of self-renewal (proliferation). 
They can exit the cell cycle to differentiate into the three neural linages of the CNS: 
neurons, astrocytes, and oligodendrocytes. During development, NSCs produce the cells 
that form the CNS, dividing many times to produce the daughter cells that create the 
eventual brain. In the adult brain, a pool of NSCs remain in the sub-ventricular zone 
(SVZ) and dentate gyrus (DG). They have a limited regenerative potential (Doetsch and 
Alvarez-Buylla, 1996, Lois and Alvarez-Buylla, 1994, Gage et al., 1998) as well as vital 
roles in processes such as memory formation (Deng et al., 2010). 
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NSCs divide and survive in specialised neurochemical niches, which help to regulate 
asymmetrical division giving rise to identical daughter cells that can divide themselves 
or migrate and further differentiate into mature cells (Temple, 1989). In the developing 
brain, a set programme of maturation gives rise to NSC populations with ever more 
regionally specific fates precise to the spatiotemporal area they develop (Temple, 2001). 
The mitogens and chemotactic factors each mitotic NSC is exposed to acts to decide the 
role and function that each cell comes to adopt within the CNS network. Understanding 
of how spatiotemporal fate is controlled and can be manipulated to artificially guide cells 
towards appropriate fates is a key process in the culturing of cells. 
 
1.11 Neurogenesis 
To comprehend the nature of cultured NPCs, endogenous in vivo neurogenesis in the 
developing mammalian embryo must first be understood. Neurogenesis is considered to 
begin when the neuroectoderm is induced into forming the neural plate, the most 
rudimental CNS structure. In mice, this process is considered to occur at about embryonic 
day 7.5 (E7.5). By E8.5, the neural plate folds into the neural tube. The neural cell 
progenitors present at this stage in vivo are thought to be the same populations that can 
be induced from embryonic stem cells (ESCs) during in vitro differentiation protocols 
(Conti et al., 2005, Pollard et al., 2008, Elkabetz et al., 2008). They are thought to divide 
and produce identical daughter cells to expand the progenitor pool along the then single 
layered ventricular zone (Gotz and Huttner, 2005). 
At around E9.5 in the mouse, a population of neural progenitors termed radial glial (RG) 
cells develop. The RG cells are a transient population with specific morphological 
hallmarks which develop from neuroepithelial cells. These cells are characterised by their 
morphology with radial process reaching from their ventral niche, to the basal surface of 
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the brain (Hartfuss et al., 2001). RG cell division produces the majority of cells that 
eventually form the brain and their scaffolding properties help to move their progeny to 
the appropriate area (Hansen et al., 2010, Noctor et al., 2008). 
RG cells in development are defined by lineage heterogeneity based on spatiotemporal 
variety (Hartfuss et al., 2001, Anthony and Heintz, 2008). Similarly, separate RG 
populations in vitro act differently depending on the area and the stage of the embryo that 
they represent (Pinto et al., 2008, Li et al., 2004). At around mouse E18 developmental 
neurogenesis is considered to end as the RG cells mostly migrate and differentiate 
(Edwards et al., 1990, Miyata et al., 2001, Shen et al., 2006, Noctor et al., 2008). 
However, some RG cells do remain, and fate mapping experiments using adult SVZ 
derived NSCs have shown this population of adult progenitors originate from a 
subpopulation of radial glia cells that become B type stem cells that survive and retain 
their pluripotency after development in vivo (Merkle et al., 2004). 
RG cells obtained from within the neural developmental window can be expanded in vitro 
and provide a valuable source of stem cells (Johe et al., 1996, Hartfuss et al., 2001, Conti 
et al., 2005). This approach is used within this thesis to produce cell models using 
transgenic mouse foetal CNS tissue. The lines between the definition of a neural stem cell 
rather than a neural progenitor cell are somewhat blurred. True neural stem cells are the 
cells that become all those which make up the nervous system, and also retain the ability 
to become each and every type of cell found in neural tissue (Ramalho-Santos and 
Willenbring, 2007, Clayton et al., 2007). Neural progenitors on the other hand are 
presumed to be restricted in terms of having regional specification, a finite mitotic 
potential, or restricted differentiation fate (Seaberg and van der Kooy, 2003). However, 
the two terms are often used interchangeably in research literature, which can cause 
confusion. 
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Cells extracted from mouse foetal brain sources are potentially more accurately termed 
RG-like neural progenitor cells (NPCs) and are referred to as such in some publications. 
Because the stem abilities of the population of cells extracted and cultured in this thesis 
were not fully characterised, they will be referred to as NPCs throughout the results 
chapters.  
 
1.12 Culturing neural stem cells 
It has long been hoped that the potential of culturing and maturing NSCs in vitro could 
allow for long-term models of the mechanics of neural networks and disease. The scalable 
potential of cell models is an ideal platform to probe treatments for many diseases on a 
mass scale. The initial attempts to obtain, purify, and expand NSCs from developing 
embryos and areas of adult neurogenesis proved problematic. Original attempts during 
the 1990s to maintain a culture of NSCs in vitro was on a small scale and varied in success 
(Reynolds et al., 1992, Reynolds and Weiss, 1992), mainly because of a lack of 
understanding of the conditions required to maintain the stable NSC physiological state 
outside the brain. 
These methods fell out of favour with more attention being diverted to the use of artificial 
immortalisation techniques to produce stable cultures. However, developments in growth 
factor-based protocols allowed cell maintenance and long term expansion as both free 
floating cell clusters termed neurospheres and adherent monolayer cell cultures. The 
breakthrough was achieved with the understanding that cells could be maintained as 
proliferative cultures in media supplemented with the morphogens epidermal growth 
factor (EGF) and basic fibroblast growth factor-2 (FGF2) (Conti et al., 2005). These 
factors allow for stable cultures extracted from the embryo to be maintained in vitro with 
relative ease. 
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1.13 From niche to dish 
NSCs can be expanded as free-floating neurospheres or as a monolayer of cells adhering 
to the plastic of the dish (Conti and Cattaneo, 2010, Conti et al., 2005) (Figure 1-4). 
1.13.1 Neurosphere system: 
Neurospheres are free-floating masses of predominantly NSCs, which can potentially 
form from a single NSC (Laywell et al., 1999, Reynolds et al., 1992). NSCs can be 
harvested from the developing mouse neural tissue between E10.5 and E18.5 or from 
areas of adult neurogenesis such as the sub-ventricular zone (SVZ) (Louis and Reynolds, 
2005, Chojnacki and Weiss, 2008). NSCs can also be created from ESCs or from iPSCs 
once neuralised (Chojnacki and Weiss, 2008). NSCs will form neurospheres when 
cultured without a surface they can adhere to and left to settle in serum-free media 
supplemented with EGF (10-20 ng/ml) and FGF-2 (10-20 ng/ml) (Singec et al., 2006). 
Under these conditions differentiated or differentiating cells do not survive, resulting in 
pure populations of mitotic NSCs. In response to media containing mitogens, the cells 
divide and produce the free-floating neurosphere masses. These clusters can then be 
expanded for long periods, dissociated and re-plated to expand the NSC population 
relatively quickly. 
The characteristics of cells that form neurospheres have been investigated in relation to 
the age of the source and the location they are isolated from. Neurosphere-forming cells 
extracted from the adult SVZ are thought to be either glial fibrillary acidic protein 
(GFAP)+ ‘B-Type’ or the distal-less homeobox (DLX)2+ ‘C–type’ cells (Doetsch et al., 
2002). Neurosphere-forming cells dissected from the embryo are less well characterised; 
the expression levels of NSC markers can differ from those observed in vivo. Many 
cultures only express the NSC marker nestin, although some also express NSC markers  
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such as SOX-2, prominin and RG markers such as RC2, the glutamate aspartate 
transporter (GLAST), and the brain-lipid-binding protein (BLBP) (Hartfuss et al., 2001). 
Evidence suggests that, with human cells at least, cells comprising neurospheres are 
mostly RG cells, which might be because these are the cells most suited to survive in the 
culture conditions. Activation or signalling of the EGF receptor using high concentrations 
of EGF (Nelson et al., 2008) produces cells that are morphologically, antigenically, and 
functionally definable as RGs when allowed to adhere (Gregg and Weiss, 2003). 
With neurospheres being a 3-dimensional bulbous of cells rather than a single monolayer, 
the cells at the centre experience a different neurochemical environment to those on the 
outside. As their size increases, this environment becomes more of a limiting factor and 
can result in cells beginning to differentiate because of the lack of contact with mitogens 
and increased notch signalling (Campos, 2004). As the neurosphere becomes larger still, 
cells towards the centre of the neurosphere can become necrotic due to lack of nutrients 




Figure 1-4. Sources for establishment of neural progenitor cell lines. ESCs derived from the 
inner cell mass of blastocysts, iPSCs derived from reprogrammed somatic cells, and the 
germinative areas of the foetal and adult brain can be used to harvest neural stem cells. 
Neurospheres and cells grown in monolayers are considered tripotent as they can give rise to 
neurons, astrocytes and oligodendrocytes. The distinctive cellular compositions of the 
neurosphere (mixed, with only a fraction of the cells exhibiting NSC properties) and NSC 
monolayer culture systems results in low and high neurogenic potential, respectively. ESC= 
embryonic stem cells; iPSCs=induced pluripotent stem cells; NSCs=neural stem cells. 
Reproduced from Conti and Cattaneo (2010) under copyright agreement with Nature Publishing 
Group, License Number: 3925970196918 
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NSCs grown as neurospheres retain their CNS tripotent differentiation potential. Over 
time and passages the potential to produce neurons decreases and a predilection to glial 
cells dominates (Bibel et al., 2007). Various differentiation protocols have been applied 
to neurospheres based on mitogen removal, exposure to bovine serum, and specific 
cytokines and substrates. However, none of these protocols produce a population of beta-
III-tubulin positive cells totalling beyond a proportion of 20% (Weiss et al., 1996, 
Grandbarbe et al., 2003, Chojnacki and Weiss, 2008). With the relative speed and ease of 
expansion of neurospheres, cell-sorting techniques such as fluorescent activated cell 
sorting (FACS) could produce large numbers of individual neurons from an appropriate 
quantity of neurospheres. 
A certain limitation of the neurosphere system could be its inability to preserve region-
specific phenotypic profiles. Cells harvested from different developmental regions of the 
brain and cultured as neurospheres keep their region-specific molecular profiles for 1-2 
passages (Hitoshi et al., 2004), however beyond this number of passages in vitro, region-
specific patterns are altered in terms of expression of both rostral-caudal and dorsal-
ventral markers (Zappone et al., 2000, Gabay et al., 2003, Hack et al., 2004). 
The neurosphere system has been used to study HD. NSCs from the cortex and striatum 
have been isolated from WT and R6/2 mice between 1 and 4 days after birth (p1-p4) 
(Chu-LaGraff et al., 2001). Most of these cells died within 24 hours, suggesting they were 
post-mitotic thus unable to survive in proliferation media. The surviving cells were grown 
as neurospheres, and maintained over many months. The authors showed that NSCs could 
be differentiated into neurons and glia upon morphogen withdrawal, however the 
majority of cells became GFAP+ glia. Differentiated neurons were found to express 
mHTT in a manner that resembled neurons during the pathogenic stages of the R6/2 
mouse model (Chu-LaGraff et al., 2001). These findings suggest that NSCs isolated from 
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the R6/2 mouse can be cultured in vitro and retain some HD-like phenotypes exhibited 
by mouse models. 
1.13.2 Monolayer system 
The initial efforts to produce homogenous monolayer NSC cultures systems were not 
very successful, with only a few examples producing stable cultures (Palmer et al., 1997, 
Alexson et al., 2006). This changed with the understanding that NSCs cultured with EGF 
and FGF-2 will remain stable and can be expanded as adherent clonal identical cell lines 
(Conti et al., 2005, Elkabetz et al., 2008, Koch et al., 2009). The presence of EGF and 
FGF-2 in this technique allows maintenance of the stable culture of adhered cells 
regardless of whether the cells are harvested from ESCs, foetal or adult tissue (Palmer et 
al., 1997). In the right conditions, monolayer NSCs have been cultured to 130 passages 
with no major differences in proliferation or differentiation patterns (Spiliotopoulos et al., 
2009). 
As a monolayer, cells divide symmetrically producing identical daughter progeny and 
retain their potential for differentiation into the three neural cell types (Conti et al., 2005). 
The cells will continue with mitotic expansion until their density reaches a point where 
contact inhibition through notch signalling triggers their differentiation. As such, 
differentiation needs to be prevented by passaging the cells into new plates when the cells 
become too confluent. Regular passaging allows monolayer cultures techniques to 
produce large NSC populations with negligible spontaneous differentiation. As with 
neurospheres, cells that form monolayer cultures display many similarities to forebrain 
neurogenic RG cells (Conti et al., 2005, Pollard et al., 2008). The monolayer environment 
probably allows for more uniform cell culture of RG-like NSCs compared with a 
neurosphere culture. Indeed, the cells enriched by the monolayer technique might be the 
RG-like NSC portion of the neurospheres. The neurogenic potential of NSCs grown as 
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monolayers appears to be maintained over several passages unlike with neurospheres 
(Goffredo et al., 2008). 
The nature of a monolayer system as an artificial 2-dimentional culture seems to prevent 
lineage restriction as well as preventing spontaneous differentiation. As such, the 
relatively homogeneous self-renewing cell population is ideal for in vitro modelling of 
genetic alternations and resulting phenotypes. Evidence suggests monolayer cultures 
could be grown for many passages while retaining their radial glial NSC identity and 
characteristics (Sun et al., 2008). One concern remains over how representative in vitro 
cultures are of their in vivo counterparts. A subpopulation might be prone to survive in 
vitro that are forced to reprogram for the culture environment (Temple, 2001), especially 
with the preservation reliance on EGF and FGF2 (Reynolds and Rietze, 2005). However, 
analysis of gene expression in RG-like progenitors derived from various areas of the brain 
show that the expression of some region-specific genes is maintained (Onorati et al., 
2011) suggesting any reprograming that takes place will not be total. When looking to 
investigate phenotypes of HD this uncertainty is worth noting. 
The monolayer approach to culture NSCs has been used by several groups to study HD. 
A full length Htt knock-in mouse model with 111 repeats has been used as a source of 
NSCs from E14 foetal mice (Reis et al., 2011). These HdhQ111 knock-in lines have been 
used by a few groups. The lines were immortalised to create clonal striatal cell lines from 
E14 HdhQ111 mice, which were established with both homozygous and heterozygous 
full length HTT expression. Expression of mHTT is found in both the cytoplasm and 
nucleus with abnormalities in endoplasmic reticulum (ER) stress and metabolic problems 
established (Trettel et al., 2000). Other groups have used these HdhQ111 knock-in lines 
to investigate the links between cellular ATP/ADP energy regulation, which is reduced 
in the HdhQ111 mouse model, and N-cadherin, a protein known to be involved with cell 
adhesion, differentiation, and synaptic function (Reis et al., 2011). 
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Knock-in mice with CAG repeats of 20, 50, 9,1 and 111 were also used to create ESC 
lines expressing the varied polyQ (Jacobsen et al., 2011). These cells were used to 
investigate gene expression against lines with 7 repeats as well as Htt null lines. Problems 
with energy metabolism and ATP/ATD levels were found in these lines, confirming 
evidence seen in other models (Jacobsen et al., 2011). Using similar knock-in cells with 
a 150 CAG repeat, neurogenesis was found to be increased (Lorincz and Zawistowski, 
2009). This model system proves ideal for the study of how the endogenous polyQ 
expansion on the mouse Htt can affect HTT-related proteins. 
Snider et al (2003) used a similar approach for cells from E14–E16 HdhQ111 along with 
R6/2 mice (Snider 2003, 12895502). The researchers created foetal cell lines on adherent 
poly-D-lysine and laminin-coated vessels, which were maintained with bovine and horse 
serum. Non-neural cell division was prevented with cytosine-arabinoside to purify the 
population. The authors observed ubiquitinated inclusions in cultured neurons from R6/2 
animals as early as 14–16 days after plating, however no data were shown to support this. 
The researchers primarily investigated the cells’ response to toxins, which had previously 
been observed to affect similar mouse models. No deleterious effects were observed in 
the HD cell lines and their WT counterparts in response to the toxin kainate, N-methyl-
D-aspartate (NMDA) receptor antagonists, proteasome inhibitor-induced death, and 
oxidative injury (Snider et al., 2003). 
Culturing of cells extracted from human foetal tissue, using the same approach as for 
mouse tissue, has also been attempted. Cells were extracted from 12–20-week old foetal 
striatal tissue and grown as adherent cultures. These human cultures could be 
differentiated into the three neural linages (Li et al., 2005). The use of such an approach 
from HD foetal tissue would be very interesting but is also extremely hard to source, and 
has ethical considerations that would limit the approach as a source of cells for research. 
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Therefore, foetal human cell lines to study HD are limited to artificial alteration of HTT 
levels in the NSC line by transduction with HTT with longer CAG repeats. 
 
1.14 Differentiation 
The simplest way to induce differentiation of NSC cultures is by the removal of the 
mitogenic growth factors from the cultures. ESC sourced NSCs differentiated in media 
with EGF and FGF2 removed and B27 added produces cells positive for the neuronal 
markers beta-III-tubulin (TUJ), gamma-aminobutyric acid (GABA) and glutamic acid 
decarboxylase (GAD67). By 7 days of culture in this differentiation media some neurons 
were found to be immunoreactive for synaptophysin (Conti et al., 2005), suggesting 
neurons with functional synapses could be produced. Further investigation with 
electrophysiology confirmed these findings. Subsequent adaption of original protocol by 
the same group allowed potential neuronal yield of around 80% after 21 days in 
differentiation media (Spiliotopoulos et al., 2009). 
Other groups have concentrated on cells from foetal sources. E12 cells were obtained 
from a population of striatal precursor cells found by dissection from the ganglionic 
eminence, the niche pool which produces the striatum (Onorati et al., 2011). These cells 
were cultured and then differentiated using a previously optimized system developed on 
maturing adult SVZ cells. After 23 days, cells positive for TUJ, microtubule-associated 
protein (MAP)2, and GFAP, and GABAergic positive neurons were present. These 
observations are consistent with the typical characteristics of in vivo striatal neurons. 
Additionally, some neuronal cells expressing growth-associated protein (GAP)-43 were 
present, which is evidence of active neurite outgrowth and plasticity. No O4-positive 
oligodendrocytes were found with this method (Onorati et al., 2011). 
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To specifically investigate the neuronal and glial fates that differentiation of these cells 
produced, this same group subsequently examined lineage-specific regional gene 
expression. Foetal striatal cells were exposed to retinoic acid (RA), a morphogen that is 
important in the fate determination of the lateral ganglionic eminence (LGE) and for 
striatal neuron differentiation, as well as the effects of valproic acid (VA), which 
promotes differentiation into GABAergic neurons (Laeng et al., 2004, Onorati et al., 
2011). The cells were exposed to these morphogens for 15 days. The researchers found 
that neither the early post-mitotic striatal precursor marker insulin gene enhancer protein 
(Isl1) nor Dlx6 or Dlx5 were expressed. Expression of these markers would be expected 
in vivo in striatal precursor cells (Stenman et al., 2003). Markers of striatal precursors and 
of the striatal medium spiny neurons, forkhead box protein (Foxp)1, Foxp2, meis 
homeobox (Meis)2, and Rarβ1 were not found to be differentially expressed when 
cultured with or without RA or VA. The medium spiny neuron marker dopamine- and 
cAMP-regulated neuronal phosphoprotein (DARPP)-32 was not seen via 
immunostaining nor visible on blots. One gene that was constitutively expressed under 
both self-renewal and differentiation conditions was cAMP-regulated phosphoprotein-21 
(Arpp-21), suggesting some striatal specificity does remain (Onorati et al., 2011). These 
results point towards NSCs harvested from the developing striatum expressing some 
striatum-specific genes during differentiation, however, the cell line they produced did 
not acquire a fully mature striatal neuron phenotype. 
 
1.15 Functionality 
NSCs cultured in vitro generate antigenically and electrophysiologically mature neurons 
when exposed to suitable differentiation conditions (Conti et al., 2005, Goffredo et al., 
2008, Spiliotopoulos et al., 2009, Onorati et al., 2011). Differentiated NSCs produce 
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voltage gated Na+ currents similar to those of in vivo neurons and can be blocked in the 
same way with tetrodotoxin (Onorati et al., 2011, Conti et al., 2005). Whole-cell patch 
clamp experiments in both current and voltage clamp modes showed about 30% of 
differentiated neurons could elicit a voltage gated fast Na+ current and the associated 
delayed K+ current to rectify the action potential (Onorati et al., 2011). Voltage-gated 
Ca2+ channel conductance has also been detected (Conti et al., 2005). The traces the cells 
produced show distinct characteristics of both low-voltage activated (LVA) and high-
voltage activated (HVA) channels. These results suggest that these cells expressed some 
of the Na+ and Ca2+ channel complement found in typical maturing neurons. 
Other groups have found similar electroactivity of NSC neurons cultured from adult 
neurogenic niches. RG-like cells established from 2-month-old mouse SVZ cultures and 
grown as neurospheres before monolayer conversion are electroactive (Goffredo et al., 
2008). NSCs derived and differentiated into neurons showed a set of markers specific to 
GABAergic neurons, which has been suggested to be the default pathway that NPC 
differentiation produces (Sah et al., 1997, Jain et al., 2003). With these neurons, GABA 
can actively be released from active synapses of NSC derived neurons. 
The ability of these electroactive foetal NSC derived neurons to form networks was 
probed by looking for the presence of ligand-gated receptors and channels that could be 
activated by excitatory and inhibitory neurotransmitters. RT-PCR confirmed the presence 
of GABA-B receptors with large percentages of cells responding to GABAergic agonists 
(Onorati et al., 2011). When GABA was applied locally to clamped cells, a GABAergic 
response occurred in 70% of striatal-derived cells from a holding potential of -80mV, 
demonstrating the ability of differentiated foetal NSC-derived neurons to form functional 
networks in vitro. RT-PCR experiments showed the consistent expression of D2 
dopaminergic receptors on these striatal cells. When a range of neurotransmitters for 
receptors found on striatal cells in vivo (glutamate, glycine, acetylcholine, nicotine, 
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carbachol, and dopamine) were applied to the neurons, no effect on membrane currents 
occurred, suggesting they lacked functional receptors for them. However, the presence of 
dopamine decreased the inward current produced by GABAergic activation, suggesting 
the dopaminergic receptors present have only developed a neuromodulator effect in this 
cell line (Onorati et al., 2011). 
With all this evidence, it is hypothesised that the harvest of NSCs from foetal R6/2 tissue 
that differentiate into mature neurons is possible and that similar phenotypes to that 
detected in the mouse models could be present in a reasonable timeframe to study in vitro. 
Because our lab can produce transgenic mouse models, an abundant source of tissue to 
create and culture NSC lines is available. NSCs from the R6/2 mouse can be used to 
complement in vivo work, mechanistically dissecting approaches found to modulate HD 
phenotypes in vivo. From there, the ability to perform high-throughput analysis of 
phenotypes will allow a thorough characterisation of alterations to be studied in detail.  
As such the aims of this thesis are to: 
 Establish HD relevant cell lines from the R6/2 mouse model. 
 Investigate phonotypes in these lines  
 Establish the potential for high-throughput screening to be applied to these lines 
and for disease modifying compounds to be tested.  
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Chapter 2 Materials and Methods 
2.1 Materials 
Reagents and media  Supplier  Cat number 
Accutase  Sigma  A6964 
Amersham ECLTM Western 
Blotting Kit 
 GE Lifesciences  RPN2109 
Amersham Hyperfilm ECLTM  GE Lifesciences  28906837 
Ammonium persulfate  Fisher  A/p470/46 
B27 supplement  Gibco  17504044 
BDNF  Source Bioscience  ABE3214 
Bovine serum albumin  Sigma  A9418 
Cell culture water  Sigma  W3500 
ColorPlus Prestained Protein Marker, 
Broad Range, 7-175 kDa 
 New England 
Biolabs 
 P7709S 
DMSO  Sigma  D2438 
DNA loading dye  Promega  G1881 
DNA loading dye     
DPBS -Ca/Mg  Gibco  14190-169 
DPX mounting media  Sigma  6522 
Dulbecco's Modified Eagle Medium: 
Nutrient Mixture F-12 (DMEM/F12) 
 Gibco  31331-028 
EDTA  Sigma  3620 
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Reagents and media  Supplier  Cat number 
Foetal Bovine Serum (FBS)  Thermo Scientific  10270106 
Gelatine  Sigma  G1890 
Giemsa stain modified solution  Sigma  48900 
Glacial acetic acid  BDH  10001CU 
Heparin  Sigma  H3149 
Hoechst dye  Invitrogen  H3570 
Lambda Hind III / phiX Hae III 
Marker 
 BIO-RAD  161-0375 
Laminin  Life Technologies  23017-015 
Methanol  Fisher  M/4000/25 
N-methyl-N-deacetyl-colchicine 
“Colcemid” 
 Roche  10295892001 
N2 supplement  Gibco  17502048 
Neurobasal media  Gibco  10888-022 
NeuroCult™ NSC Basal Medium  STEMCELL 
Technologies 
 5700 
NeuroCult™ NSC differentiation Kit  STEMCELL 
Technologies 
 5704 





NeuroCult™ NSC Proliferation Kit  STEMCELL 
Technologies 
 5702 





Normal donkey serum  Sigma  D9663 
Normal goat serum  Sigma  G9023 
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Reagents and media  Supplier  Cat number 
paraformaldehyde (PFA)  PCR  R/38 
Penicillin-streptomycin  Sigma  P4333 
Pierce® BCA protein assay kit  Thermo Scientific  23225 
Poly-DL-ornithine hydrobromide  Sigma  P8638 
Proteinase K  Thermo Scientific  EO0491 
Protogel®  Thermo Scientific  EC- 890 
Protogel® Resolving Buffer  Thermo Scientific  EC- 892 
Protogel® Stacking Buffer  Thermo Scientific  EC- 894 
Recombinant mouse epidermal 
growth factor (EGF) 
 Peprotech Inc  315-09 
Recombinant mouse fibroblast 
growth factor 2 (FGF2) 
 Peprotech Inc  450-33 
Sodium pentobarbital  J.M.L  103-9130 
Sucrose  Fisher Scientific  744771 
TAE  Thermo Scientific  B49 
TEMED  Sigma  T-8133 
Thermo-Start master mix  Thermo Scientific  AB0908B 
Thermo-Start master mix  Thermo Scientific   
Tissue-Tek optimum cutting 
Temperature (O.C.T.) compound 
 VWR  25608-930 
Tris  Sigma  T1503 
Triton X-100  Sigma  X100 
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Reagents and media  Supplier  Cat number 
Trypan blue solution  Sigma  Sigma 
TUNEL: In situ cell death detection 
kits, fluorescein 
 Roche  11-684-795-
910 
Vectorshield mounting solution  Vector  H1000 
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Equipment Supplier Cat number 
24 well plate Falcon 353047 
96 well opaque walled plates Falcon 10281092 
CFX96 with C1000 Thermal cycler BIO-RAD - 
Consort power pack Consort E802 
Coverslips VWR 23801-202 
Cryostat Bright- OTF 
Cuvettes Fisher Scientific FB55147 
Gel-Doc UV trans-illuminator BIO-RAD - 
Glass slides VWR 631-0446 
Hydrophobic Wax pen DAKO S2002 
Mr. Frosty™ Thermo Scientific 5100-0001 
Nanodrop Thermo Scientific 1000 
Neubauer cell counting chamber VWR HIRS8100103 
Nitrocellulose membrane BIO-RAD 162-0115 
Photometer (Bio-Photometer) Eppendorf - 
SIM µ-Dish Ibidi 81158 
SuperFrost slides VWR 631-0446 
T175 culture flask Falcon 353112 
T25 culture flask Falcon 353109 





2.2.1 Culture media 
In this section the compositions of cell culture media used in this thesis are described. 
Adaptations that have been made to cell culture media compositions are stated in text 
where appropriate. Working solutions were made up in 50 ml stock solutions and the 
formulation for each media is outlined for this quantity (Table 2-1). 
2.2.2 Proliferation medium 
The proliferation medium was based on a commercially available stem cell maintenance 
kit from STEMCELL Technologies that was specifically formulated to culture mouse 
neural stem cells. The NeuroCult™ NSC Proliferation Kit (mouse; STEMCELL 
Technologies, Cat#05702) consists of NeuroCult™ NSC Basal Medium (mouse; 
STEMCELL Technologies, Cat#05700) to which NeuroCult™ NSC Proliferation 
Supplement (mouse; STEMCELL Technologies, Cat#05701) must be added before use. 
Standard growth factors, recombinant mouse epidermal growth factor (EGF, 20 ng/ml; 
Peprotech Inc, Cat#315-09) and recombinant mouse fibroblast growth factor (FGF2, 10 
ng/ml; Peprotech Inc, Cat#450-33) along with heparin (2 μg/ml; Sigma, Cat#H3149), 
were added to the media to maintain cells in a proliferative state. 
2.2.3 Dissection medium 
Dissection of embryos and cells was performed in a modified proliferation medium 
containing penicillin/streptomycin (pen/strep; 10 ml/l; Sigma, Cat#P4333) and without 
growth factors or heparin. 
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Table 2-1. Summary of media compositions. 
 
2.2.4 Differentiation medium 
The basic differentiation medium is a commercially available product and an adaption of 
the NSC Proliferation Kit the NeuroCult™ NSC differentiation Kit (mouse; STEMCELL 
Technologies, Cat#05704). It is made up of NeuroCult™ NSC Basal Medium (mouse; 
STEMCELL Technologies, Cat#05700) to which NeuroCult™ NSC Differentiation 
Supplement (mouse; (STEMCELL Technologies, Cat#05703) must be added before use. 
2.2.5 Modified differentiation media 
Based on the modifications of Spiliotopoulos and colleagues (2009) to their 
differentiation protocol, adaptions were made to the medium used for differentiation. This 
contained the Neurocult proliferation kit, mixed with Dulbecco's Modified Eagle 
D1 A Bs Bw
Neurocult base 
media








- - 5ml - - - -
DMEM/F12 - - - 6.25ml 6.25ml 6.25ml 6.25ml
Neurobasal - - - 18.75ml 18.75ml 18.75ml 18.75ml
FGF2 50µl - 25µl 20µl 12.5µl 5µl
EGF 50µl - - - - -
Heparin 50µl - 25µl 20µl 12.5µl 5µl
N2 - - - 250µl 250µl 250µl 250µl
B27 - - - 1ml 1ml 1ml 1ml
BDNF - - - - 100µl 150µl 150µl











Medium/ Nutrient Mixture F-12 (DMEM/F12; Gibco, Cat#31331-028) and Neurobasal 
media (Gibco, Cat#10888-022) in a ratio of 4:1:3. All media included 10 l/ml pen/strep 
when required. 
The differentiation medium mixture was supplemented with 1% B27 (Gibco, 
Cat#17504044) and 0.5% N2 (Gibco, Cat#17502048). FGF, heparin and BDNF (Source 
Bioscience, Cat#ABE3214) were added at varying concentrations depending on the 
differentiation protocol step 
 
2.3 Culturing surface and substrates 
2.3.1 Plastics 
Cell were grown in flasks (Falcon: T25, Cat#353109, T75, Cat#353135, T175, 
Cat#353112) of varying sizes for proliferation. For smaller culture experiments, cells 
were grown in 24-well (Falcon, Cat#353047) or 96-well opaque walled plates (Fisher 
Cat#10281092). Specialised glass bottomed ‘µ-Dish’ plates were used to grow cultures 
for SIM (Ibidi, Cat# 81158) 
2.3.2 Gelatine 
Gelatine-coated plates were prepared by applying a 0.1% gelatine (Sigma, Cat#G1890) 
in Dulbecco's Phosphate-Buffered Saline (dPBS) with no calcium, no magnesium (–
Ca/Mg; Life technologies, Cat#14190-169) for at least 2 hours before use at 37C. Coated 
plastic can be stored for up to 48 hours at 37C in a 5% CO2 incubator. 
2.3.3 Poly-DL-ornithine 
Poly-DL-ornithine hydrobromide (PRN; Sigma, Cat#P8638) was prepared at 0.1 mg/ml 
in sterilized cell culture water (Sigma, Cat#W3500). Aliquots were stored at -20C until 
required. Culture surfaces were covered with the solution for at least 4 hours at 37C but 
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for no longer than 24 hours. The excess solution was washed off with sterilized PBS for 
three washes before use. When laminin was used with PRN, 5 g/ml natural mouse 
laminin protein (Life Technologies, Cat#23017-015) in dPBS was applied for a further 2 
hours. Prior to use, the coating liquid was removed before culture medium was applied. 
2.3.4 Laminin 
3ug/ml natural mouse laminin protein (Life Technologies, Cat#23017-015) in DPBS was 
applied for at least 2 hours but no longer than 24 hours. Prior to use, the coating liquid 
was removed before culture medium was applied. 
2.4 Cell culture procedures 
2.4.1 Dissection of radial glial niches 
Neural stem cell/progenitor lines were established from isolated foetal brain tissue at 
embryonic gestation day 14 (E14.5). CBA×C57BL/6 F1 female mice 
(B6CBAF1/OlaHsd, Harlan Olac, Bicester, UK) were mated with R6/2 males. Resulting 
pregnant females were euthanized by cervical dislocation before the uterus was dissected 
and placed into a petri dish of warm dissection medium (45 ml Neurocult Basal media, 5 
ml proliferation supplements: EGF 10 ng/ml, FGF 10 ng/ml, heparin 2 l/ml and 
pen/strep 20 l/ml). Individual embryos were removed from the uterine membrane and 
transferred to a petri dish containing dissection medium. Under a stereomicroscope, the 
embryo head was isolated, and the rudimental skull and meninges were carefully peeled 
away to expose developing brain tissue, which was eased away from the head (Azari et 
al., 2011). Using micro-scissors, the dorsal part of the developing cortex was cut away to 
reveal the ganglionic eminences through the rudimental ventricles. The medial side of the 
cortical tissue and the ganglionic eminences both lateral (LGE) and medial (MGE) were 
carefully removed using curved forceps and transferred to tubes containing fresh 
dissection medium. 
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Tissue solids were manually homogenised using repetitive pipetting before centrifugation 
at 100 x g for 7 minutes at room temperature. All subsequent centrifugation was 
performed at these settings. The supernatant was discarded and the cell or tissue pellet 
was resuspended in 6 ml Neurocult proliferation medium (as dissection medium above 
without pen/strep) and transferred to uncoated T25 flasks to proliferate for 5-7 days, 
depending on growth rates and a visual assessment of neurosphere size, in a 37°C 
incubator with 5% CO2. Incubators remained at these settings for all subsequent culture. 
2.4.2 Liquid nitrogen storage and revival. 
Cells banked for storage in the liquid nitrogen cell bank were removed from culture plates 
and centrifuged at 100 x g for 7 minutes at room temperature to form a pellet. Cells were 
resuspended in 1 ml of a 10% DMSO (Sigma, Cat# D2438) Neurocult proliferation 
medium mix and frozen in a Mr. Frosty™ cryopreservation chamber (Thermo Scientific, 
Cat# 5100-0001) overnight at -80°C. The vials were transferred into liquid nitrogen 
storage vessels for long-term storage. For revival, vials were removed from liquid 
nitrogen and immediately brought back to 37°C. Cells were washed in 10 ml PBS before 
centrifugation at 100 x g for 7 minutes at room temperature to form a pellet. Cells were 
then counted and used as required. 
2.4.3 Harvest, fixation, cryoprotection and cryosectioning of whole embryo brains 
Embryo brain tissue for immunohistochemistry (IHC) was dissected from the uterine 
membrane and the rudimental skull, before being transferred directly into 15-ml falcon 
tubes containing 4% paraformaldehyde (PFA, PCR, Cat#R/38). After one-week fixation, 
embryo brains were transferred to a 30% sucrose solution (Fisher Scientific, 
Cat#0744771) for cryoprotection. The point at which the brains had sunk to the bottom 
of the solution was when they were judged to be ready for sectioning but it is possible to 
store the brains for at least a month before sectioning. For sectioning, embryo brains were 
rinsed in PBS (Gibco, Cat#14190) before being snap-frozen onto a specimen stage that 
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was cooled on dry ice. The embryo brain was then covered in Tissue-Tek optimum cutting 
temperature compound (O.C.T.; VWR, Cat#25608-930), which solidifies when below -
10°C. Using a cryostat (Bright-OTF), 25-μm frozen coronal sections were collected 
directly onto SuperFrost slides (VWR, Cat#631-0446) and stored at -20°C. 
 
2.5 Passage of lines 
2.5.1 Neurospheres 
Tissue from embryo brains that was dissected as described above was placed in uncoated 
plastic plates in proliferation medium and placed in a 37°C incubator with 5% CO2, to 
allow NPCs to proliferate and form neurospheres. Fresh proliferation medium was added 
if the medium containing the neurospheres began to discolour. After 5-7 days, when the 
neurospheres had reached a suitable size and opaqueness for harvesting, roughly 100 m 
in diameter, all medium was transferred from the culture flask into tubes and centrifuged 
at 100 x g for 7 minutes at room temperature. The supernatant was removed and the cell 
pellet was resuspended in 1 ml accutase (Sigma, Cat#A6964) for 5-7 minutes to dissociate 
the neurospheres. The cell suspension was washed by adding 10 ml basal neurocult 
medium without supplements to the accutase cell solution and centrifuged. The 
supernatant was removed and the cell pellet was resuspended in 1 ml neurocult 
proliferation medium before cell counting. Cells were then either placed into fresh 
uncoated plastic plates in proliferation medium, at a ratio of around 1:10, to continue 
growth as neurospheres or converted into monolayers. 
2.5.2 Monolayer culture 
Cells that have been enzymatically dissociated from neurospheres or from other 
monolayer cultures can be plated onto substrate-coated plastic to encourage adherence 
and the formation of monolayer cultures. Those cells that adhere to the substrate will stay 
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attached and divide until they reach confluence and cell division is prevented by contact 
inhibition. When confluence reached 80-90%, the cells were dissociated from the plastic. 
The proliferation medium was removed and 100 μl/cm2 accutase was added to cover the 
plate for 5-7 minutes. 10 ml fresh proliferation medium was added to dilute the accutase 
before the total liquid cell suspension was removed and centrifuged at 100 x g for 7 
minutes at room temperature. Cell pellets were resuspended in 1 ml fresh media for 
quantification and replated at the required densities. 
2.5.3 Quantification of cells and amplification 
To quantify the number of cells within a culture during passaging, cell pellets were 
resuspended in 1 ml fresh medium and a 10 μl sample was taken and mixed with 90 μl 
0.4% trypan blue solution (Sigma, Cat# Sigma). 10 μl of this 100 μl counting solution 
was placed in a glass Neubauer cell counting chamber (VWR, Cat#HIRS8100103) to 
quantify the concentration of cells. The average number of cells in each of the four 
counting squares was used to estimate the total cells in the counting solution. This total 
was then scaled up by 1×105 to estimate the total cells in the cell pellet. The desired 
quantity of cells was then calculated and the required volume was diluted into new plates 
containing medium. 
2.6 Differentiation 
2.6.1 Neurocult differentiation kit 
To induce differentiation, cells were grown with the NeuroCult™ NSC differentiation 
Kit. This was either applied upon passage when cells were replated into differentiation 
medium or when the cells reached the desired confluence, when the medium was replaced 
with differentiation medium. The medium was replaced every 48-72 hours as required 
and cells were maintained in differentiation medium until the required time point. 
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2.6.2 Spiliotopoulos and colleagues protocol 
Spiliotopoulos and colleagues (2009) published an adapted version of the differentiation 
procedure, which was tried initially in this thesis to differentiate NPCs. In their protocol, 
Spiliotopoulos and colleagues adapted the medium in 3 steps to gradually lower mitogen 
levels and introduce BDNF (Source Bioscience, Cat#ABE3214; Table 2-1). Here, 
cultures were dissociated using accutase and replated at a density of 1×105/cm2 onto 
uncoated plastic plates in D1 medium (Table 2-1). Cells were left in the plates for 3 days 
with fresh medium added after 2 days. Secondly, cells that had adhered to the uncoated 
plastic during the 3 days were dissociated with accutase and collected. These cells were 
then counted, resuspended, and plated onto laminin-coated plastic at a density of 
5×104/cm2 into medium A (Table 2-1). Cultures were maintained in this media for 3 days 
and half of the medium was replaced after 48 hours. Lastly, the medium was changed to 
medium B (Table 2-1) and cultures were differentiated for the indicated time. Day 1 of 
differentiation was counted from when the differentiation medium was first applied. 
2.6.3 Adapted Spiliotopoulos and colleagues protocol 
Within this thesis, the Spiliotopoulos and colleagues protocol was adapted to meet the 
needs of NPCs created here. The first step above was altered so that cultures were 
dissociated using accutase and replated at a density of 1×105/cm2 onto laminin-coated 
plastic plates (3μg/ml) in D1 medium (Table 2-1). Cells were left in the plates for 3 days 
with fresh medium added after 2 days. The rest of the protocol was continued as above. 
2.6.4 Compound containing media 
For compound differentiation experiments, stock compound solutions were diluted 1:10 
in distilled water to a working solution, before mixing to appropriate experimental 
concentration using the adapted Spiliotopoulos and colleagues protocol and medium. 
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2.7 Fixation and Harvest 
To fix cells for histological purposes, cultures were washed with PBS (–Ca/Mg) before 
fixation in 4% PFA for 15 minutes. Cultures were then washed twice in PBS (–Ca/Mg) 
before storage in PBS at 4°C until processed. To harvest cells for analysis (genotype 
analyses, western blot), cultures were washed in PBS (–Ca/Mg) before lysis. To lyse cells, 
cultures were either removed from plates. 100μl/cm2 accutase was applied to cover the 
plate for 5-7 minutes. 10 ml fresh proliferation medium was added to dilute the accutase 
before the total liquid cell suspension was removed and centrifuged at 100 x g for 7 
minutes at room temperature. Cell pellets were washed in PBS (–Ca/Mg) before lysis 
buffer was added. The alternative approach saw cells lysed directly in the plate with lysis 
buffer after one wash with PBS (–Ca/Mg). All lysates were kept on ice until used for 
analysis. 
To harvest brain tissue, 16-week WT and R6/2 mice were anesthetised with an injection 
of 100 μl sodium pentobarbital (J.M.L, Cat#103-9130) and failure to respond to a toe and 
tail pinch was ensured. Once unresponsive, mice were transcardially perfused with PBS 
followed by perfusion with 4% PFA solution (PRC, Cat#PRC/R/38) until riga mortis had 
taken place. Whole heads were removed and stored in PFA until processed. 4-week-old 
WT and R6/2 mice were euthanised by 100 μl sodium pentobarbital. Death was confirmed 
with decapitation. Mouse heads were stored in 4% PFA at 4°C for at least 48 hours prior 
to being processed. 
2.8 DNA extraction 
To extract DNA from mouse tissue or cell pellets, samples were incubated in 100–300 µl 
lysis buffer (50 nM Tris-HCL, 100 mM EDTA, 0.5% SDS, 0.5 mg/ml Proteinase K) at 
50°C. Tissue was lysed overnight and cells were lysed for a minimum of 2 hours. Once 
lysed, 300 µl saturated NaCl solution was added to the samples and mixed thoroughly 
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before centrifugation at 1.7 x 104 x g for 30 minutes. The resulting supernatant was 
transferred into twice the volume of 100% ethanol, mixed and centrifuged at 1.7 x 104 x 
g for 15 minutes. The resulting pellet was washed in 300 µl 70% ethanol and allowed to 
dry at room temperature. The DNA pellet was then resuspended in 300 µl 0.1 x TAE and 
dissolved overnight. DNA concentration was measured using a NanoDrop (Thermo 
Scientific, Cat#1000) 
2.9 Gentotyping PCR 
After DNA extraction, R6/2 cell lines were identified by amplifying the HTT exon 1 
transgene DNA using PCR. The 10-µl reaction mixture consisted of 100 ng DNA, 1 × 
Thermo-Start master mix (Thermo Scientific, Cat#AB0908B), 1 µl DMSO, 10 ng/µl 
forward primer 33727 [5′-CGCAGGCTAGGGCTGTCAATCATGCT-3′] and 10 ng/µl 
reverse primer 32252 [5′-TCATCAGCTTTTCCAGGGTCGCCAT-3′] and DNA was 
amplified using cycling conditions of 15 min at 95°C, 35 × (30 s at 94°C; 30 s at 60°C, 
60 s at 72°C) and a final extension at 10 min at 72°C (BIO-RAD CFX96 with C1000 
Thermal cycler). The amplified R6/2 transgene product was 272 bp. 
Once amplified, the PCR products were mixed with 2 µl 6x DNA loading dye (Promega, 
Cat#G1881) and separated by electrophoresis at 125 V/cm2 for 30 min in a 1% agarose 
gel in a 1x TAE buffer (Thermo Scientific, Cat#B49). The products were visualised using 
Gel-Doc UV trans-illuminator and their size was determined against a Lambda Hind III / 
phiX Hae III Marker (BIO-RAD, Cat#161-0375) 
2.10 Protein extraction 
Cells were lysed either as washed pellets or directly in plates in ice cold RIPA buffer (150 
nM NaCl, 1% NP-40, 0.5% sodium deoxycholete, 0.1% SDS, 50 mM Tris-HCl pH8, 1 
nM 2-mercaptoethanol, 10 nM DTT, 1 mM PMSF, proteinase inhibitors [1 tablet per 50 
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ml]). Lysates were kept on ice through all subsequent processes unless stated. Lysates 
were collected and protein concentration was measured using Pierce® BCA protein assay 
kit (Thermo Scientific, Cat#23225). Serially diluted bovine serum albumin (Sigma, 
Cat#A9418) was used as a concentration standard. Samples were placed in cuvettes 
(Fisher Scientific, Cat#FB55147) and analysed with a photometer (Bio-Photometer, 
Eppendorf). Protein lysates were stored at -80°C and used within 48 hours. 
2.10.1 Quantification and loading buffers 
To analyse protein by western blotting, a 7.5-mm thick 10% resolving gel (for 2 gels: 
3.33ml Protogel® [Thermo Scientific, Cat#EC-890], 2.6 ml 4x Protogel® Resolving 
Buffer [Thermo Scientific, Cat#EC- 892], 3.96 ml distilled water, 100 L 10% 
ammonium persulfate [Fisher, Cat#A/p470/46], 10 L TEMED [Sigma, Cat#T-8133]) 
was poured and topped with butanol to level the surface and remove any bubbles. After 
the gel had set, the butanol was washed away and the surface was dried before a stacking 
gel (for 2 gels: 0.65 ml Protogel® [Thermo Scientific, Cat#EC-890], 1.25 ml 4x Protogel® 
Stacking Buffer [Thermo Scientific, Cat#EC- 894], 3.05 ml distilled water, 50 L 10% 
ammonium persulfate [Fisher, Cat#A/p470/46], 10 L TEMED [Sigma, Cat#T-8133]) 
was poured on top and a loading comb placed inside to structure the loading wells. 
The cast gels were placed inside an electrophoresis tank filled with 1X electrophoresis 
running buffer (25 mM Tris, 129 mM glycine and 0.1% SDS.). The appropriate protein 
quantity required was diluted in distilled water and 2X laemmli buffer (125 mM Tris-HCl 
pH8.8, 20% glycerol, 4% SDS, 0.01% [w/v] bromophenol blue) and denatured at 85°C 
for 10 minutes. These protein solutions were then loaded into individual running lanes 
alongside a ColorPlus Prestained Protein Marker, Broad Range, 7-175 kDa (New England 
Biolabs, Cat#P7709S) for size reference. The gel was then electrophoresed for the 
appropriate time at 150 V/cm2 (Consort E802). 
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The resolved proteins were transferred from the gels to 0.45 μm nitrocellulose membrane 
(BIO-RAD, Cat#162-0115) using wet transfer. The transfer was carried out in transfer 
buffer (15.4 g/L glycine, 3 g/L Tris, 20% methanol in dH2O) for 90 minutes. On 
completion the membranes were treated with 3% milk (non-fat dry milk powder, Marvel) 
in PBS for 60 minutes. After five washes in PBST (0.02% Tween PBS), the membranes 
were incubated in 1% milk-PBST solution containing the primary antibody at 4°C 
overnight. 
The following day, the membranes were treated with five PBST washes before a 1-hour 
incubation in the appropriate secondary antibody. After the membranes were treated with 
five more PBS washes they were ready to be developed. The membranes were developed 
using an Amersham ECLTM Western Blotting Kit (GE Lifesciences, Cat#RPN2109) and 
Amersham Hyperfilm ECLTM (GE Lifesciences, Cat#28906837). 
 
2.11 Immunohistochemistry and immunocytochemistry 
Cells for immunocytochemistry (ICC) were grown in black-walled 96-well plates with 
optical bottoms specialised for microscopy (Fisher Scientific, #10281092). Cells were 
fixed with 100 l of 4% PFA for 15 minutes. Cells were then washed three times with 
100 l PBS. Cell plates were stored in PBS until processed for staining. Slides of cut 
embryo brains were removed from frozen storage and allowed to thaw to room 
temperature. Before staining, a hydrophobic band was drawn round tissue sections using 
a wax pen (Dako, Cat#S2002). 
Cells and embryo slices were washed in 100 l PBS before a 2 hour incubation step in 
100 l blocking solution of 0.1% Triton X-100 (Sigma, Cat#X100) PBS for cells and 
0.3% Triton X-100 PBS for embryo tissue, both with 10% normal goat serum (Sigma, 
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Cat#G9023) or normal donkey serum (Sigma, Cat#D9663). Primary antibodies were 
applied at the appropriate concentration (Table 2-2) in 100 l fresh blocking solution 
overnight at +4°C. Appropriate goat or donkey secondary antibodies, matched to primary 
antibody host species and desired emittance spectrum were applied for 2 hours at room 
temperature. Secondary antibody solution was removed and Hoechst dye (Invitrogen, 
Cat#H3570) was applied in 100 l PBS for 15 mins to label cell nuclei. Cells and embryo 
slices were washed three times in 200 l PBS between all of the above steps. Cell plates 
were stored in PBS and tissue and embryo slides were coverslipped (VWR, Cat#23801-
202) using Vectorshield mounting solution (Vector, Cat#H1000). 
TUNEL staining was performed using ‘in situ cell death detection kits, fluorescein’ 
(Roche, Cat#11-684-795-910). This procedure was carried out according to the 
manufacturer’s instructions. Pre-fixed cells were permeabilized with 0.1% Triton X-100 
PBS prior to application of the TUNEL reaction mixture for 1 hour at 37°C. Samples 
were then washed three times with 100 l PBS prior to analysis with ICC. Negative 
controls were performed without terminal transferase in the TUNEL reaction mixture. 
Positive controls were performed on cells pre-treated with recombinant DNase 1 to induce 
DNA strand breakage. 
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Table 2-2. Antibodies and concentrations used. 
 
2.12 Karyotype analysis 
When cells reached 80% confluence, mitotic activity was arrested using fresh medium 
including 75 ng/ml of N-methyl-N-deacetyl-colchicine “Colcemid” (Roche, 
Cat#10295892001) for 2 hours. The cells were then washed twice with 5 ml PBS and 
removed from culture plates by incubating with accutase for 3 minutes. Detached cells 
were collected in a hypotonic solution of 3 ml of 5% fetal bovine serum (FBS, Thermo 
Scientific, Cat#10270106) in dH2O in 15 ml tubes and incubated for 20 minutes at 37°C. 
Karyotype fixative was 75% methanol (Fisher scientific, Cat# M/4000/25) and 25% 
glacial acetic acid (BDH, Cat#10001CU). The fixative was made immediately prior to 
use and 300 μl was added to the cell solution. The cells were pelleted from the hypotonic 
solution at 250 x g for 5 minutes. The supernatant was removed and the cell pellet was 
Antibody Species Dilution Supplier Catalog # Usage
Actin Mouse 1:500 SantaCruz sc-71210 ICC
Atp5b Mouse 1:30000 Abcam ab14730 WB
Doublecortin (DCX) Rabbit 1:400 Cell Signalling 4604S ICC
GFAP Rabbit 1:2000 Dako Z0334 IHC/ICC
Glutamine Synthase (GS) Mouse 1:400 Millipore MAB302a ICC
Ki67 Rabbit 1:200 Abcam ab15580 IHC/ICC
MAP2 Rabbit 1:500 Millipore AB5622 IHC/ICC
Nestin Mouse 1:200 Abcam ab81755 ICC
NeuN Rabbit 1:500 Abcam ab177487 IHC/ICC
SQSTM1 (p62) Mouse 1:500 MBL Int'l PM045 IHC/ICC
S100b Rabbit 1:100 Sigma S6677 ICC
S830 -Huntingtin (ex1/PolyQ) Sheep 1:2000 GB Lab S830 IHC/ICC/WB
Synaptophysin Rabbit 1:200 Abcam ab8049 ICC
Tubulin - Alpha Mouse 1:10000 Sigma T6074 WB
Tubulin - Beta III (TUJ1) Rabbit 1:400 Millpore MAB5564 IHC/ICC
Ubiquatin Rabbit 1:500 DAKO z0458 ICC
Vimentin Rabbit 1:1000 Abcam ab92547 ICC
ICC - Immunohistochemistry, IHC - Immunocytochemistry, WB - Western blot
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twice resuspended and pelleted using 3 ml fixative. The final cell pellet was resuspended 
in 500 μl of fixative and incubated at -20°C for at least 3 hours. 
The cell suspension was mixed by vortexing and 100 μl was dropped onto a glass slide 
(VWR, Cat# 631-0446) from a height of 1 m to ensure well separated metaphase spreads. 
Once the slides were dry they were submerged in 10% giemsa stain modified solution 
(Sigma, Cat#48900) in PBS for 5 minutes followed by five washes in 50 ml PBS. The 
slides were left to dry in air before cover-slipping with DPX (Sigma, Cat# 06522) and 
glass coverslips (VWR, Cat# 631-1575). Images of chromosomes were 15 individual 
geimsa-stained metaphase spreads captured by light microscopy and exported into TIFF 
files. The chromosomes were manually counted offline using ImageJ (Fiji) cell counting 
tool (ImageJ: http://imagej.nih.gov/ij/index.html). 
 
2.13 LD50 toxicity calculation 
The toxicity of compounds was calculated by estimating the concentration of each 
compound at which it reduced cell number by 50% (LD50). Brightfield images were 
captured at days 1, 3 and 7 of differentiation in the presence of compounds. Manual cell 
counts were carried out and compared with the no compound control in each plate. Total 
surviving cells were graphed to estimate the LD50. 
 
2.14 Imaging 
Geimsa-stained metaphase spreads for chromosome counting were captured using a Ziess 
Axioscope 2 plus with an AxioCam HRc camera. Images were saved as ZVI files using 
Ziess Axiovision software and exported as TIFF files. Bright field images of live cell 
cultures were captured using a Nikon eclipse TS100 with DS-Fi1 cameral and Nikon 
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Digital sight display. Images were saved in TIFF format and exported. Non-confocal 
widefield fluorescent images were captured using a Nikon Eclipse Ti-E Inverted Live 
Cell Imaging System and Cool SNAP HQ 2. Images were saved as ND2 files and 
processed using Nikon NIS Elements AR software. Final images were exported as TIFF 
files. Confocal microscopy was captured using a Nikon Eclipse Ni-E Upright A1 confocal 
system with DS-U3 Digital Sight Colour Camera. Images were saved as ND2 files and 
processed using Nikon NIS Elements C software. Final images were exported as TIFF 
files. Super resolution fluorescent images were captured using a Nikon Eclipse Ni-E N-
SIM Super Resolution system and Andor Ixon camera. Images were saved as ND2 files 
and processed using NIS Elements AR software with n-SIM module. Final images were 
exported as TIFF files images and AVI videos. 
2.15 Image analysis 
Individual images were captured and converted to TIFF and were analysed by counting 
by eye using image-J software offshoot Fiji (Schindelin et al., 2012). Cells whose nucleus 
touched the bottom or left hand sides of the image were excluded, while those that 
touched the top or right sides remained included. The number of cells were recorded using 
the DAPI stained nuclei before the identity of each cell was counted using the appropriate 
antibody. Each well was considered a technical replicate and each line considered a 
biological replicate. Within these replicates any outliers were identified using Grubbs test 
and excluded. These values were subsequently used to calculate a mean ± standard 
deviation for each condition from the corresponding number of experiments performed. 
The PerkinElmer Operetta High-Content Imaging System was combined with the 






Statistical analysis was performed using SPSS (IBM) software, version 22, with Student 
t-test set to 95% confidence when analysing two groups and performed as a one-way 
analysis od variance (ANOVA) test with bonferroni post-hoc test when analysing groups 






Chapter 3 Results 1: Creation of neural progenitor lines from the R6/2 
mouse model of Huntington’s disease 
3.1 Introduction 
Creation of models of HD in vitro that mimic phenotypes of the human disease is an 
important research target to develop potential treatments. Understanding of the disease at 
a cellular level is vital to dissect disease mechanisms, and to then enable a platform for 
disease modifying interventions to be tested. 
The R6/2 mouse model is one of the most widely used models of HD. R6/2 mice exhibit 
a rapid aggregation phenotype in neurons throughout their brains until their death at 
around 16 weeks of age. In theory, NPCs can be extracted from any viable mouse model 
that survives the first 2 weeks of gestation. On this basis, the work in this chapter 
attempted to create NPC lines from the R6/2 mouse model and WT litter mates. These 
populations would allow for investigation of in vivo findings using the R6/2 mouse and 
for phenotypes to be probed at a cellular level. Once established these cells needed to be 
examined for their ability to retain stable genetic characteristics and to differentiate into 
the neurons and glia, which make up the brain. 
 
3.2 Chapter aims: 
The aims of the experiments performed in this chapter were to: 
1. Establish novel NPC lines with and without the presence of mHTT, which are viable 
long term, with the potential to be differentiated from a progenitor state into mature 
functional adult cells, as found in the mature brain. 
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2. Assess how the stability of the NPC lines changes with increasing passage numbers 
with a view to investigate how mHTT affects this. 
3. Induce NPCs to exit the cell cycle by the removal of growth factors and allow them to 
differentiate into mature cells found in the adult CNS and characterise how these 
populations are affected by mHTT expression. 
 
3.3 Establishing neural progenitor cell lines. 
Maintenance of cells in the cell cycle allows them to remain in a proliferative self-
renewing state, as long as space and nutrients allow. This approach was using by Conti 
and colleagues who sustained proliferative cultures of NPCs using the mitogens, EGF 
and FGF2 (Conti et al., 2005). Despite a variety of approaches to establish NPC in vitro 
cultures, from embryo, foetal and adult sources, many lines produced showed various 
similar characteristics (Conti et al., 2005, Pollard et al., 2006, Chojnacki and Weiss, 
2008). Foetal-derived NPCs express identical histological markers of RG and neurogenic 
cells compared to those seen in NPCs derived from ESCs (Conti et al., 2005). Consistent 
profiles were also seen with mRNA using RT-PCR and by gene-chip analysis. Foetal-
derived NPCs also differentiate into glial and neuronal lineages when they exit the cell 
cycle. Therefore, they are considered to share the same properties of neural cell lines 





Figure 3-1 Harvesting of NPCs from E14.5 mouse embryos. (A) Pregnant dam was euthanized 
by cervical dislocation, 14.5 days after mating. An incision was made from ribcage along the 
medial line to allow access to uterine system. The uterus was removed and placed in a dish 
containing dissection media. Each individual embryo was removed from uterine sack and the head 
isolated for dissection. Under the microscope, the rudimental skull and meninges are cut and 
peeled away from the brain to leave the developing cortices. (B) Coronal cross sections of E14.5 
embryos were cut on a cryostat into 15 m sections, immunohistochemically stained for the 
marker of neural progenitors, nestin (green) and for the cell cycle maker Ki67 (Red). (C) Adjacent 
E14.5 cross sections stained for the differentiation makers for neurons (TUJ1, red) and for glia 
(GFAP, green). Both panels are stained for the nuclear marker DAPI (blue). (D) This technique 
allows for distinct and specific areas of the developing brain to be accessed and cells lines created 
from each region. These lines can be expanded and banked in vitro. NPCs=neural progenitor cells, 
CTX=cortex, LGE=lateral ganglionic eminence, LV=lateral ventricle, MGE=medial ganglionic 
eminence, TUJ1= beta-III-tubulin, GFAP=glial fibrillary acidic protein. Scale bars 50 m. 
87 
3.4 Generation of neural progenitor cell lines from E14.5 foetal brains 
Wildtype embryos were used to initially establish the technique to isolate foetal NPCs. 
C57BL/6TxCBA/Ca female F1 mice were bred with males and on embryonic day 14.5 
(E14.5) uteri were dissected from pregnant female mice and each embryo was isolated 
from the uterine sack (Figure 3-1A). Each embryo was dissected to reveal and isolate the 
neural tissue from the rudimental meninges and the RG-like niches were isolated (Figure 
3-1A). Reynolds and Weiss pioneered this process in 1992 (Reynolds et al., 1992) by 
using the extracted niche tissue to establish primary cell cultures. 
The areas of the developing brain containing progenitor cell populations exist as niches 
around the ventricles towards the centre of the rudimental brain (Hartfuss et al., 2001). In 
mice, the earliest time point at which the brain starts to develop distinct lineages of NPCs 
is around embryonic day 7.5 (E7.5) (Gotz and Huttner, 2005). By E14.5 the brain has 
established itself with a structure reminiscent of the adult brain with lateral ventricles, 
cortices, and a rudimental striatum (Edwards et al., 1990) (Figure 3-1B). To visualise 
these areas E14.5 embryos were harvested, sectioned, and processed for 
immunohistochemistry (Figure 3-1B). 
The niche from which cells are extracted can determine the gene expression pattern when 
these cells differentiate (Hartfuss et al., 2001, Anthony and Heintz, 2008). These separate 
niches were dissected individually to create distinct lines (Figure 3-1C). When cultured 
and matured in vitro, similar expression patterns to that seen in the corresponding adult 
brain areas could affect the fate of cells in that culture (Hartfuss et al., 2001, Anthony and 
Heintz, 2008). 
This method of directly creating NPC lines from their in vivo niche has some distinct 
advantages over other methods, such as differentiating them from ESC. Firstly, the NPCs 
have been grown in situ to the point of dissection and so avoid the extra artificial steps 
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needed to proliferate and differentiate ESCs, which can introduce unwanted variety and 
separate populations (Conti et al., 2005, Pollard et al., 2006, Conti and Cattaneo, 2010). 
Secondly, lines can be created from any available genetic cross that can survive gestation 
until E14.5. This gives the decisive advantage of producing genetically distinct lines from 
transgenic and knock-in mouse models. However, this does mean the genetic model must 
be available, and viable, to establish the cell lines in the first place. In short, allowing 
neural progenitor niche populations to be created naturally in vivo creates the best source 
of these cells we can currently access (Conti et al., 2005). 
NPCs cultured from neural progenitor niches are not necessarily a homogenous 
population. The lines are created from a pool of cells which may have already began to 
differentiate along specific linages resulting in cells that are different from their 
neighbours. This could generate variation in cultures and may mean that any cells with a 
selective advantage, such as proliferating at a higher rate, could come to dominate 
cultures at later passages. Different areas of the brain are established by distinct pools of 
RG cells, which migrate and differentiate into the mature cells of the brain (Hartfuss et 
al., 2001). After dividing, RG daughter cells migrate along the processes of their parent 
cells (Figure 3-1B) to travel to the areas where they will eventually become integrated 
into the mature brain (Figure 3-1C). 
 
3.5 Culture of cells as free-floating neurospheres or adherent monolayers 
Once cells are extracted from their niche (Figure 3-2A) they can be grown as free-floating 
neurospheres (Figure 3-2B) or adherent monolayers (Figure 3-2C). Both growth states 
can be maintained using mitogens but need to be passaged. For neurospheres, this point  
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Figure 3-2. Establishment of cell lines from embryo dissections. (A) Tissue was removed from 
the desired area of the brain, mechanically broken up with pipetting before plating straight into 
uncoated flasks. These cells can then grow as (B) neurospheres or onto substrate coated plastic to 
grow as (C) monolayers. Representative images here are from LGE dissections. Scale bars 50 
m. LGE=lateral ganglionic eminence.  
 
is when the sphere becomes too large and cells inside cease to proliferate due to lack of 
contact with mitogens and increased notch signalling (Campos, 2004). Cells towards the 
centre of the neurosphere can also become necrotic due to lack of nutrients (Xiong et al., 
2011, Moeller and Dimitrijevich, 2004). As such, larger neurospheres need to be broken 
apart; either chemically with accutase or trypsin, or mechanically, using repeated 
pipetting to produce smaller neurospheres or singular cells. Monolayer cells will keep 
dividing until they become confluent and run out of space to adhere to in the dish. Similar 
to neurospheres, this lack of space results in increased notch signalling and cells will 
begin to differentiate (Liu et al., 2010, Borghese et al., 2010). 
90 
To optimise the methods to establish NPC cultures, a comparison of the two approaches 
was performed. Cells from WT embryos were grown as both neurospheres (Figure 3-2B) 
and as primary monolayers (Figure 3-2C) directly from the dissected tissue. The rate of 
expansion of lines was quicker for neurospheres, potentially because of their ability to 
grow in 3-dimensional space rather than under the 2-dimensional constraints of 
monolayer cells. As such, the lines were initially grown as neurospheres for 5 days after 
dissection for a rapid expansion of cell number before plating down into monolayers 
(Figure 3-2D). Cell lines from this point, passage 1 (p1), were maintained as monolayers 
for ease of proliferation and differentiation. 
Uncoated cell culture plastics alone can allow for adhesion of cells but this method is 
unreliable. The degree of adherence differs between brands and culture vessel sizes and 
it is likely that cells will lift off with changes of media. A number of substrates are 
available to help cells adhere to the plastic surface such as gelatine, laminin, and poly-dl-
ornithine (PRN). 
NPC lines created from mouse foetal tissue were plated onto both PRN and laminin 
coated plastic to investigate which substrate produced the best growth conditions. Both 
substrates supported substantial adherence of monolayer cultures (Figure 3-3A,B). 
Laminin was chosen as the most suitable as the monolayer cultures grew more evenly 
(Figure 3-3A), while coating plates with PRN resulted in increased clumping of cells in 
patches (Figure 3-3B). Gelatine coated plastic generally resulted in cells growing in 
mounted clumps before detaching from the surface and floating away as neurosphere-like 
bodies within a few days. These gelatine bodies were indistinguishable from 





Figure 3-3. Establishment of cell lines from embryo dissections. Neurospheres can be broken 
up and plated onto substrate coated plastic to produce monolayer lines. Various substrates can be 
used. (A) Laminin produces the better growth conditions for monolayer cell lines, here compared 
to (B) PRN. PRN=poly-dl-ornithine. Scale bars 50 m. 
 
3.6 Initial establishment of A and B lines, from the LGE of WT and R6/2 mice 
To establish the first HD cell lines in this thesis, R6/2 male mice were bred with 
C57BL/6TxCBA/Ca female F1 mice. 14.5 days after the detection of a plug, the embryos 
were removed from the pregnant mother and dissected. The first attempts to dissect lines 
of both genotypes focused on the LGE cell population located laterally to the lateral 
ventricle (LV, Figure 3-4A). These progenitors differentiate into the cells that later 
become the neurons of the striatum (Nat and Dechant, 2011, Rubenstein et al., 1994, 




Figure 3-4. Creation of the initial cell lines from the LGE region. (A) LGE is depicted in red. 
The larger area dissected for the A lines is represented by the dotted red line.  Genotyping of (B) 
‘A’ lines and (C) ‘B’ lines. Lines with lower PCR band express the exon 1 HTT transgene. (D) 
WT monolayer lines were indistinguishable by eye from (E) R6/2 lines, in terms of morphology 
and organisation. (F) WT and (G) R6/2 genotypes remain in proliferative states in vitro expressing 
markers of neural progenitors (nestin) and the cell cycle (Ki67). LGE=lateral ganglionic eminence 
area, HTT=huntingtin, WT=wildtype. Scale bars 50 m. 
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In the experiments performed here, the A lines were generated from dissections that 
captured more tissue than just the niche (Figure 3-4, red dotted area). The technique was 
optimised after the establishment of Line A, and a more accurate niche area was dissected 
to establish line B. Tissue from each individual embryo was used to determine the 
genotype of that embryo and the resulting cell lines using PCR for HTT exon 1. 
Approximately half the embryos would be expected to have inherited the R6/2 transgene 
and the other half WT. Of the embryos used for dissections, 3/9 of A lines (Figure 3-4B) 
and 5/10 of B lines (Figure 3-4C) expressed the R6/2 transgene. Expression of the HDAC 
4 gene was used as a PCR positive as a control. The resulting cell lines were grown as 
neurospheres and converted to monolayers on laminin. These lines were passaged at least 
4 times before banked as frozen stocks, prepared for long-term storage in liquid nitrogen. 
No distinguishable differences were observed between the morphology of the WT (Figure 
3-4D) and R6/2 lines (Figure 3-4E). At p10, cells were fixed and immunoprobed with 
nestin to assess the presence of neural progenitors and Ki-67 to mark proliferative cells. 
Nuclei were also stained with DAPI. While maintained in Neurocult proliferative media 
with mitogens, most cells remained in proliferative cells and were positive for Ki67 and 
nestin (Figure 3-4F,G). Higher-powered magnification showed the Ki67 staining in the 
nucleus, where it is involved in mitosis (Scholzen and Gerdes, 2000), while nestin, an 
intermediate filament protein thought to be involved in the disassembly of vimentin to 
allow splitting during mitosis (Park et al., 2010, Chou et al., 2003), was mainly expressed 
in the cytoplasm and highlights the morphology of the cell body (Figure 3-4F,G). 
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3.7 Establishment of the D lines from the cortex, LGE, and MGE of WT and 
R6/2 mice 
After NPC lines were successfully established from foetal brains, a better understanding 
of the E14.5 brain was developed and the surgical technique in the process had become 
familiar, sub-regions of the brain were dissected from similar embryos and cultured in 
separate flasks to create matched lines of distinct progenitor populations (Figure 3-5A). 
Genotype analysis of rudimental tail tissue revealed that 4/9 embryos expressed the exon 
1 transgene and were R6/2 while the others were WT (Figure 3-5B). These ‘D lines’ were 
identified as D1-11 and subdivided as Dc (cortex), Dl (LGE) and Dm (MGE) dependent 
on the brain region from which they were derived. The D lines were banked at p4 once 
there were sufficient quantities of cells. Lines D6c, D6l, and D6m grew the most slowly 
and were excluded from later experiments leaving the D4, D5, and D7 sets of R6/2 lines. 
Three WT lines were chosen as controls. ‘C’ lines were not produced as these embryos 
were used for histological sectioning (Figure 3-1A,B).  
To test for markers of proliferation, Dl, Dl, and Dm cultures were revived from liquid 
nitrogen storage and plated on laminin, as adherent monolayer cultures. Cells were grown 
for 48 hours before being fixed and stained by ICC (Figure 3-6A). Each of the D lines 
showed markers of proliferation with nestin (green) and Ki67 (red) staining easily 





Figure 3-5. Creation of cell lines from multiple progenitor regions. (A) Cells were dissected 
from the CTX, LGE, and MGE. (B) Genotype analysis identified 7 WT and 4 R6/2 embryos from 
one pregnant female. CTX=cortex, LGE= lateral ganglionic eminence, MGE= medial ganglionic 
eminence. 
 
3.8 Expansion of lines and longitudinal characterisation at specific passages 
The number of times a cell line is passaged while in vitro could have a dramatic effect on 
the cells in the dish. For instance, there is a gradual loss of neurogenic potential in 
neurospheres over passages (Conti and Cattaneo, 2010). However, even though this has 
not been seen on monolayer cultures (Gregg and Weiss, 2003), each time cells are 
removed, and a subset are either banked or used for the next passage, could affect the 
remaining cells. To investigate the effect of passaging on these neural progenitor cell 
lines, Dc lines were banked in liquid nitrogen at p15, p30, and p40. 
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Figure 3-6. Proliferation status of multiple progenitor regions. (A) Cells were grown as 
adherent from progenitor areas for Dc, Dl, and Dm lines. All D-lines were grown as monolayers 
after an initial expansion period as neurospheres. All lines showed markers of proliferative neural 
progenitor cells with most of the cultured cells expressing nestin (green) and Ki67 (red). 
CTX=cortex, LGE= lateral ganglionic eminence, MGE= medial ganglionic eminence, Dc=D line 
from cortex, Dl= D line from LGE, Dm= D line from MGE. Scale bars 50 m.  
 
Two WT and two R6/2 Dc cell lines at p15, p30, and p40 were recovered from liquid 
nitrogen and grown for 4 days as proliferative monolayer cultures in parallel under the 
same conditions to investigate the effects of longer passage numbers. Each of the lines 
tested maintained their respective genotypes as expected (Figure 3-7A). To check 
whether a normal karyotype had been maintained, metaphase spreads were prepared and 
stained with giemsa (Figure 3-7B). The normal diploid mouse karyotype has 40 
chromosomes. The number of chromosomes in 15 cells was counted for each passage 
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number of each line. The vast majority of karyotype images (around 80%) showed a 
normal 40 chromosome count with comparable variability in all lines at all 3 passage 
numbers (Figure 3-7C). This variance was most likely due to chromosome movement or 
loss induced by the technique. Care was taken to minimize this but some chromosome 
spreads might have lost or gained a chromosome from neighbouring spreads. There was 
no evidence of chromosome instability or that chromosome instability increased with 
passage number. 
The R6/2 mouse model exhibits gametic instability, which results in an increase in the 
CAG repeat when inherited through the male line and a decrease through the female line 
(Mangiarini et al., 1996). Somatic instability also occurs in a tissue-specific and cell-
specific manner (Gonitel et al., 2008). The CAG repeat length was therefore also 
monitored in the p15, p30, and p40 R6/2 cortical cell lines. These lines were created from 
an R6/2 male mouse with 219 CAGs. The CAG repeat number of the embryos from which 
the cells were harvested was not recorded in an oversite. 
Both lines analysed showed a small increase in repeat length, which could have occurred 
through gametic instability in the sperm of the R6/2 male, with peaks of equivalent sizes 
(Figure 3-7D). Readings from the summits of the peaks showed one line decreasing from 
230 to 222 CAG while the other slightly increased from 228 to 235 and then down to 232 







Figure 3-7. Genetic characteristics of cells lines at increasing passage number. Two WT and 
two R6/2 cell lines derived from the cortex and banked at p15, p30, and p40 were revived from 
storage and grown as monolayers. (A) The genotype of each line was tested throughout passage 
expansion and expression of the appropriate transgene was maintained in the R6/2 lines. (B) 
Representative geimsa stained metaphase spreads used for karyotype analysis. (C) Number of 
chromosomes per metaphase was consistent with most cells maintaining the appropriate number 
of chromosomes (murine, 40). (D) Size of the CAG repeat analysed by PCR with fluorescent-
tagged primers and sized using an ABI3730 DNA analyser to produce traces of PCR products. 
The WT spread above shows only the red peaks from the size marker ladder while the bottom 
trace also shows a blue CAG peak against the red markers. Note: the software used for analysis 
automatically rescales the Y-axis, to the top peak so scales are equivalent. (F) Top of the peak 
was used to calculate CAG repeat length. The CAG repeat length remained fairly stable with a 
slight expansion in one line and a retraction in the other.  
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3.9 Assessment of proliferation rates in cell lines of increasing passage 
number 
To assess proliferation rates, p15, p30, and p40 cells from WT and R6/2 cortical cell lines 
were plated in equivalent densities of 1x104 cells/cm2 in multiple plates. Every 24 hours 
the cells in a plate for each line were dissociated and an estimation of the number of cells 
in that plate performed. There was a dramatic increase in proliferation rate as the passage 
number was increased particularly between p15 and p30, where there was an almost 3-
fold increase in the final cell numbers in all lines apart from WT line 1 (Figure 3-8). WT 




Figure 3-8. Growth rates of cells lines at increasing passage number. WT and R6/2 lines from 
the cortex with increasing passage numbers were grown in cohorts and harvested every 24 hours 
for cell number estimation. (A) Cell number expansion rate increased in all lines as passage 
number increased. No noticeable difference in rate was observed between lines with the exception 
of the slower growing WT line 1 at P30. WT line 1 had an equivalent proliferation rate to the 






The increase in proliferative rate levelled off after p30; at p40 all lines were similar to 
that of the increased rates seen at p30 with the proliferation rate of WT line 1 also having 
increased with respect to p15. 
These cultures are not homogenous cell populations and the initial cells dissected would 
have varied in their proliferation rates. Longer passage times will tend to favour selection 
and amplification of those cells with an increased proliferation rate as there will simply 
be more of them due to the speed with which they create daughter cells. As such this 
result is to be expected and must be taken into account when comparing results from lines 
grown from different passage numbers. 
 
3.10 Differentiation of the neural progenitor cells using Neurocult 
differentiation media 
HD is a late onset neurodegenerative disease, which affects the mature adult cells across 
the brain. Mitotic cells appear unaffected possibility due to mHTT not reaching a 
concentration threshold to affect them (Bates et al., 2015, Colby et al., 2006). As such, 
NPCs were differentiated into neurons and glia to gather meaningful insights into HD at 
a cellular level. To induce cells to exit the cell cycle and differentiate, the media culture 
was changed. To study cell differentiation, WT and R6/2 lines from the cortex were plated 
on laminin at a density of 2x104/cm2 in the commercially available Neurocult 
differentiation media without growth factors. 
The cells adhered as monolayers upon plating as they did when passaged. By 7 days of 
differentiation, noticeable differences in the cell morphology were observed by light 
microscopy. The cells looked less 3-dimensional and displayed less of the uniform shape 
typical of NPCs. Some cells had a star like shape while others were longer with processes 
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stretching out of each image (Figure 3-9). Differentiation was continued for 21 days at 
which stage the morphology of different cells was hard to distinguish using just light 
microscopy. Cells appeared to have an increased soma size and to have flattened out 
considerably (Figure 3-9). Little difference was detected between the WT and R6/2 lines. 
ICC antibody markers GFAP and TUJ1 are markers of astrocytes and neurons, 
respectively. GFAP is an intermediate filament protein expressed by CNS astrocytes in 
mammals (Eng and Ghirnikar, 1994, Sofroniew and Vinters, 2010). GFAP is thought to 
be a structural protein and therefore, antibodies against GFAP stain the soma and 
cytoskeleton of astrocytes. GFAP is also expressed in non-CNS cells such as in cells of 
rat kidneys (Apte et al., 1998) but it is widely used for the purposes of glial cell 
identification (Eng and Ghirnikar, 1994). Beta-III-tubulin or ‘TUJ1’ is a microtubule 
protein found exclusively in neurons (Lee et al., 1990, Menezes and Luskin, 1994). ICC 
for these markers was used to show that neither of these proteins were present in either 
WT or R6/2 cells while they were still proliferative. After induction of differentiation, a 
very high proportion of WT and R6/2 cells stained positively for GFAP indicating that 
they had differentiated toward the astrocyte lineage (Figure 3-10A). ICC also revealed 
that some TUJ1+ neurons were present in WT and R6/2 cultures but these were few and 
far between (Figure 3-10B). These TUJ1+ cells displayed the traditional neuronal shape 




Figure 3-9. Differentiation of NPCs using Neurocult differentiation media. The NPCs 
remained in the cell cycle as proliferative lines with growth factors in the medium. Removal of 
these growth factors and application of Neurocult differentiation media induced differentiation 
into mature neural cells. (A) Cell morphology was noticeably changed from that in the 
proliferative cultures after 7 days of differentiation (7DIV) with cells having a flatter, less 3- 
dimensional morphology and longer, thinner processes (black arrow). These changes continued 
as cells mature further (14DIV and 21DIV) with larger astrocyte-like cells becoming more 
prominent (white arrow). Plates of cells were fixed every 7 days up to 21 days post differentiation. 




Figure 3-10. Analysis of differentiated neural progenitor cells using ICC. Differentiated cells 
were fixed every 7 days up to 21 days. (A) ICC staining was applied to determine the 
differentiation fate of cells at the fixed time points using GFAP+ (green) glia, and TUJ1+ (red) 
neurons. GFAP staining was very prominent while fewer examples of (B) TUJ1+ neurons were 
seen (white arrowhead). ICC=immunocytochemistry, GFAP=glial fibrillary protein, TUJ1=beta-
III-tubulin. Scale bars 50 m. 
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To assess the number of cells that differentiate in to neurones and glia, cell counts were 
performed on cells from the rudimental cortex from three different WT and R6/2 lines. 
Four wells were analysed for each line and 15 individual images were captured at x20 
magnification at the same co-ordinates for each well using a non-biased grid system. Each 
well was considered a technical replicate and each line considered a biological replicate. 
Within these replicates any outliers were identified using Grubbs test and excluded. These 
data were pooled for the three biological replicates for each genotype. Statistical analysis 
was performed using SPSS (IBM) with Student’s t-test set to 95% confidence for 
genotype. Analysis was performed by counting by eye using image-J software offshoot 
Fiji (Schindelin et al., 2012). DAPI+ cells were counted and then identified as glial or 
neuronal based on their cytoplasmic staining. Overall, the number of R6/2 cells per image 
was higher than the number of WT cells, which was seen at all three time points 
investigated (Figure 3-11A). This effect is likely to be due to the R6/2 cells surviving the 
process of seeding in larger numbers. The levels of cells also stay constant throughout the 
differentiation time points suggesting little cell death had occurred over this period. A 
pruning process might occur during the first few days of differentiation, which could also 
account for the lower number of WT cells than R6/2 cells that survived the first 7 days of 
differentiation. The loss of NPCs upon differentiation is well documented (Conti et al., 
2005, Biella et al., 2007). 
Of the cells analysed, 80% were GFAP+ glia by day 7 (Figure 3-11B), which increased 
to 90% by day 21.  The same effect was observed for both genotypes.  The highest level 
of TUJ1+ cells was seen at 7 days, when 2% of WT cells were stained as neurons (Figure 
3-11C). Few neurons were seen throughout the continuing differentiation period. Some 
DAPI+ cells were not accounted for with either GFAP+ or TUJ1+ staining. Such cells 
were also negative for the oligodendrocyte marker, O4. 
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Figure 3-11. Cell types of differentiated cells. (A) Cell counts carried out at three time points 
up to day 28 on two WT and two R6/2 cortical lines. Both WT (black) and R6/2 (white) survived 
in large cell numbers throughout the time-points analysed. The vast majority of cells were positive 
for (B) GFAP staining while few were positive for (C) TUJ1, with those cells that were TUJ1+ 
decreasing over the longer differentiation period. ICC=immunocytochemistry, GFAP=glial 
fibrillary protein, TUJ1=beta-III-tubulin. 
 
3.11 Differentiation of neural progenitor cells using an alternative adapted 
differentiation media 
Spiliotopoulos and colleagues (2009) used an adapted protocol based on that of Conti and 
colleagues. (2005) in an attempt to improve cell viability upon differentiation and 
increase the number of cells showing a neuronal cell fate (Spiliotopoulos et al., 2009). 
This protocol involved a gradual reduction of FGF2 concentration while brain-derived 
neurotrophic factor (BDNF) was introduced and then gradually increased in 
concentration. This protocol was applied to the HD NPC lines developed in this thesis. 
The initial step of the process is to plate the cells onto uncoated plastic before detaching 
them after 3 days and re-plating the cells onto a substrate as previously described. This 
additional process was termed the neuralisation step (Table 2-1). 
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Two WT and R6/2 cell lines from the cortex were used to test this adapted protocol. All 
lines had previously been grown to p15 and banked in liquid N2 and allowed one 
complete passage after being recovered. In response to this uncoated plastic neutralisation 
step the cells initially attached but soon gathered in clumps that resembled neurospheres 
(Figure 3-12A). After 48 hours, some of the larger clumps began to detach and become 
free-floating bodies. These detached clumps were lost in the media change that was done 
at this stage. The cells that remained attached, both as single cells and as the clumps, were 
dissociated and reseeded in A-media with no EFG and a lower level of FGF-2 (Figure 
3-12B). From here, the cells remained attached as a monolayer as the media was adapted 
further to become the B media (Table 2-1, Figure 3-12B). Cells remained in the dish and 
were differentiated for up to 28 days with cohorts being fixed for ICC every 7 days 
(Figure 3-12C). As with the previous differentiation protocol using neurocult 
differentiation media, little noticeable difference was evident between WT and R6/2 cells 
using light microscopy. Both lines underwent noticeable changes to morphology as the 
cells differentiated. A large amount of debris formed over small clumps of cells (black 





Figure 3-12. Differentiation of the neural progenitor cells using an alternative adapted 
differentiation media. The differentiation protocol was adapted from that of Spiliopoulos and 
collegues (2009), who used the concept of a graduated transition from media containing growth 
factors FGF2 (and EGF) to one containing increasing amounts of BDNF. (A) Cells were passaged 
and plated onto uncoated plastic in D1 media as an initial ‘neutralisation step’ for 3 days. During 
this time, cells adhere to the plastic and begin to gather in clumps similar to neurospheres. After 
3 days, the cells were removed again and re-plated onto laminin-coated plastic with A media. The 
media used was then altered every 3 days from A-media followed by B media containing lower 
(Bs) and then the lowest (Bw) levels of growth factors. The cultures were then maintained in Bw 
media for the duration of the culture and media was half changed every 48 hours (purple bars). 
(B) The gradual reduction in growth supplement FGF2 while increasing levels of BDNF through 
4 different media compositions takes the cells from a proliferative state to differentiated and 
mature state. Green bars represent media composition changes with purple bars representing half 
media changes with the media composition appropriate for that point of the experiment. (C) At 7 
days a cohort of cells was usually fixed or removed for analysis with subsequent cohorts taken 
every 7 days. EGF=epidermal growth factor, FGF=fibroblast growth factor, BDNF=brain derived 
neurotrophic factor. Scale bars 50 m.  
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3.12 Differentiation counts using the adapted protocol 
Two WT and R6/2 cell Dc lines were differentiated for 28 days in the adapted protocol 
and cohorts fixed and stained for ICC at 7-day time-points using antibodies against GFAP 
and TUJ1. In all cell lines, there was an evident increase in the level of TUJ1+ cells 
compared with the previous differentiation attempts using the Neurocult commercial 
differentiation media protocol (Figure 3-13A). After 7 days, less TUJ1 staining was seen 
compared with the later time points which might be because a proportion of cells 
remained in an immature state, in which mature proteins for neurons remain at low levels. 
As such, analysis of cell fate was only undertaken at the time points later than 7 days. 
Analysis was performed by taking a series of images using a non-biased grid system and 
counting by eye using image-J. DAPI+ cells were counted and then identified as glial or 
neuronal on the basis of their cytoplasmic staining. In these differentiation experiments, 
cells were grown in both 24-well and 96-well plates. 
The number of cells per image was not significantly different between the WT and R6/2 
lines, nor between the 24-well and 96-well plates (Figure 3-13B,E). The total number of 
cells in the 21-day cohort was slightly reduced in all lines from 14 days but this could be 
due to random variation in the plate seeding rather than cell loss (Figure 3-13B). The 
percentage of GFAP+ cells remained around 80% in the 24-well plates throughout the 
time points studied, while it was consistently around 60% in the 96-well plates (Figure 
3-13C,F). This finding suggests that less cells differentiated to a glial fate in the smaller 
wells. Indeed, this effect was echoed in a larger percentage of cells being TUJ1+ in the 
96-well plates compared with the 24-well plates. Around 10% of cells were TUJ1+ by 14 
days in the 24-well plates, which reduced to around 5% by 28 days (Figure 3-13D). In 
the 96-well plates around 20% of cells stained positive for TUJ1 at 14 days, decreasing  
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Figure 3-13. NPC differentiation cell type counts using the Spiliopoulos and colleagues 
protocol. The differentiation fate of NPCs using the adapted protocol was analysed using ICC. 
(A) When staining using the neuronal marker, TUJ1 (green), and astrocytic marker, GFAP (red), 
the increase in number of neurons was easily noticeable by eye. To compare the effect of different 
size growth environments, cells were grown in 24-well and 96-well plates. 24-well plates: (B) 
total cells, (C) percentage of cells positive for GFAP and for (D) TUJ1. 96-well plates: (E) total 
cells, (F) percentage of cells positive for GFAP and for (G) TUJ1.  Cell numbers were counted 
from images captured using an automated grid and total cells, as well as the numbers of GFAP+ 
astrocytes and TUJ1+ neurons captured. NPCs=neural progenitor cells, 




to ~10% of cells at 28 days (Figure 3-13G). Again, no difference in TUJ+ cell numbers 
were observed between the genotypes of the cells. 
3.13 Differentiation of neural progenitor cells into mature cell types 
As neurons mature, the pattern of protein expression alters and can be used to identify the 
maturity of neurons and give an indication of their potential of becoming 
electrophysiologically active. Doublecortin (DCX) and microtubule-associated protein-2 
(MAP2) are both markers of neurons from the microtubule-associated protein family 
(Sanchez et al., 2000, Francis et al., 1999). Although DCX and MAP2 are members of 
the same family, their expression in neurons changes as they differentiate from NPCs. 
DCX is expressed early upon neuronal differentiation and has been suggested as an 
alternative marker of neurogenesis in areas of the brain where the process still takes place 
(Francis et al., 1999, Brown et al., 2003). The levels of DCX decrease as neurons mature 
and as other markers, such as TUJ1 and MAP2, begin to increase (Brown et al., 2003). 
This expression pattern, seen during neurogenesis in the developing and mature brain, 
was echoed in the neurons in vitro. To examine the maturity of cells differentiated into 
neurons in this thesis, R6/2 and WT NPCs were differentiated into neurons and stained 
for DCX and MAP2 by ICC. By 7 days, R6/2 neurons expressed DCX while only the odd 
neuron had begun to also express MAP2 (Figure 3-14A). From 14 days, fewer neurons 
expressed DCX and more neurons co-expressed DCX with MAP2 (Figure 3-14B). By 21 
days the vast majority of remaining DCX-positive cells also expressed MAP2. Some 
MAP2+ cells were present that expressed only very low levels of DCX, suggesting these 
cells had matured further (Figure 3-14C). By 28 days, the few DCX+ cells left co-








Figure 3-14. Mature R6/2 NPCs. Differentiated NPCs express different markers 
as they mature. R6/2 NPCs were differentiated into neurons for varying lengths of 
time and stained by ICC for DCX, MAP2, and synaptophysin. (A) At 7-days 
multiple cells expressed the early immature marker of neurons, DCX, (green), 
while only a few expressed the marker MAP2 (red) considered to be expressed in 
more mature neurons. (B) As cells were cultured for a longer period more cells 
expressed MAP2 while numbers of DCX alone cells begun to decrease, which 
continued to (C) 21 days. (D) By 28 days, almost all DCX signal was co-localised 
with that of MAP2 and remaining neurons exhibited a mature neuron shape with 
processes that resemble classical dendrites and axons. (E) Synapse formation, 
visualised with the synaptophysin antibody, represents evidence of 
neurotransmission potential between neurite branches. Synaptophysin (green) is 
present where TUJ1 positive neuronal branches meet and interact. (F) Orthogonal 
views through the Z stack shows synapse formation taking place on both sides of 
the neuronal process. WT cells showed similar phenotypes. NPC=neural 
progenitor cells, DCX=doublecortin, MAP2=microtubule-associated protein. 






Although cells might have the morphology and express neuronal-associated proteins, the 
true measure of a mature neuron is its ability to communicate with the other neurons and 
to form neural networks. This communication takes place at synapses, which are located 
along the dendrites of neurons and on dendritic spines (Gray, 1959, Ballesteros-Yanez et 
al., 2006). Synaptophysin is a protein found at the synapse and involved in the mechanism 
vesicles use in neurotransmitter storage and release (Wiedenmann et al., 1986). To assess 
the neurons found in the cultures differentiated for up to 28 days, cells were stained using 
ICC with antibodies against MAP2 and synaptophysin. In both 24-well and 96 wells 
plates the presence of synaptophysin was abundant on the mature MAP2 and TUJ1+ 
neurons (Figure 3-14E). Punctate intensities of synaptophysin staining were present along 
the dendritic processes, suggesting synaptic expression (Calakos and Scheller, 1994, 
Kwon and Chapman, 2011). These intensities of staining are junctions where other large 
dendritic branches from neighbouring neurons cross. Using stacked images though the Z-
plane, an orthogonal view of these synaptic interaction zones was visualised (Figure 3-
14F). At these junctions the synaptophysin staining is present between the two dendritic 
processes as a marker of where neurotransmission takes place (Figure 3-14F). These data 
suggest the neurons identified in the differentiated cultures have the potential for 
neurotransmitter release and that rudimental neural networks have the potential to form. 
 
3.14 Chapter discussion 
3.14.1 Existing HD cell models 
Despite concerted efforts to model HD in vitro, few reliable cell models exist that 
replicate measurable HD-like phenotypes. HD cell lines have long been rather limited to 
immortalised artificial lines but with the advent of iPSCs and gene editing technology 
there are new possibilities in the application of cell lines to advance HD research. These 
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lines have the potential to replace many existing cell lines used to model HD; however, 
they are unlikely to replace the need for animal models which have been vital for the 
identification of HD-like phenotypes and study of the onset and development. However, 
some of these system-wide findings have been hard to interrogate further at the cellular 
level without time-consuming techniques, such as breeding new lines and dissecting the 
underlying disease mechanisms. Creation of cell lines from foetal HD mouse models 
complements the work done in vivo using animal models and allows measurable, and 
relatable phenotypes to be translated in vitro for dissection in more user manageable 
settings. 
Groups who have created cell lines from R6/2 mice have not observed the same results 
in aggregation pattern expression as observed in this thesis. Chu-LaGraff and colleagues 
used neonatal p1–p4 R6/2 mice to establish primary cell cultures that they grew and 
passaged as neurospheres before differentiating for 2 weeks (Chu-LaGraff et al., 2001). 
The authors presented examples of cells stained with an HTT amino-terminal specific 
antibody, which had speckled nuclear staining throughout the cytoplasm and nucleus. 
This aggregation phenotype observed by Chu-LaGraff and colleagues were less robust 
than those seen in the cells developed in this thesis. The staining pattern is they observed 
was more reminiscent of the diffuse stain that was initially seen in this thesis, before the 
protocol was adapted to facilitate the detection of the aggregation phenotype. The range 
and reliability of HTT antibodies used to observe aggregation have improved since this 
work was published in 2001, and so it is hard to compare the aggregation profile detected. 
Chu-LaGraff and colleagues only differentiated cells for 14 days, which was the lower 
time limit needed for aggregation to become visible in the cells described in this thesis. 
Other groups have produced cell lines which exhibit an aggregation phenotype but these 
have been produced via transfection of polyQ constructs into immortalised cells rather 
than from mouse models. Aggregation is present in HD mouse models and can be 
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synthetically created in the test tube (Ehrnhoefer et al., 2006, Heiser et al., 2002), or with 
primary cells from HD mouse models (Hackam et al., 1998) but creating cell lines to 
replicate these phenotypes without immortalisation has been less successful.  
The NPCs in this thesis were differentiated into neurons and glia from radial glia cells 
that were extracted from the foetal brain, which have been allowed to develop in situ for 
the first 14 days of development. This extra time in vivo might allow the cells to develop 
the potential for phenotypes, such as aggregation, observed in the adult mouse, that are 
not observed in neurons created from embryonic stem cells in vitro (Verlinsky et al., 
2005, Conforti et al., 2013, Trettel et al., 2000). The results presented here suggest the 
R6/2 NPCs lines which exhibit aggregation could be one of the most useful in vitro 
models to study the aggregation of HTT. 
3.14.2 Regional specific dissection of lines 
To develop the cell lines in this thesis, cells were extracted from distinct regions of the 
developing mouse brain that would go on to produce different cell populations in the adult 
brain. Only two of these cell populations were examined in detail: the lines from the 
cortex and LGE. Both of these lines produced cell populations that were affected in the 
R6/2 mouse model and would translate to cell populations that degenerate in human HD 
patients. The cells from the MGE that were established as lines but not investigated 
beyond ascertaining they were Nestin/Ki-67+ progenitor cells. These cells would produce 
an interneuron population in the brain. Although these cells were not further characterised 
they could be a valuable resource to examine in the future to investigate the effect of the 
HD mutation in the interneuron population. No analysis of regional specification was 
carried out on these lines to assess whether region-specific traits were retained. It was not 
considered to be initially important to investigate this unless differences between cells 
from different progenitor regions were found.  
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Groups who have taken a similar foetal cell approach to establish HD lines have extracted 
whole brain populations for culture with cells from all regions cultured together. Ritch 
and colleagues (2012) created NPC lines using foetal knock-in HdhQ140 mice in a 
manner very similar to the approach used in this thesis, maintaining the cells as mitotic 
using growth factors EGF/FGF2 and differentiating them in the presence of an increasing 
BDNF gradient (Ritch et al., 2012). Using these lines, the authors found reduced BDNF 
expression pathways and cholesterol levels within the cells after differentiation. They also 
found that the foetal NPCs has a much lower neuronal differentiation potential compared 
to the work of Spiliotopoulos and colleagues (2009), much like that observed in this 
thesis. Although these cell lines are similar to the cultures analysed here, in that regional 
traits are probably unimportant for most of the questions we might want to answer, an 
advantage of the cell lines developed in this thesis is that the source of the cells in the 
dish is known and was carefully controlled. This regional source information will allow 
potential future experiments that involve regional-specific traits to be investigated, if 
required.  
To further characterise the cultures from different dissected areas the expression of 
markers from these regions could be analysed. This could be achieved by either assessing 
these markers at the RNA or protein level using PCR or ICC. The use of transcriptome 
analysis to assess when and where genes are expressed is of crucial importance to 
understanding and predicting the physiological role of genes and proteins (Diez-Roux et 
al., 2011). Applying findings of these analyses to maps of the embryo help relate them to 
regional development. Using such atlases and applying the relevent genes and proteins to 
analysis on in vitro cell culture can help assess how much regions specific genetic 
expression is maintained in the dish. Examples in this thesis would be to assess if levels 
of protein and RNA are expressed in LGE and CTX lines and retained over multiple 
passages and differentiaton.  
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3.14.3 Monolayer cultures over neurospheres 
The cultures established here were initially grown as primary free-floating neurospheres 
before dissociation and expansion as adherent monolayers. Maintenance of cultures as a 
monolayer provided distinct advantages over further expansions of the population as 
neurospheres. Neurospheres have a reduced neurogenic potential after longer culture 
periods, whereas in monolayer cultures neurogenic potential is maintained (Bibel et al., 
2007, Conti and Cattaneo, 2010). There is evidence to suggest that although population 
expansion is quicker when growing cultures as neurospheres, the cells produced from 
monolayers cultures are less prone to spontaneous differentiation and cell death (Conti 
and Cattaneo, 2010). Monolayer cultures have the distinct advantage of being applicable 
to high content screening, which uses automated microscopy and requires a single layer 
of cells at a relatively consistence depth to maintain and limit variability in the focus plane 
(Danovi et al., 2012). The use of monolayer cultures in this thesis enabled the use of the 
Operetta and a platform to screen the effects of novel compounds on the R6/2 HD 
phenotypes.  
 
3.14.4 Differentiating neural progenitor cells into mature neurons and glia. 
HD-like phenotypes, such as inclusion formation and CAG repeat instability, observed in 
the human disease and mouse models are mainly found in post-mitotic neurons (Gonitel 
et al., 2008). It is not known if this is because the concentration of mHTT fails to reach 
the threshold needed to trigger pathological events, because the pool of mHTT is reduced 
with each mitotic event, or if it is because of another protective mechanism (Bates et al., 
2015). As such, to study these phenotypes in culture it was necessary to arrest mitosis and 
induce the cultures to differentiate. The protocol used to differentiate cells was adapted 
throughout the thesis and eventually was based on the removal of growth factors and 
alteration of base medium to produced cultures of mixed glia and neurons. The resulting 
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cultures were mostly compromised of GFAP+ astrocytes with roughly 10% of cells being 
neurons. The neural percentage was much lower than previously reported in the papers 
that the protocols were adapted from, in which cultures contained up to 80% neurons 
(Spiliotopoulos et al., 2009). The cells used in the Spiliotopoulos and colleagues protocol 
were NSCs that had been derived and differentiated from ESCs, so differ from those used 
in this thesis. This could explain the difference in the percentage of neuronal cells 
observed here and with those obtained by other labs using foetal derived NPCs (Ritch et 
al., 2012). The lower neuronal number was not a problem within this thesis, however it 
could be a limiting factor for techniques that might be applied in the future. Techniques 
such as electrophysiology require a large number of neurons in culture, as patch-clamping 
has to be performed by eye and without fluorescent markers for selection, therefore the 
neuronal density determines how easy it is to establish connections and gather data.  
A population of cells also were negative for markers of neuronal and glial fate. The 
identify of these cells remains a mystery although they seem to correlate with those cells 
discussed in the following chapters which contain aggregation. It is possible these cells 
maybe other cell types such as Neuroepithelial cells, which would be the precursor cells 
to the presumed radial glial population maintained as NSCs. These cells have the potential 
to differentiate into other non-neural cell types which could be present in cultures. A 
further characterisation of the cells that are present before and after differentiation of 
NPCs would help to identify these cells.  
Although the use of immunofluorescence has revealed the presence of synaptic markers, 
observation of electrophysiological parameters would be required to assess neuronal 
functionality. For example, iPSC neurons that show a similar expression profile for neural 
ICC markers have shown high states of functional immaturity (Belinsky et al., 2011). 
Groups using similar techniques to culture NSCs have shown that differentiated neurons 
can be electrophysiologically active in the dish (Hogg et al., 2004, Song et al., 2002, 
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Spiliotopoulos et al., 2009). Electrophysiological properties of neurons are central to their 
function yet the development of these properties in the cultures used here remains 
unknown.  
The differentiation protocol used in this thesis, adapted from that of Spiliotopoulos and 
colleagues (2009) used the gradual addition of BDNF to cultures. BDNF was introduced 
and gradually increased over the differentiation period to help improve neuronal survival. 
Disruption of BDNF transcription, trafficking and signalling has been observed in HD 
(Zuccato and Cattaneo, 2007) and overexpression of the Bdnf transgene in the R6/1 mouse 
model can reverse some phenotypes such as weight loss and the mice exhibit an improved 
motor function (Gharami et al., 2008).  
Whether BDNF was also disrupted in the R6/2 NPC cells was not investigated but would 
be of interest to follow up. To achieve this, BDNF supplementation in the medium would 
need to be controlled to check for the BDNF baseline levels in the cells. However, 
removal of BDNF from culture medium could challenge cell survival and those cells with 
reduced BDNF expression could be lost before a quantitative analysis could be 
performed. The experiment could therefore be performed at the early differentiation 
phase, after removal of EGF and with low levels FGF before and after BDNF is first 
introduced into the media. The BDNF pathway involves BDNF binding to the TrkB 
(Tropomyosin receptor kinase B) receptor and activation of first PI (Phosphoinositide) 3-
kinase and then PDK1 (3-phosphoinositide dependent protein kinase-1), which 
phosphorylates the pro-survival effector molecule AKT (Zuccato and Cattaneo, 2007). 
As well as levels of BDNF, the downstream pro-survival effector molecule AKT could 
be analysed to assess whether survival factors are affected within these cultures.  
In the mouse brain neither BDNF mRNA nor BDNF protein are present in neuronal cell 
bodies of the striatum, but rather as in puncta in the neuropil. Conversely, the cortex, of 
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BDNF mRNA is easily detected in neurons of cortical layers responsible for projecting 
to the striatum (Altar et al., 1997). It is from these neurons which the punctate BDNF 
found in the striatum is supplied. On the basis of these observations one would expect 
variation in how NPC cultures, derived from different areas of the brain, would express 
BDNF and its downstream molecules. These regional differences would be interesting to 
explore. 
3.15 Summary 
Establishment of a new NPC line to investigate HD is of high importance. The aim of this 
chapter was to create stable NPC lines from three district regions of the brains of WT and 
R6/2 foetal mice, which can be maintained in vitro and manipulated to differentiate into 
mature neural cells. Cell lines were established from E14.5 foetal mouse brains and 
cultured in vitro to remain in the cell cycle. These cells retained a stable karyotype 
throughout a series of passages and extended time in cultures. R6/2 lines showed little 
variation in their CAG repeat length over time. Cultures were induced to exit mitosis by 
removal of growth factors. Cells differentiated into neuronal and glial cells after adaption 
of the differentiation protocol with gradual addition of BDNF. Markers of synaptic 
activity were detected on the dendritic branches of neurons suggesting the potential for 
neurotransmission and the formation of rudimental neural networks. These cell lines are 
an ideal culture system to probe for HD-like phenotypes and to complement findings in 







Chapter 4  Results 2: Characterising phenotypes present in cell lines 
created from the R6/2 mouse model of Huntington’s disease 
4.1 Introduction 
The clinical effects of mutations in the HTT gene manifest in a series of complex changes 
to behaviour, cognition, and personality. How these changes relate back to the 
lengthening of the polyQ within the gene is not well understood. At a cellular level, 
mHTT results in cellular aggregates. These aggregates gather as inclusions within the 
cell. Inclusion formation of aggregates is a hallmark of HD at the cellular level. The R6/2 
mouse model exhibits a detectable aggregation phenotype in neural cells soon after birth. 
This aggregation increases progressively in both the number of affected cells and quantity 
of aggregated protein throughout the 16-week R6/2 mouse lifespan. The link between cell 
dysfunction and the progressive aggregation of mHTT is still not fully understood and 
difficult to study in vivo. The R6/2 NPC cultures established in the previous chapter are 
potentially a usual model to examine the disease mechanism as they are essentially the 
cells which would eventually form the R6/2 mouse brain. On that basis, the WT and R6/2 
NPC cultures established in the last chapter were differentiated and probed for HD-like 
phenotypes using immunohistochemical analysis of mHTT expression and microscopic 
techniques to visualise the aggregation. 
4.2 Chapter aims: 
The aims of the experiments performed in this chapter were to: 
1. Establish whether differentiated R6/2 NPCs develop HD-related phenotypes 
representative of those found in the brains of HD patients and HD mouse models. 
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2. Investigate how these phenotypes appear to develop in the R6/2 NPC model. 
4.3 Huntingtin aggregation in the brains of adult R6/2 mice. 
The development of HD mouse models with HD-related phenotypes has been vital in the 
study of disease progression and mechanisms. The R6/2 mouse exhibits a rapid onset of 
HD-like symptoms. HD is a late-onset neurodegenerative disease, yet the R6/2 mouse 
typically reaches its equivalent human endpoint around 16 weeks of age. At this point, 
the mouse exhibits profound behavioural (Carter et al., 1999) and cognitive (Lione et al., 
1999) problems, as well as severe atrophy to muscles, and weight loss (Mangiarini et al., 
1996, Davies et al., 1997, Rattray et al., 2013). HTT aggregates also appear early within 
the R6/2 mouse brain, before the onset of many other phenotypes (Davies et al., 1997). 
To visualise deposition of the aggregated form of the mutated huntingtin protein (mHTT), 
16-week-old R6/2 mouse brain sections were examined by immunohistochemistry (IHC) 
using the polyclonal sheep antibody ‘S830’. The S830 antibody was raised against exon 
1 of HTT with 53 glutamines (Sathasivam et al., 2013) and was developed in this lab. The 
antibody is now used throughout the field to label the polyQ expansion of the mHTT 
(Refs). Multiple antibodies have been developed both commercially as well as within 
individual laboratories. Each antibody corresponds to different epitopes along the mHTT 
protein and can be selected based on the structural conformer of mHTT being 
investigated. Within the R6/2 mouse, the highly expanded PolyQ is thought to allow for 
robust staining using the S830 antibody. The sections were also stained with an antibody 
against MAP2 to identify neurons. S830+ mHTT (green) inclusions were mostly but not 
exclusively found in neurons, as shown by co-localisation with MAP2 (Figure 4-1). 
S830+ mHTT inclusions were abundant in the cortex (CTX) and striatum (STR), but were 




Figure 4-1 Huntingtin aggregation in the brains of R6/2 mice. mHTT inclusions in the R6/2 
mouse brain can be visualised using the S830 antibody (green) and visualised in neurons using 
MAP2 (red). (A) Macroscopic and (B) further higher powered microscopic views of a slice taken 
around bregma 1.10mm containing both cortex and striatum, which have widespread S830 
staining, separated by the CC which contains little to none S830+ nuclei. (C) Similarly 
macroscopic and (D) more microscopic views of the more caudal hippocampal region around 
bregma -2.30mm. (E) The neuronal nuclei rich DG and (F) CA1 structures show intense S830 
staining with particular large intensities in the neurons projecting from the CA1. mHTT=mutant 
huntingtin, CTX=cortex, STR=striatum, LV=lateral ventricle, CC=corpus callosum, DG=dentate 
gyrus, CA1,CA3=cornus ammonis regions 1 and 3. Scale bars 50 m 
 
Because of the apparent predilection for mHTT inclusions in neurons, the hippocampus, 
which contains highly dense neurons, is a useful region of the brain to monitor 
aggregation. The dentate gyrus (DG) and cornus ammonis (CA) hippocampal regions are 
neural dense structures where adult neurogenesis has been shown to take place (Eriksson 
et al., 1998). Similarly to the striatum and cortex, show high levels of S830+ mHTT 
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aggregates present in the DG (Figure 4-1C) and CA (Figure 4-1D) at the end stage of the 
disease. At high power magnification, it was evident that S830+ inclusions were present 
in the nuclei of neurons in the DG (Figure 4-1E). These inclusions were also seen in the 
CA regions, where the MAP2+ neurons were evident projecting out from the nuclear 
layer, each with an S830+ inclusion in the nucleus (Figure 4-1F). These data were 
collected to guide the use of the S830 antibody to identify aggregated inclusions in 
affected R6/2 cells. Understanding the potential expression of the mHTT protein is 
important to identify similar expression in vitro. 
 
4.4 Huntingtin aggregation in the brains of 4-week-old R6/2 mice 
The use of traditional wide-field optical microscopy has been useful when combined with 
the ability to label proteins through antibodies tagged with fluorescence, however this 
type of microscopy does have certain limitations. Secondary or X-ray fluorescence can 
be emitted from samples, which limits the resolution of the features of interest. Out of 
focus light is also a problem, especially when sections are thicker than about 2 µm. These 
problems can be nullified by the use of ‘laser scanning confocal microscopy’ (hereon just 
referred to as confocal microscopy). With this technique, a spatial pinhole eliminates out 
of focus light to produce optical slices within a thick object and increases both resolution 
and contrast. The sample is also not bathed in light as with wide-field microscopy, rather 
lasers scan across the specimen at the point of focus, which lowers the level of 
fluorescence bleaching at the same time as only exciting fluorescence within that optical 
slice. 
The quantity and size of detectable mHTT inclusions increases with age in R6/2 mice. 
Many studies have shown the presence of inclusions in R6/2 mice between 3-4 weeks of 
age (Davies et al., 1997, Morton et al., 2000, Li et al., 1999b, Meade et al., 2002) while 
125 
others have shown they can be detected even earlier, in p1 neonates (Stack et al., 2005) 
although at low concentrations. The presentation and onset of HD-like phenotypes in 
R6/2 mice can vary depending on the length of the expanded CAG repeat (Morton et al., 
2009). The R6/2 mice used here have repeats lengths of around 220, and so have a 
comparable repeat length consistent with many previous studies from this lab. To 
investigate whether younger mice have detectable levels of mHTT inclusions, 4-week-
old R6/2 mouse brains were fixed and sectioned while frozen into 25-µm coronal sections 
using a cryostat. Confocal microscopy was used to assess the presence of mHTT 
inclusions stained using the S830 antibody alongside an antibody against TUJ1 to identify 
neurons. The age of the cells within these sections would represent those in the 28-day-
old differentiated cultures described in Chapter 3. As positive and negative controls for 
the staining of mHTT+ inclusions, 16-week-old R6/2 end-stage mice and WT mice 
sections were also used. 
The optical sectioning and resolution of the confocal microscope allows for identification 
of individual cells within dense areas of neurons, which is particularly useful for studying 
the neuronal nuclei of the hippocampus, and in particular the dense neuronal cell bodies 
of the DG. This density makes it an ideal region to investigate the presence of detectable 
mHTT inclusions. In R6/2 end-stage mice, S830+ neurons are detectable in the DG of the 
hippocampus (Figure 4-2A) while these were absent from sections from WT littermates 
(Figure 4-2B). 
In the 4-week-old R6/2 mouse sections both nuclear and extra-nuclear S830+ inclusions 
were detected using IHC (Figure 4-2C). At the resolution and magnification used, 
inclusions were detected at a relatively low frequency (arrows). The inclusions appeared 
smaller than those detected in the end stage R6/2 mouse sections. The S830+ stained 
nuclei often appeared to contain multiple individual inclusions, although multiple optical 
slices through the Z-plane would be needed to confirm this. Because inclusions were 
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successfully identified in the 4-week R6/2 mouse brain using IHC, if the same process 
takes place in vitro, it would be expected that inclusions should be detectable in 
differentiated NPCs. 
 
Figure 4-2. Huntingtin inclusions in the brains of 4-week-old R6/2 mice. The R6/2 mouse 
exhibits a detectable aggregation phenotype from an early age. (A) S830+ positive mHTT 
inclusions are evident in end-stage R6/2 tissue hippocampal sections but absent in (B) their WT 
littermates. (C) Presence of S830 staining in 4-week-old R6/2 mouse sections showed mHTT 
aggregation as inclusions by this time-point. Both cytoplasmic (short arrows) and nuclear 
inclusions (longer arrows) were observed. mHTT=mutant huntingtin, WT=wildtype, TUJ1=beta-
III-tubulin. Scale bars 50 m 
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4.5 Assessment of aggregation in differentiated neural progenitor cells 
To assess whether aggregation of HTT was taking place in vitro, R6/2 and WT Dc lines 
were differentiated using the modified Spiliotopoulos and colleagues (2009) method 
developed in Chapter 3. p15 Dc cells were differentiated for 28 days with cohorts 
harvested and fixed every 7 days. Differentiated cells were immunostained using ICC 
with the anti-exon1 mHTT antibody S830 and neuronal marker MAP2 (Figure 4-3). A 
diffuse cytoplasmic staining was apparent throughout most cells in both WT and R6/2 
lines. The most pronounced S830 staining was observed at the earliest time point studied 
(Figure 4-3A) at 7 days. This diffuse cytoplasmic staining remained throughout the 
differentiation period but was less evident as the cells matured from 14 days (Figure 
4-3B). 
The strongest staining was presumed to be in non-neuronal cells as it mostly appeared in 
cells that did not stain with the neuronal marker MAP2. However, some MAP2+ neurons 
did co-localise with S830 staining. Little change to the staining profile was observed at 
the later time points. S830 staining was still mostly cytoplasmic in both WT and R6/2 cell 
lines. However, in one R6/2 line at 21 days, the intensity of S830 staining had increased 
in the nucleus of a R6/2 mature MAP2+ neuron (Figure 4-3C). This finding was not 




Figure 4-3. Assessment of aggregation in differentiated NPCs. Aggregation of mHTT in cells 
of the CNS is a hallmark of HD and is present in many models of the disease. ICC staining using 
S830 in differentiated cells can determine whether this neuropathological phenotype occurred in 
vitro. (A) NPCs were grown in differentiation media on uncoated plates for 3 days and then 
switched to laminin-coated plates for further differentiation. At 7 days, cells were stained for 
MAP2 to identify neurons, (red) and for S830 to identify mHTT (green). (B) After 14 days and 
(C) 21 days of differentiation, a distinct haziness around cell nuclei in both WT and R6/2 cell 
lines was present, with a higher degree of staining around MAP2- cells. (D) At 28 days, the hazy 
S830 staining was still present and mostly in the cytoplasm with little staining co-localised with 
DAPI+ nuclei. A marked difference was not observed between the WT and R6/2 lines. 
NPCs=neural progenitor cells, CNS=central nervous system, HD=Huntington’s disease, 
ICC=immunocytochemistry, MAP2=microtubule-associated protein 2, WT=wildtype. Scale bars 
50 m. 
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Classically, aggregation is detected in inclusions, as shown previously here in vivo 
(Figure 4-1, Figure 4-2). The staining profile exhibited in these cells does not represent 
what would be expected from mHTT aggregation and indeed is present in equal quantities 
in both WT and R6/2 cell lines. It is unlikely that this staining is the endogenous WT 
mouse HTT because S830 does not recognise endogenous mouse HTT (Landles et al., 
2010). These data suggest that S830 cross reacts with a cytoplasmic protein other than 
HTT. S830 is a polyclonal antibody for which the epitopes have not been mapped and 
any proteins with which it cross reacts are unknown. 
 
4.6 Adjustment of the differentiation media and the effect on aggregation 
The neuralisation step that Spiliotopoulos and colleagues developed was designed to 
increase the neuronal content of their cultures (Spiliotopoulos et al., 2009). The 
Spiliotopoulos method converts ESCs to NPCs to neurons; in their method, proliferative 
cells were plated without a substrate, and the differentiation protocol that followed also 
did not use substrates for the first differentiation step (Table 4-1 – Spiliotopoulos 
original). By contrast, in the protocol developed in this thesis, proliferative cells were 
grown on a substrate of laminin. The neuralisation step in the improved differentiation 
protocol that was presented in Chapter 3 involved a switch from laminin-coated plates to 
uncoated plates and then back to laminin-coated plates (Table 4-1 - NPCs). To investigate 
whether this switching step was a necessary adaption to the protocol, the differentiation 
experiment was repeated as previously performed, but without the switch to uncoated 
plates (Table 4-1 – adapted protocol). This adaptation allowed cells to be directly 
switched between proliferative and differentiation protocols without the extra disruption 
of removal from the plates during the neuralisation step. It also allowed a higher number 
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of cells to be used for differentiation because cells are lost during neuralisation if they do 
not remain adhered to the uncoated plastic. 
 
Table 4-1 Substrates used for adherence in the Spiliotopoulos and colleagues protocol 
adaption in this thesis. 
 
This adapted method without the switch to uncoated plates was followed and the same 
differentiation and ICC staining was performed as described above to identify S830+ 
mHTT aggregation and MAP2+ neurons. 
At day 7 and day 14 of differentiation, diffuse cytoplasmic staining was observed in cells 
differentiated on laminin similar to with those that were switched to uncoated plates. This 
staining pattern was observed for both WT and R6/2 lines (Figure 4-4A, B). At 21 days, 
a distinct change in the S830 staining prolife was observed. In the WT lines, the diffuse 
cytoplasmic staining pattern remained; by contrast, in R6/2 lines, intense S830+ 
inclusions appeared in the nuclei of some cells (Figure 4-4C arrows). These inclusions 
appeared similar to those seen in the brain of the R6/2 mouse (Figure 4-2C). The 
inclusions were seen at both 21 days and later at 28 days in the R6/2 lines (Figure 4-4C,D 
arrows) in a small number of cells per region of interest. The cells that contained nuclei 
with inclusions did not appear to co-localise with MAP2+ staining. On the basis of these 
results, all subsequent experiments were performed using laminin-coated plates 
throughout the differentiation process. 
Self-renewal D1 A B
Spiliotopoulos 
et al - Original
– –
Laminin            
(3 g/mL)
Laminin            
(3 g/mL)
Spiliotopoulos 
et al - NPCs
Laminin            
(3 g/mL) –
Laminin            
(3 g/mL)




Laminin            
(3 g/mL)
Laminin            
(3 g/mL)
Laminin            
(3 g/mL)








Figure 4-4. Adjustment of substrate coating and the effect on S830 staining. Adaption of the 
Spiliotopoulos and collegues protocol with removal of the uncoated plastic step to the use of a 
consistent laminin monolayer. (A) NPCs were grown for 7 days and (B) 14 days in differentiation 
media on laminin-coated plates and stained with S830 to identify mHTT (green) and MAP2 to 
identify neurons (red). (C) After 21 days of differentiation, S830+ inclusions were present in the 
nuclei of some cells (arrows). No inclusions were present in the WT cells. (D) At 28 days, S830 
inclusions were present in the nuclei of some R6/2 cells (arrows) and absent from WT cells. 
NPCs=neural progenitor cells, mHTT=mutant huntingtin, MAP2=microtubule-associated protein 
2, WT=wildtype. Scale bars 50 m. 
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4.7 Identification of the location of the aggregation signal. 
The mechanism by which mHTT aggregates and forms inclusions in specific locations is 
important for the assessment of their role as part of the HD disease mechanism. mHTT 
inclusions exist both in the nucleus and cytoplasm of cells in the brains of HD patient and 
mouse models (DiFiglia et al., 1997, Davies et al., 1997). Inclusions present in the 
cytoplasm can be cleared by autophagy (Martin et al., 2015), a process that does not occur 
in the nucleus (Martin et al., 2015, Kaushik et al., 2010). 
Images taken of inclusions found in R6/2 cell lines (Figure 4-4) suggest that inclusions 
were mainly nuclear. To confirm this hypothesis, confocal microscopy can be used. Thus, 
to investigate whether the inclusions were intra-nuclear, a stack of images from R6/2 cells 
was taken through the Z plane to produce a 3-dimensional image (Figure 4-5A). An 
orthogonal view shows the profile of a cell though the dotted lines below (Figure 4-5B) 
and to the side of the image (Figure 4-5C). The large bright S830 inclusions were located 
inside the nucleus. Such inclusions account for 4% of the nucleus by volume and appear 
as single continuous objects at the resolution used. Two large inclusions could be seen 




Figure 4-5. Identification of the location of the aggregation signal within an R6/2 cell.  A 
series of images were taken through the Z-plane to form a stack and allowed a 3-dimentional 
representation to be constructed. (A) A single DAPI stained (blue) nucleus with inclusions stained 
with S830 (green). Dashed white lines represent intersection of orthogonal slices though the stack 
of images with the nucleus of interest marked with a white arrow. (B) Panel represents profile of 
staining marked by vertical dashed line and (C) through the horizontal dashed line. Nucleus with 
inclusions marked with white arrow. Green S830+ inclusion evident throughout the nucleus and 




4.8 Assessment of mHTT using western blot analysis 
Western blotting can be used to quantify protein levels and as an alternative approach to 
detect detergent insoluble protein aggregation. To assess whether a mHTT aggregation 
signal could be detected using western blot analysis, whole cultures from 75cm2 plates 
were lysed for protein extraction. Lysates from R6/2 and WT Dc cells after 28 days of 
differentiation were produced and proteins separated by SDS-PAGE and immunoprobed 
using the S830 antibody (Figure 4-6A). While WT cells showed no evidence of S830+ 
mHTT, in the R6/2 lines, prominent bands were present at around 90 kDa, indicative of 
the soluble R6/2 transprotein. A signal was also present within the stacking gel, which is 
likely to have been insoluble mHTT that does not enter the resolving gel. The WT lines 
were free from any mHTT S830 bands at around 90 kDa, confirming the ICC results 
previously seen (Figure 4-4). Non-specific bands between 83 and 62 kDa were present in 
lanes of both genotypes and might represent the other proteins that the S830 antibody 
detected by ICC. The loading control was alpha tubulin, which has a molecular weight of 
around 50 kDa (Figure 4-6B). 
An identical cohort of cells was differentiated for 28 days and processed for ICC in 
parallel to those cultures used for protein lysates. These cells were stained for S830 and 
the neuronal marker MAP2 (Figure 4-6C). As previously observed, a subset of cells had 
inclusions of S830+ mHTT within the nucleus. A persistent feature of the nuclei with 
mHTT inclusions was that they rarely stained for markers of neurons or glia. Indeed, these 
nuclei were located in cells that were more often separated from clumps of cells and 
appeared relatively isolated. The cells located in clumps appeared less likely to contain 
inclusions. These data from western blot analysis and ICC provide strong evidence to 
confirm that mHTT was expressed and that the aggregation process occurs in R6/2 NPC 
cultures, appearing as inclusions within the nuclei of some cells. 
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Figure 4-6. Assessment of mHTT using western blot analysis and ICC.  WT 
and R6/2 cells lines differentiated for 28 days were harvested to examine mHTT 
expression. Whole cell lysates were examined by western blotting and were 
immunoprobed with (A) S830 antibody and (B) alpha-tubulin antibody as a 
loading control. Two protein concentrations of 50 g and 100 g were assessed. 
Bands around 90 kDa represent the soluble mHTT transprotein. Bands above the 
interphase are detergent insoluble mHTT aggregates, which do not enter the 
resolving gel. Other bands between 62 and 83 kDa are most likely to be non-
specific protein. (C) R6/2 cells grown in parallel to those used in the lysates were 
stained by ICC to visualise protein in situ. ICC staining for S830 (green) shows 
mHTT colocalised with DAPI stained (blue) nuclei (white arrows). No MAP2+ 
cells (red) in these cultures appeared to have mHTT co-expression. (D) WT cells 
grown and stained in parallel with those above. (E) Control images for R6/2 clls 
with no secondary antibody included to rule out autofluorescence. 
ICC=immunocytochemistry, WT=wildtype, mHTT=mutant huntingtin, 





4.9 Use of confocal microscopy to examine aggregation in differentiated 
neural progenitor cells 
Confocal microscopy was used to clarify the identity of the R6/2 cells with mHTT 
inclusions. As discussed previously, confocal microscopy has advantages over widefield 
microscopy, with increased resolution and reduction of noise; it also allowed for the 
addition of the far-red channel to visualise three different proteins at once in addition to 
DAPI. 
R6/2 Dl cell cultures were used to assess whether aggregation occurred in lines from the 
LGE and the cortex. Cells were differentiated for 28 days to reveal inclusions. In these 
Dl cultures, a distinct dual population of cells with nuclei containing inclusions (white 
arrows) and those without was apparent (Figure 4-7). Those cells that contained 
inclusions tended to be separate from clumps of cells, although not exclusively. 
The mature cell type, that these inclusion containing nuclei belonged to, was difficult to 
identify. Neurons in the differentiated R6/2 (and WT) cultures did not express FOX3 and 
so could not be identified using the antibody NeuN; as such, no nuclear-based markers 
could be used to identify them (Figure 4-8). Instead, cytoplasmic or cell surface markers 
had to be used. However, use of cytoplasmic markers made it difficult to identify 
individual cells containing inclusions within clumps because of the dense intertwined 
nature of the cells.  
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Figure 4-7. Use of confocal microscopy to identify inclusions in differentiated R6/2 NPCs. 
Confocal images of differentiated R6/2 cultures after 28 days with staining for DAPI (blue), 
astrocyte marker S100b (green), neuronal marker MAP2 (red) and mHTT marker S830 (white). 
Numerous S830+ nuclei were present (white arrows). NPCs=neural progenitor cells, 
MAP2=microtubule-associated protein 2. Scale bar 50 m 
 
Figure 4-8. Assessment of neuronal marker expression in NPCs. (A) Adult R6/2 mouse 
hippocampal sections stained with the cytoplasmic neuronal marker MAP2 and the nuclear 
marker NeuN. (B) 21 day differentiated R6/2 NPCs expressed a staining for MAP2 neurons but 
no signal for NeuN was observed. NPCs=neural progenitor cells, MAP2=microtubule-associated 
protein 2. Scale bar 50 m 
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4.10 Counting of S830+ cells in R6/2 cultures 
The age of cells, as measured by the number passages a cell line has experienced, could 
affect the number of cells within the culture which exhibit aggregation. The levels of 
mHTT in these cells when mitotic may increase over multiple passages although no 
aggregation is detectable while they remain proliferative. As the aggregation of mHTT is 
thought to be a concentration dependent event an increased baseline in cells when they 
shift to post-mitotic differentiated cells might alter the appearance and levels of 
aggregation in these mature cells. To study any effect of time spent in culture and passage 
number on the quantity of cells containing S830 inclusions, lines previously grown and 
banked for 15 (p15), 30 (p30) and 40 (p40) passages were used.  R6/2 cells from two Dc 
and two Dl lines were used for each of these three passage numbered lines. Cells were 
removed from liquid nitrogen storage and allowed one passage to recover, before being 
plated in differentiation media, fixed and then stained in cohorts after 21 and 28 days. 
Images were captured from 15 regions of interest from each well using an established set 
of coordinates. Thus the user did not influence the contents of the captured images. These 
images were used to manually count the number of nuclei with an S830+ inclusion signal. 
These data are summarised in Table 4-2. S830+ nuclei were detected in R6/2 Dc and Dl 
cell lines differentiated from NPCs at three passage numbers. Within the Dc lines, 
significantly more cells per image had a nuclear S830 signal in cultures started at p40 
compared with the lines with started at lower passages at both time points (Figure 4-9A). 
However, this finding was not reflected in the percentage of the total nuclei containing 




Table 4-2. Summary of S830+ cell counts in R6/2 Dc and Dl lines of different passage 
numbers and duration of differentiation. Statistical analysis performed as one way ANOVAs 
with bonferroni post-hoc test: *p≤0.05, **p≤0.01, ***p≤0.001. Dc=D line from the cortex, Dl=D 






Figure 4-9. Proportion of R6/2 cells containing nuclear S830 inclusions. (A) R6/2 Dc cultures 
from three lines were stained for S830 and DAPI. The total number of DAPI nuclei that contained 
an S830+ inclusion were counted for lines differentiated for 21 and 28 days. (B) Percentage of 
Dc DAPI nuclei co-localised with S830. (C) The same analysis was carried out on three R6/2 Dl 
lines for total number of S830+ DAPI nuclei and (D) a percentage of the cultures that these 
consisted of. Error bars are standard deviation. Dc=D line from the cortex, Dl=D line from the 
lateral ganglionic eminence. Statistical analysis performed as one way ANOVAs with bonferroni 




time point (Figure 4-9B). Within the Dl lines, significantly more cells per image had a 
nuclear S830 signal when started at p40 compared with the lines initiated with lower 
passage numbers after 28 days of differentiation, but not at 21 days (Figure 4-9C). When 
viewed as a percentage of the total nuclei within the culture those lines started at p30 had 
a significantly higher percentage of cells with S830+ inclusions after 21 days compared 
with those initiated at the other passages. This significant increase compared with lines 
started at p15 was retained at 28 days, however the percentage of cells with S830+ 
inclusions in p40 initiated lines had increased to a similar percentage as the p30 started 
lines at this time point and were also significantly higher than those started at p15. (Figure 
4-9D). 
4.11 Assessment of cell death in differentiated cultures 
HD causes neurodegeneration in the human brain. Data for whether the R6/2 mouse 
model replicates this neurodegeneration phenotype are conflicting. A stereological 
analysis by Stack and colleagues in 2005 found a 25% reduction in striatal neurons in 
R6/2 mice compared with their WT littermates at 12 weeks of age (Stack et al., 2005). 
However, analysis performed in our lab found little cell death in R6/2 mice compared 
with their WT littermates at 16 weeks of age in either the striatum or the cortex (Rattray 
et al., 2013). Lack of cell death was apparent, despite a widespread inclusion phenotype 
and dramatic progressive reduction of brain volume and of cortical thickness measured 
using MRI. Many other groups have also found low levels of cell death in the brains of 
R6/2 mice (Davies et al., 1997, Zhang et al., 2010a). The reasons behind this finding 
could be technical variation but also due to variables such as CAG repeat length, which 
can impact how the disease manifests (Morton et al., 2009). 
Apoptosis is the process of preprogramed cell death. During development, apoptosis is a 
common process to allow for tissue populations of the correct size and to select for those 
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cells that are best suited to thrive (Glucksmann, 1951, Kerr et al., 1972, Deckwerth and 
Johnson, 1993). Within brains affected by neurodegenerative disease or following 
traumatic brain injury and stroke, apoptosis can be a major process behind cell death 
(Dragunow et al., 1995, Mochizuki et al., 1996, Broughton et al., 2009, Smith et al., 
2012). Evidence exists for HTT having an anti-apoptotic function. Overexpression of 
HTT in conditionally immortalised human striatal cells in vitro is protective against lethal 
stresses such as deprivation of serum or introduction of 3-nitropropionic, a mitochondria 
toxin (Rigamonti et al., 2000, Rigamonti et al., 2001). 
As a cell becomes apoptotic it morphologically shrinks, retracting processes, and begins 
karyopyknosis; the condensation and fragmentation of nuclear chromatin (Kerr et al., 
1972). This DNA fragmentation can be detected using ‘Terminal deoxynucleotidyl 
transferase dUTP nick end labelling’ (TUNEL) (Gavrieli et al., 1992). TUNEL staining 
allows cells with DNA damage to be labelled and therefore will identify those cells in 
apoptosis. The R6/2 NPCs with inclusions have an altered morphology and limited 
mature protein expression compared to those without inclusions, when analysed by ICC. 
This altered expression could be related to apoptotic processes such as karyopyknosis. 
Mouse models with postnatal inactivation of the Htt gene resulted in apoptotic cells in 
the cortex, striatum, and hippocampus, and a reduction in axonal processes (Dragatsis et 
al., 2000). However, there is no evidence of apoptosis within the R6/2 mouse model brain 
(Turmaine et al., 2000), apart from within the olfactory zone, where TUNEL staining was 
slightly increased from normal cell death here (Kohl et al., 2010). Potentially this could 
be due to the R6/2 mouse retaining two copies of normal Htt with limited evidence of 
loss of endogenous HTT function with the presence of the mutant form. One mechanism 
by which HTT could help moderate apoptotic cell death is blocking of the creation and 
function of the apoptosome complex and activation of caspase-3 and caspase-9 
(Rigamonti et al., 2000, Rigamonti et al., 2001, Zhang et al., 2006). 
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To study the extent of cell death in differentiating cultures, R6/2 and WT Dc cells were 
grown in differentiation media and fixed and stained in 7-day cohorts up to 28 days. The 
cells were then stained with a commercial ‘In Situ Cell Death Detection Kit, Fluorescein’. 
Proliferative cultures, which have minimal cell death, were used as negative controls. As 
positive controls, hydrogen peroxide was applied to induce DNA damage in all cells in 
the culture which could be detected with the green fluorescent TUNEL stain (Figure 
4-10A). The proliferative negative control cells that were not treated with hydrogen 
peroxide displayed little if any green TUNEL staining (Figure 4-10B). 28-day-old R6/2 
cultures that contained mHTT aggregation showed some TUNEL+ cell death but 
TUNEL+ cells did not correlate with the cells containing S830+ inclusions (short white 
arrows, Figure 4-10C). The TUNEL staining occurred mainly in cells present in clumps 
with only a few outside the clumps being labelled. Due to the nature of the culture, there 
is cellular debris that gathered between cells. This debris often labelled as TUNEL+ and 
so maybe cells which have died during the culture process. These data suggest the R6/2 
cells with mHTT inclusions are not apoptotic. WT cells had similar levels of TUNEL 
staining, suggesting the cell death was caused by the in vitro environment rather than an 
HD-related phenotype. Some areas of intense S830 signal were detected outside and away 
from nuclei (long white arrows, Figure 4-10C). The size and location of these objects is 






Figure 4-10. Assessment of the levels of cell death in differentiated cultures. TUNEL staining 
was used to assess whether mHTT cells were apoptotic and the level of cell death in the culture 
(A) Proliferative R6/2 cells were treated with hydrogen peroxide to damage DNA as a positive 
control. (B) Proliferative R6/2 cells without treatment. (C) S830+ mHTT inclusions (red) were 
apparent in cells without TUNEL staining (green, short white arrows) in R6/2 cells after 28 days 
of differentiation. Some S830+ staining apparent outside of the nucleus (long white arrows), 
which is most likely to be autofluorescent debris. TUNEL=terminal deoxynucleotidyl transferase 
dUTP nick end labelling, mHTT=mutant huntingtin. Scale bars 50 m. 
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To study the extent of cell death in cultures and how this is related to cells with S830+ 
inclusions, lines previously grown and banked at p15, p30 and p40 passages were used. 
R6/2 cells from two Dc and two Dl lines were used for each of these three passage 
numbered lines. Cells were removed from liquid nitrogen storage and passaged once to 
recover, before being plated in differentiation media, fixed, and then stained in cohorts 
after 21 and 28 days. These cells were stained with a commercial ‘In Situ Cell Death 
Detection Kit, Fluorescein’ kit for TUNEL alongside S830. 
Images were captured from 15 regions of interest from each well using an established set 
of co-ordinates. Thus, the user did not influence the contents of the captured images. 
These images were used to manually count the number of nuclei with an S830+ inclusion 




Table 4-3. Summary of S830+ cell counts in R6/2 Dc and Dl lines of different passage 
numbers and duration of differentiation, after TUNEL+ cells were excluded. Statistical 
analysis performed as one way ANOVAs with bonferroni post-hoc test: *p≤0.05, **p≤0.01, 
***p≤0.001. Dc=D line from the cortex, Dl=D line from the lateral ganglionic eminence, 
Std.D=standard deviation, Sig=statistical significance of p-value, TUNEL= terminal 
deoxynucleotidyl transferase dUTP nick end labelling. 
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S830+ nuclei were detected in R6/2 Dc and Dl cell lines at all passage numbers despite 
the exclusion of cells displaying TUNEL staining. Within the Dc lines, significantly more 
TUNEL negative cells per image with a nuclear S830 signal were identified at the 21 day 
time point in the lines started at p40 compared with the cultures initiated at lower passages 
(Figure 4-11A). By 28 days, the number of TUNEL negative cells per image with a 
nuclear S830 signal in the lines started at p40 was only significantly higher than those 
started at p15 and not in those initiated p30. Once again this finding was not reflected as 
a percentage of the total TUNEL negative nuclei within the cultures at either time point, 
(Figure 4-11B). 
Within the Dl lines, significantly more TUNEL negative cells per image with a nuclear 
S830 signal were identified in the lines started at p30 compared with those started at p15 
at both time points (Figure 4-11C). After 28 days the percentage of the total TUNEL 
negative nuclei within the culture which contained S830+ inclusions was significantly 
higher in the p30 initiated lines compared with those started at p15, but not in those 
initiated at p40. (Figure 4-11D). These data show that the S830+ population of cells are 
not selectively dying within these cultures. 
These data suggest that there is a variation in the aggregation profile of R6/2 lines with 
different passage numbers. The percentage of cells with inclusions increases at later 
passages but this effect is not consistent between lines derived from different progenitor 
pools. Regardless of the passage number or area the lines were derived from an S830+ 





Figure 4-11. Proportion of TUNEL negative cells containing a nuclear S830+ inclusion. 
Manual cell counts were carried out on cells which were negative for TUNEL. (A) R6/2 Dc 
cultures from three lines where differentiation was initiated at increasing passage numbers were 
stained for S830 and DAPI while a TUNEL stain was applied to exclude nuclei showing signs of 
cell death. The total number of TUNEL negative DAPI nuclei that contained an S830+ inclusion 
were counted for lines differentiated for 21 and 28 days. (B) Percentage of Dc TUNEL negative 
DAPI nuclei co-localised with S830. (C) The same analysis was carried out on three R6/2 Dl lines 
for total number of TUNEL negative S830+ DAPI nuclei and (D) a percentage of the cultures that 
these consisted of. Error bars are standard deviation. Dc=D line from the cortex, Dl=D line from 
the lateral ganglionic eminence, TUNEL=terminal deoxynucleotidyl transferase dUTP nick end 
labelling, mHTT=mutant huntingtin. Statistical analysis performed as one way ANOVAs with 




4.12 High throughput automated fluorescence analysis – Operetta 
Quantification of cell parameters by eye is time consuming and can be biased even when 
the user is blinded to experimental groups. The Operetta® High-Content Imaging System 
(PerkinElmer, here-on just called Operetta) is specifically designed to analyse cultures in 
multi-welled plates using four channels of fluorescence. The automated stage and pre-
programmed knowledge of plate design gives control over which wells are imaged and 
where in the well to focus. The captured images can be analysed using the built-in 
software, which has an intuitive sequence of algorithms that are pre-programmed to 
identity cells with specific stains as well as morphological aspects to the culture such as 
size and shape. 
To test the effectiveness of the Operetta to analyse NPC cultures, three R6/2 and three 
WT Dl lines were grown in 96-well optical plates. These cells were differentiated up to 
day 28 and fixed for ICC and analysed using the Operetta. Using a x40 lens, the system 
was instructed to take 15 images per well in 4 wells per cell line (Figure 4-12A). The 
DAPI signal from these images was then used to identify individual cell nuclei (Figure 
4-12B) and to count the number of nuclei in each image. The size and shape of each 
nucleus was also recorded. The level of S830 staining was then analysed in the area 
covered by the DAPI nuclei to assess whether the nucleus contained mHTT nuclear 
inclusions (Figure 4-12C). The nuclei were labelled as S830+ or S830-, as shown in the 
green and red examples (Figure 4-12C). The S830 signal within the S830+ nuclei were 
then further analysed. Individual inclusions, with a higher S830 signal than the 
background for the nuclei, were highlighted as individual intensities (Figure 4-12D). The 
number of these inclusions per nuclei was then calculated. These analyses were combined 
in an automated sequence of algorithms and applied to each image as it was taken, or 




Figure 4-12. High throughput automated fluorescence analysis: Operetta. Automated image 
acquisition and analysis using the Operetta. (A) Images were obtained in 4 fluorescent channels 
from R6/2 and WT Dl lines grown in 96-well optical plates. (B) DAPI+ nuclei were identified 
using built-in locator modules, which allowed each individual cell nucleus to be identified and 
counted. (C) Within the boundaries of each nucleus, the level of S830 signal was assessed and a 
threshold was set to allow each nucleus to be labelled as S830+ (green) or S830- (red). (D) Within 
the S830 population, brighter intensities of S830 signal were identified and labelled with random 
colours for clarity. The number of these intense signals was counted per nucleus. (E) Examples 
of width and length measurements of a nuclei. (F) The software analysis was set to ignore 
oversized objects, above a set threshold, to avoid non-cellular objects and un-segmented nuclei. 
These are labelled in red. Extreme example of 2000 m2 object excluded as seen in the image and 
resulting graph (arrow) 
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The automated nature of any system needs optimisation and the Operetta was no different. 
The maximum area of each nucleus was manually set to only record nuclei less than 200 
m2 (Figure 4-12F). This setting safeguarded against larger pieces of debris being 
excluded, such as the 2000-m2 object detected in Figure 4-12F (arrows), ensuring that 
the system did not identify this as a single nucleus. The minimum size of nuclei was set 
to 60 m2. 
Most DAPI+ nuclei will have some background level of signal in the other fluorescent 
channels by the nature of how fluorophores fluoresce. As such, a cut-off criteria were 
applied to the S830 signal colocalised with a DAPI+ nucleus to detect true S830 
immunofluorescence. A level of 175 was set on the arbitrary scale within the relevant 
algorithm related to mean signal intensity to identify the S830+ cells. 
Nuclei with inclusions can be selected by the mean intensity (Figure 4-13A). As well as 
total S830 signal (Figure 4-13B). These two measures did not differ in their ability to 
select S830+ nuclei to a huge degree and indeed the cells they identified correlated 
strongly (Figure 4-13C). However, the mean intensity was slightly more reliable at 
selecting those nuclei that were positively counted by eye, and therefore was the measure 
chosen for future analysis. This 175 level was chosen based on capturing the population 
with a signal above that of the S830- noise (red points, Figure 4-13D) and used to 
segregate the subpopulation with S830+ inclusions from those without. When the 
threshold was applied to the WT cells almost the entire population of DAPI+ nuclei fell 
below the S830+ threshold. The few WT cells that were labelled as S830+ by these 





Figure 4-13. Establishing Operetta analysis thresholds. Automated image acquisition and 
analysis using Operetta® High Content Imaging System. (A) The mean intensity of S830 signal 
used as the selection criteria for S830+ nuclei. A value of 175 was set on the arbitrary scale. (B) 
The total S830 signal (sum) could be used as a selection but was less reliable at identifying the 
population that would be counted by eye. (C) The mean and sum intensity of S830 signal 
correlated. (D) The mean S830 signal within each nucleus was used to separate the R6/2 
population into those S830+ (green) and S830- (red). (E) When the threshold was applied the 
majority of cells in WT cultures fall under the cut off and are labelled red. Some outliers were 
still registered as S830+ but were removed from later analysis. WT=wildtype. 
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4.13 High content analysis of WT and R6/2 cells using the Operetta 
To quantify differences in the morphology and size of nuclei between WT and R6/2 lines, 
three WT and three R6/2 Dl cell lines, which had previously been passaged at least 15 
times prior to differentiation, were differentiated in 96-well plates and stained for DAPI. 
Cohorts of cells were fixed every 7 days from day 14 of differentiation. Four wells were 
analysed for each line and 15 individual images were captured at a x40 magnification at 
the same co-ordinates for each well. Each well was considered a technical replicate and 
each line considered a biological replicate. Within these replicates any outliers were 
identified using Grubbs test and excluded These data were pooled for the three biological 
replicates for each genotype. Statistical analysis was performed using SPSS (IBM) with 
Student t-test set to 95% confidence for genotype. 
Within each genotype, the total number of cells per replicate did not significantly change 
between the various post differentiation time points (Figure 4-14A). At 21 days, 
significantly more cells were present in the WT cultures compared with R6/2 cultures, a 
trend which continued after 28 days but that was not statistically significant (Figure 
4-14A). The mean area of each nuclei was recorded. The R6/2 nuclei were significantly 
larger than WT nuclei at all time points (Figure 4-14B). This increased area remained 
constant between the time points within each genotype. 
The Operetta can measure the roundness of each nucleus. This reading was given on a 
scale between 0 and 1, with 1 being perfectly round. No difference in the roundness of 
the nuclei was observed between the genotypes or at any of the time points analysed 
(Figure 4-14C). The width and length of each nucleus was also recorded. These 
measurements were taken by considering the longest part of the nuclei from side to side 
through the centre point as the length, and the perpendicular measurement to this as the 
width. For both length and width, a significant difference was observed between the WT  
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Figure 4-14. High content analysis of WT and R6/2 cells using the Operetta. The automated 
sequence of algorithms of the Operetta was applied to differentiated cultures at 3 time points up 
to day 28. (A) Total cells were counted based on DAPI nuclear staining. A selection criterion that 
excluded nuclei <60 µm2 and >200 µm2 was applied. Nuclear morphology was analyses for (B) 
mean size, (C) roundness, (D) length, (E) width, and (F) length:width. Error bars are standard 
deviation. Statistical analysis performed as Students t-test *p≤0.05, **p≤0.01, ***p≤0.001. 
 
and R6/2 nuclei at each time point. (Figure 4-14D,E) with R6/2 nuclei being longer and 
wider. A product of these data was a ratio of the length against the width. This ratio 
measure is different to the roundness measure generated by the Operetta and differences 
in this would signify a change in the overall shape of the nucleus. No significant 
difference was observed in the ratio of length:width between R6/2 and WT cell lines at 
any time points. A trend for a higher length:width ratio was observed at 14 days 
(p=0.159), however this trend was no longer present by day 21 and 28 (Figure 4-14F). 
These data suggest that the nuclei driving the trend for the longer lengths are potentially 




 Table 4-4. Summary of data from high content analysis of WT and R6/2 cells using the 
Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, ***p≤0.001. 
Std.Dev=standard deviation, Sig=statistical significance of p-value. 
 
The mean intensity of the S830 signal was used to separate two populations within each 
genotype, in which those above the threshold were considered to be S830+. The number 
of nuclei that reached this S830+ threshold was minimal for the WT cell lines as expected 
(Figure 4-15A). 
In the R6/2 cell cultures, the number of S830+ cells increased over the three time points 
(Figure 4-15A). This finding was reflected in the percentage of cells reaching the 
threshold (Figure 4-15B). This analysis of the number of S830+ cells did not necessarily 
include all nuclei with inclusions but instead was a reproducible system of identifying 
those cells that had the highest levels of S830 immunoreactivity. This approach accounts 
for the fact that manual cell counts recorded a larger percentage of cells with an S830 
signal compared with the Operetta: cells with weaker S830+ signals were included in 
manual counts as the user can more robustly identify true staining and, by eye, the issue 
of debris and clumping was not so limiting. 
Aggregation within the R6/2 nuclei appeared as inclusions that stained with bright 
intensities (Figure 4-12D). These intensities were recorded as ‘S830+ spots’ These spots 
could be segmented within the nuclei and the number of individual spots per nuclei was 
counted. The mean number of spots per nuclei increased with the length of time in culture 
in all three R6/2 lines (Figure 4-15C). 
156 
 
Figure 4-15. High content analysis of S830 signal in WT and R6/2 cells using the Operetta. 
The automated sequence of algorithms of the Operetta were applied to differentiated cultures at 
3 time points up to day 28. (A) The number of nuclei with a S830 mean intensity above the 
threshold were counted and (B) displayed as a percentage of the total cells analysed. (C) The 
number of individual intensity spots was calculated and displayed at each time point for the three 
R6/2 lines. The population of S830- and S830+ R6/2 nuclei were compared with WT cells for (D) 
mean size, (E) roundness, (F) length, (G) width, and (H) length:width. Error bars are standard 
deviation. Statistical analysis performed as one-way ANOVA with bonferroni post-hoc test. 
Difference between genotype/subpopulation: *p≤0.05, **p≤0.01, ***p≤0.001. Difference within 




Table 4-5. Summary of data from the high content analysis of nuclei with S830+ signal in 
WT and R6/2 cells using the Operetta. Statistical analysis performed as Students t-test: 
*p≤0.05, **p≤0.01, ***p≤0.001. Std.D=standard deviation, Sig=statistical significance of p-
value. 
 
To determine whether differences in nuclear morphology exist between S830+ and S830- 
R6/2 cells, the R6/2 cells were separated into S830+ and S830- subpopulations and the 
same analysis was run as above. WT cells were also re-analysed with any cells having 
reached a threshold for the S830 signal excluded. Statistical analysis was performed using 
SPSS (IBM) for one-way ANOVA with bonferroni post-hoc test. 
Analysis of the mean nuclear area showed that S830- R6/2 cells had significantly larger 
nuclei compared with WT at all three time points (Figure 4-15D). This observation 
reflected the data from the R6/2 cells as a whole. The nuclei in the S830+ R6/2 cell 
population were only significantly larger than the WT nuclei at the 21-day time point 
although there remained a trend for larger nuclei at the other time points (p=0.080 at 14 
days and 0.079 at 28 days). No difference in the size of nuclei was observed between the 
S830+ and S830- R6/2 cell subpopulations (Figure 4-15D). 
Analysis of the roundness of the nuclei on the Operetta scale revealed significantly 
decreased roundness between the S830+ and S830- R6/2 cell subpopulations at 14 days 
(Figure 4-15E). This difference in the subpopulation was not seen at the later time points. 
The only significant change in roundness observed in the WT population was in the 
S830+ population being rounder at 21 days, although there was also a trend for rounder 
nuclei in the S830- population (p=0.067, Figure 4-15E). Within the S830+ R6/2 
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population, the nuclei became significantly more round over time from 14 days to both 
the later time points (Figure 4-15E). Analysis of nuclear length and width revealed no 
significant difference between the S830+ and S830- R6/2 cell subpopulations (Figure 
4-15F,G). The nuclei in the S830- R6/2 cell population were significantly longer and 
wider than the WT nuclei at all time points as was seen with the R6/2 combined 
population (Figure 4-15F,G). The nuclei in the S830+ population of cells were only 
significantly longer at day 21 (Figure 4-15F) and wider from day 21 onwards (Figure 
4-15G). 
The ratio of the length to width showed a similar result to the roundness in that the 
length:width ratio of S830+ nuclei increased over time and after 21 days the ratio was 
significantly increased compared with the WT lines (Figure 4-15H). At 28 days this 
increase remained and was also significant between the S830- and S830+ subpopulations 
(Figure 4-15H).  
 
 
Table 4-6. Summary of data from the Operetta with R6/2 lines split based on S830 signal. 
Statistical analysis performed as one-way ANOVA with bonferroni post-hoc test. Difference 
between genotype/subpopulation: *p≤0.05, **p≤0.01, ***p≤0.001. Difference within 





The Operetta is a high-throughput system that provides non-biased data based on 
replicable sequences of algorithms. The data reveal significant differences between WT 
and R6/2 nuclei, most notably in size. Further analysis of the R6/2 cultures based on the 
presence of inclusions revealed this difference is predominately driven by the S830- 
population. 
4.14 Super resolution microscopy and R6/2 mouse brain aggregation 
The resolution of light microscopy is limited due to the physics of the diffraction limits 
of light (Neice, 2010). As such it had traditionally been impossible to reach an image 
resolution of beyond around 250 nm (Gustafsson, 1999). This resolution limit makes it 
difficult to precisely view ICC staining in enough detail to visualise anything smaller than 
the largest cellular inclusion. Novel systems have now been developed to capture images 
beyond the diffraction limit with higher resolutions (Gustafsson, 2000, Galbraith and 
Galbraith, 2011). These super-resolution systems allow for greatly increased detail to be 
obtained using ICC. One such system is structured illumination microscopy (SIM). SIM 
applies the theory of structured light, a process of using a known pattern or grid, which is 
projected over and slightly moved between multiple images (Gustafsson, 2000, Galbraith 
and Galbraith, 2011). This produces the Moiré pattern, a phenomenon where the light at 
the fringes of each pattern is slightly deformed (Gustafsson, 1999, Gustafsson, 2000). 
The computational reconstruction of the multiple images, using this deformation to its 
advantage, allows for the superior resolution achieved in the final composite image. 
To test the resolution of the SIM, end-stage R6/2 mouse tissue was processed for IHC 
onto glass slides. 50-µm sections were stained for the autophagy related protein SQSTM1 
(P62), ubiquitin and S830. These sections were then visualised using a Nikon N-SIM 
microscope with x100 lens. Using this system, a resolution of 31.19 nm/pixel was 
achieved. Multiple images were obtained in the z-plane to allow a 3-dimensional 
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reconstruction. In the end-stage R6/2 cortex, large inclusions were found inside the nuclei 
of a large proportion of neurons. These inclusions were present as large single bodies, 
with co-localised staining for S830, P62 and ubiquitin (Figure 4-16A). Using an 
orthogonal view, the location of the large inclusion was clearly contained within the 
nuclear envelope of the cell (Figure 4-16B,C). The Nikon ‘Elements’ microscope’s 
imaging software can be used to create 3-dimensional projections of the reconstructed 
images while retaining the resolution. The structure of the large inclusion can be made 
out to be a hollow ‘doughnut’ shape (Figure 4-16D). These images are an example of the 
potential of the SIM system to visualise structures beyond standard traditional 
fluorescence microscopy. Not all inclusions in the R6/2 mouse brain have this doughnut 
shape. 
4.15 Super resolution microscopy and aggregation in R6/2 neural progenitor 
cells 
The resolution afforded by SIM allows for smaller inclusions to be visualised, which 
would have been indistinguishable using conventional microscopy. To use SIM to 
analyse NPCs, R6/2 Dl cells were grown and differentiated in specialised glass-bottomed 
plates with an optical refractive index suitable for SIM. Cohorts of WT and R6/2 Dl cells 
were differentiated and fixed at 7-day time points up to day 21. The cells were processed 
for ICC using antibodies against P62 (green), S830 (red) and ubiquitin (far red, pink) 
(Figure 4-17A). Strong co-localised staining for all three antibodies was observed in large 
inclusions in the nuclei of some R6/2 cells, similar to those seen in the R6/2 mouse brain 
at end-stage (Figure 4-16). In the mouse brain, many cells had just one large inclusion 
while in the NPCs multiple inclusions were apparent. Rotation of the projected image 




Figure 4-16. Super resolution microscopy and R6/2 mouse brain aggregation. The SIM 
microscope was used to visualise aggregation in cells of the adult R6/2 mouse cortex. Multiple 
images were obtained in the Z plane to provide a 3-dimensional image of the cells. (A) ICC 
staining for P62 (green), ubiquitin (red) and S830 (far red, pink) was used to identify inclusions 
within the DAPI stained nuclei. The orthogonal view allows the location of a large inclusion to 
be identified within the nuclear envelope (B) With the multiple z plane images and the higher 
resolution a 3-dimensional computational representation of the inclusion could be projected. 
Rotation of the image revealed detail to the stained inclusion not normally possible. 




Figure 4-17. Super resolution microscopy and aggregation in R6/2 NPCs. R6/2 cell after 21 
days in differentiation media with inclusions viewed using SIM. (A) A single R6/2 DAPI nucleus 
(blue) stained using ICC for antibodies P62 (green), S830 (red) and ubiquitin (far red, pink). (B) 
Rotation of the projected image helps reveal the location of the inclusions inside the nuclear 
envelope and the co-localisation with (C) the staining for the other proteins of interest. Outside 
the nucleus, S830 aggregation was clearly visible in the cytoplasm that did not co-localise with 
P62 or ubiquitin. A side view of the image confirms the co-localisation of the proteins inside the 




inclusions were relatively round in shape and that the inclusions were located throughout 
the centre of the nucleus (Figure 4-17B). 
Immunostaining with antibodies against P62, S830 and ubiquitin produced signals 
throughout the cytoplasm thereby highlighting the morphology of the cell (Figure 4-17C). 
Little co-localisation was observed between the signals obtained with the three antibodies 
outside the nucleus in the R6/2 cells. The staining pattern was further visualised using a 
side view of the image (Figure 4-17D). The co-localisation of P62, S830, and ubiquitin 
was clearly visible and the proteins were located relatively centrally in the nuclei. As 
from other angles, little co-localised staining could be seen outside the nucleus. The 
nuclear envelope of this cell appears to be grooved with potential invagination. This 
observation is reminiscent of work by Davies et al in 1997, where similar invagination of 
the nuclear membrane was seen in R6/2 mouse striatal neurons using electron microscopy 
(Davies et al., 1997). 
 
4.16 Using super resolution microscopy to assess the R6/2 neural progenitor 
cells without aggregation 
The previous sections established that only a subset of cells in R6/2 cultures contain 
mHTT aggregates at levels detectable by confocal microscopy and the Operetta. To 
determine whether aggregation can be assessed using SIM, R6/2 Dl cultures were 
differentiated for 21 days and analysed by capturing images of more than one nucleus 
present in the same field of view. A marked difference was apparent between a cell that 
contained S830+ mHTT aggregation and one that did not (Figure 4-18A). The cell to the 




Figure 4-18. Super resolution microscopy and aggregation differences 
between R6/2 NPCs. R6/2 cells after 21 days in differentiation media with S830 
positive punctate staining viewed using SIM to identify one cell with and one cell 
without S830+ aggregation. (A) A 3-dimensional projection of the SIM image as 
viewed from above through the Z-plane. ICC for antibodies P62 (green), S830 
(red) and ubiquitin (far red, pink) were used to visualise mHTT and the proteins 
with which it co-localises. Side panels for individual fluorescent channels show 
DAPI, P62, and S830 staining equivalent to the larger image. (B) A rotated view 
of the projection allows depth of staining to be visualised. (C) Combined P62 and 
S830 images to visualise co-localised staining and an indication of its size and 
depth into the nucleus. NPCs=neural progenitor cells, mHTT=mutant huntingtin, 





This aggregation did not seem to be localised in the large inclusions seen in previous 
examples of R6/2 cells and in the R6/2 mouse brain. The other nucleus in this image did 
not appear to have any S830 signal apart from two small specks, one located in the nucleus 
and the other slightly outside the nucleus in the cytoplasm (Figure 4-18A, arrow heads). 
These specks of staining could be non-specific immunoreactivity or could be the initial 
stages of inclusion formation. 
P62 staining was present in large, and by eye, equal amounts in both the cell with an 
inclusion and that without (Figure 4-18A). Using a slightly rotated view of the cells 
(Figure 4-18B), P62 staining did not appear to co-localise with the S830 staining in the 
cytoplasm (Figure 4-18C) However, P62 co-localisation was detected for some of the 
marginally larger S830 nuclear inclusions (long arrows). Whether the other cell pictured 
here without aggregation would eventually start to accumulate aggregates is not easy to 
answer. To find this out would require long-term live imaging of the cells that could use 
a method of marking the aggregation process. 
Notably, because the S830 staining present in the S830+ cell has more diffuse punctate 
staining, this cell might not have been recorded as S830+ by the Operetta exclusion 
criteria. 
 
4.17 Use of super resolution microscopy to assess R6/2 neural progenitor cells 
earlier in the differentiation process 
In the previous sections, manual cell counts and the Operetta were used to show that the 
number of cells with inclusions increases over time throughout the differentiation 
process. Aggregation was detected as early as 14 days by the Operetta after the start of 
differentiation in R6/2 cells. To assess this earlier aggregation, R6/2 Dl cultures were 
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differentiated for 14 days and analysed using SIM. These cultures were stained with ICC 
with antibodies against S830, the cytoskeletal protein vimentin and P62. As before, an 
image with two separate nuclei was captured with one cell that appeared to have S830+ 
aggregation throughout the nucleus and cytoplasm and the other with a much lower S830 
signal (Figure 4-19A). 
The cell to the left side of the image has S830+ signal present throughout the nucleus 
when viewed from above (Figure 4-19A). The orthogonal view of the nucleus allows the 
location of the S830 signal to be displayed through the dashed line. This signal was 
represented as several smaller inclusions. The orthogonal view cutting the image 
horizontally, displayed underneath, also showed the cell on the right in which the nucleus 
did not appear to have S830+ inclusions: no aggregation was visible in this view. 
However, aggregation was apparent in the cytoplasm of both cells (Figure 4-19A). 
Use of an alternate view of the captured Z stack made the image seem translucent and 
displayed the total staining throughout the cells. With this view, more aggregation could 
be detected and the cell on the right appeared to have some S830+ signal in the nucleus 
(Figure 4-19B, Arrows). However, rotating the projected image showed that this 
aggregation was located outside the nuclear envelope (Figure 4-19C). This rotated view 
indicated that only cytoplasmic aggregation was present in this cell. The cell with nuclear 
inclusions had a vast amount of aggregation in its nucleus. Both cells have relatively 
similar levels of aggregation in the cytoplasm; however, the boundary between each cell 
is only estimated and without a marker of the plasma membrane it was not possible to 





Figure 4-19. Super resolution microscopy and differences in aggregation in 
R6/2 NPCs. R6/2 cells after 14 days in differentiation media with inclusions 
viewed using SIM to identify one cell with and one cell without S830+ nuclear 
inclusions. (A) A projected view of the cells from above the z-stack with 
orthogonal views through the dashed line to reveal S830 stained inclusions 
throughout the nucleus of one cell with no S830 signal in the other nucleus. (B) 
An average blended view though the z-stack from above showing average levels 
of staining and giving the cell a transparent quality. The left nucleus had a lot of 
individual S830 inclusions throughout. The cell on the right side appears to have 
staining in the nucleus, but (C) when the image was rotated, the staining could be 
seen to be outside the nuclear envelope and was cytoplasmic. NPCs=neural 






4.18 Use of super resolution microscopy to assess aggregation in R6/2 neural 
progenitor cells at earlier time points 
So far in this thesis, the earliest time point studied after induction of differentiation was 
7 days, and at this time point evidence of mHTT aggregation had not been detected. To 
assess whether aggregation could be detected with the more sensitive SIM technique, 
R6/2 Dl cultures were differentiated for 7 days and stained using ICC with antibodies for 
S830, vimentin, and P62 (Figure 4-20A). A projected image from above shows very little 
S830 staining anywhere within the R6/2 cell. Orthogonal views show a nucleus free from 
staining, sitting on top of a base layer of vimentin-stained cytoskeleton. A rotated view 
of this projected image shows that some S830 signal might have been present, which 
could potentially be the first stage of aggregate formation. There was a P62 signal 
throughout the cytoplasm in the form small sparse entities that did not correlate with the 
other fluorescent signals. 
 
4.19 Use of super resolution microscopy to assess wildtype neural progenitor 
cells 
As a comparison to R6/2 cells, WT Dl cells were grown alongside R6/2 cells for 21 days 
and ICC stained for antibodies against P62, S830, and ubiquitin (Figure 4-21A). An S830 
signal could not be detected in these cells beyond a few specks at the outer limits of the 
image (Figure 4-21A, Arrow). The ubiquitin signal was reduced compared with the R6/2 
cells at 21 days (Figure 4-17). P62 staining was abundant throughout the cytoplasm and 
present the nucleus. In this thesis, previous observations of P62 in the nucleus have come 
in tandem with an S830 inclusion signal. P62 is most commonly identified for its role in 




Figure 4-20. Super resolution microscopy to detect aggregation in 7 day R6/2 neural 
progenitor cells. (A) A projected image of the combined Z stack throughout the 7-day 
differentiated cell stained for S830 (green), vimentin (red), and P62 (pink). Orthogonal views 
display a DAPI nucleus sitting above a vimentin-stained cytoskeleton that did not contain S830 
signal. Some evidence of S830 and P62 signals were present in the cytoplasm. (B) A rotated 
projection again displayed the nucleus on top of a cytoplasm cytoskeleton. Some S830 signals 
appeared to be forming in the cytoplasm.  
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Figure 4-21. Super resolution microscopy and aggregation in 21 day WT NPCs. (A) WT cells 
after 21 days in differentiation media stained for ICC using P62 (green), S830 (red) and ubiquitin 
(pink) viewed using SIM. A single S830 stained element in the presumed cytoplasm highlighted 
by arrow. (B) A rotated projection of the WT cells shows no S830+ aggregation and weak 
ubiquitin staining. WT=wildtype, NPCs=neural progenitor cells, SIM=structured illumination 
microscopy. 
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nucleus in aggregated proteins of many neurodegenerative diseases (Ravikumar et al., 
2002, Liebl and Hoppe, 2016). However, P62 has many roles within the cell beyond the 
autophagy system; it is known to be important in regulation of cell growth, survival and 
proliferation (Sanchez et al., 1998). Within this function in healthy cells P62 is shuttled 
in and out of the nucleus via its nuclear localization signal (NLS) and nuclear export 
signal (NES) sequences (Pankiv et al., 2010, Zhang et al., 2016). During times of 
oxidative stress, inflammation, or starvation, P62 can be found located in the nucleus as 
well as the cytoplasm (Zhang et al., 2016), however its role in these situations is still not 
fully understood. A rotated view of the WT cell image projection showed these P62 
stained units have some depth and are large objects within the cells (Figure 4-21B). S830+ 
cytoplasmic signal did not co-localise with P62 signal in the cytoplasm of WT cells unlike 
the staining that was observed in the time matched R6/2 cells. 
4.20 Chapter discussion 
4.20.1 Modelling aggregation 
The aggregation of mHTT and the appearance of cellular inclusions is one of the 
hallmarks of HD observed in the human disease and mouse models. These inclusions are 
a useful phenotype to study the disease because they can be visualised and used as a 
readout of aggregation. The mechanisms driving the complex and numerous cellular 
pathologies of HD and the role that mHTT aggregation plays within the context of the 
disease are still not fully understood. Aggregation of mutant or modified protein is 
observed in a variety of neurodegenerative diseases including Alzheimer’s disease, 
Parkinson’s disease, and amyotrophic lateral sclerosis, as well as many others. Whether 
this process is correlative or causative in each case has been vigorously investigated and 
debated, but not definitively answered.  
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Some studies of aggregated HTT have suggested these aggregates could be a protective 
mechanism against the disease (Arrasate et al., 2004, Saudou et al., 1998, Nucifora et al., 
2012). However, correlations between detectable inclusions and cell death are hard to 
measure because much of the early underlying aggregation and its precursors are too 
subtle to detect with current microscopy techniques. The aggregation process probably 
contributes to the pathogenesis of HD disease. However, the presence of larger 
microscopically detectable inclusions might not be vital for all HD pathology.  
In the R6/2 mouse, inclusions progressively increase throughout the brain and their 
number correlated with the severity of behavioural and cognitive phenotypes, although 
the appearance of inclusions proceeds the onset of these phenotypes. Although limited 
cell death is observed within the 16-week R6/2 mouse lifespan, neuronal density increases 
with brain shrinkage (Rattray et al., 2013) and neural dysfunction is widespread (Cepeda 
et al., 2003, Davies et al., 1997), thus replicating some HD-like phenotypes. HTT 
inclusions are ubiquitinated, suggesting that they are targeted for degradation. The 
ubiquitin-proteasome system (UPS), however, is impaired in R6/2 mice (Maynard et al., 
2009). This impairment might be caused by saturation of the UPS by mHTT, either by 
providing excessive substrate or by directly inhibiting the proteasome (Ciechanover and 
Brundin, 2003, Bence et al., 2001, Cummings et al., 1998). This theory suggests, 
regardless of HTT’s overall pathology, the presence of mHTT inclusions will affect the 
cells ability to function efficiently.  
Aggregated mHTT inclusions can be visualised using ICC and quantified using western 
blot analysis with antibodies raised against different epitopes along the protein. In this 
thesis, the S830 sheep polyclonal antibody was used to identify aggregation. S830 
recognises the N-terminus of the protein with an elongated polyQ and so will detect even 
the smallest mHTT fragments including the exon1 HTT found in the R6/2 mouse model 
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(Sathasivam et al., 2013, Sathasivam et al., 2001, Mangiarini et al., 1996, Landles et al., 
2010).  
4.20.2 Aggregation in R6/2 cell cultures 
Aggregated mHTT inclusions were visualised in a population of R6/2 cells using ICC 
confocal and super resolution microscopy from day 14 of differentiation. The presence 
of mHTT aggregation was confirmed using western blot analysis to separate soluble HTT 
by size within the resolving gel and detergent insoluble mHTT. A sizable amount of 
detergent insoluble mHTT protein was present in the stacking gel, indicative of mHTT 
aggregated complexes. Within the cells, inclusions could be seen using confocal 
microscopy, and the S830 polyclonal antibody, in a subset of R6/2 nuclei. By 28 days of 
culture, around 10-20% of cells in the R6/2 cultures from striatal and cortical progenitors 
had aggregated inclusions in their nuclei. In the R6/2 mouse, the vast majority of neurons 
in the striatum and cortex have inclusions by 15 weeks of age (Meade et al., 2002). 
Whether similar proportions of cells with aggregates would eventually be present in R6/2 
cultures, if they could be maintained for longer, remains to be determined. Preliminary 
experiments suggest that the number of surviving cells greatly decreases beyond 28 days 
of culture, in both WT and R6/2 cell lines, which could hamper such experiments.  
Super resolution microscopy was successfully used to visualise aggregation in the 
cytoplasm of the R6/2 cell lines, which had not been distinguishable using confocal 
microscopy. Staining was more abundant in the cytoplasm at later time points, and seen 
alongside nuclear aggregation. Cytoplasmic aggregates appeared small and diffuse, 
which explains why they were not detected using brightfield or confocal techniques with 
lower resolution. Super resolution microscopy appeared to show that the larger inclusions 
in the nuclear colocalised with markers of autophagy and were ubiquitinated. These 
observations were similar to the co-localisation pattern seen in the R6/2 mouse brain. In 
cultured cells differentiated for 21 days, the nuclear aggregates appeared smaller but more 
176 
numerous than the aggregates seen in end stage R6/2 mice brains; these small inclusions 
did not colocalise with ubiquitin to the same extent as the inclusions in vivo. Because the 
aggregation process is progressive, the cultured cells might not  have reached the extent 
of aggregation observed in vivo yet. This could also suggest that the quantity of smaller 
aggregates has overwhelmed the UPS or that they are not yet prioritised for degradation. 
The smaller inclusions also did not appear to colocalise with p62, which suggests they 
might not be targeted for autophagy like the larger inclusion bodies. It is known that P62 
function is neuroprotective in some neurodegenerative conditions (Kuusisto et al., 2001) 
and colocalises with inclusions throughout the neurons in the R6/2 model (Nagaoka et 
al., 2004). However, it is also known that P62 is dysregulated in the presence of mHTT 
in the R6/1 mouse brain (Rue et al., 2013). This suggests that the function of P62 can 
become compromised in the presence of mHTT. However, P62’s role in the cell is not 
limited to autophagy (Sanchez et al., 1998), and indeed, autophagy is carried out by other 
protein families or pathways (Lu et al., 2014, Komatsu et al., 2007) suggesting that further 
study is needed before conclusions can be drawn. 
Using the super resolution microscopy, it was observed that the cells with larger 
inclusions appear to have some invagination of their nuclear envelope. This observation 
is reminiscent of work by Davies and colleagues in 1997, where similar invagination of 
the nuclear membrane was seen in R6/2 mouse striatal neurons using electron microscopy 
(Davies et al., 1997). The mechanism underlying this phenomenon is not known. It is 
possible the nuclear export signal at the terminus of HTT might draw the envelope and 
inclusion together and so in turn misshape the nucleus into the invaginated shape. This 
physical misshaping of the nuclear envelope could affect the function of other nuclear 
processes.  
The use of super resolution imaging within this chapter has allowed the visualisation of 
smaller cytoplasmic inclusions. It is known that this aggregation type exists within HD 
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in the human brain and may be the toxic component within the disease which results in 
the vast cell death observed. Because of its more disuse and smaller nature the 
cytoplasmic aggregation can be easily missed when focus to paid to the nuclear 
aggregated HTT. Using super resolution this cytoplasmic aggregation can be detected and 
could be used as an indication of how the disease is affecting cell function.  
4.20.3 Aggregated R6/2 cell fates 
The R6/2 cells exhibiting nuclear inclusions rarely showed cell fate signals using ICC 
and antibodies for classical makers of neurons and glia. The reason for this remains 
unclear. The cells with inclusions do not have long processes but have a cytoplasmic 
structure that can be identified with cytoskeletal markers such as actin. At first it was 
thought that these cells could have retracted their processes to an extent that they had little 
remaining cytoplasm with which to distinguish markers, however this was not the case. 
The volume of the cytoplasm of the cells with aggregation, but no fate markers, was not 
measured in detail here. However, in cells of the R6/2 striatum, cells are known to shrink 
up to 20% of their total size without cell death (Klapstein et al., 2001), which could be 
similar to what was observed in the NPCs. It could be that the cells with inclusions remain 
undifferentiated, however the change in morphology and lack of expression of NSC 
makers nestin and Ki67 suggest this was not the case. The presence of inclusions and the 
lack of differentiated markers suggests that if these cells have differentiated, then the 
proteins recognised by common antibodies as markers might be downregulated in the 
presence of aggregating mHTT. Alternatively, it could be that these cells initially do start 
to differentiate but that this process terminates before the cell can mature to the point at 
which they express the specific markers of neurons or glia that were probed.  
An alternative possibility is that these cells are quiescent stem cells, which do not express 
nestin or Ki-67 when in their quiescent G0 state (Maslov et al., 2004, Codega et al., 2014). 
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It would be unlikely that the inclusion-forming population, which can make up to 20% of 
the total R6/2 culture, could be quiescent stem cells—however, this was not investigated. 
An alternative explanation could be that the inclusion-containing cells have become 
apoptotic. As a cell undergoes programmed cell death, proteins are downregulated and 
processes are retracted—similar to the inclusion-containing cells observed in R6/2 
cultures. However, there was no evidence that the presence of inclusions increased cell 
death in the R6/2 cultures or that the inclusion-containing cell population was specifically 
apoptotic. These findings are in line with most evidence from the R6/2 mouse brain, in 
which cell death is minimal despite the widespread aggregation phenotype and apoptotic 
markers are not present (Rattray et al., 2013, Turmaine et al., 2000). This is not to say 
those cells in the mouse model with inclusions are not compromised in other ways. Gene 
expression changes have been detected in the striatum and cortex of R6/2 mice as early 
as at 6 weeks and become more pronounced with age (Luthi-Carter et al., 2000). These 
could be related to the lack of mature cell markers observed in the R6/2 inclusion-
containing cells.  
Apoptotic cell death was observed throughout both WT and R6/2 cultures from day 21 of 
differentiation with TUNEL+ cells being present in most regions of interest studied. This 
suggests that something about the in vitro culture system induces cell death once cells are 
post-mitotic and have differentiated. In development, apoptosis is not necessarily a 
negative process because it is required to remove cells that have become surplus to 
requirement during neurogenesis (Yeo and Gautier, 2004, de la Rosa and de Pablo, 2000, 
Meier et al., 2000). In culture, a similar effect might be observed with cells not receiving 
the required signals for their maintenance. If it could be determined why this apoptotic 
cell death was taking place across cultures of both genotypes, then longer culture 
durations could become feasible. 
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4.20.4 High content analysis of cultures 
Because monolayer cultures were used, high-throughput imaging and analysis using the 
Operetta was possible to assess the presence of S830 inclusions in cell nuclei. Using this 
system, it was possible to count and analyse tens of thousands of cells across single 96-
well plates for morphological changes and to separate data from the subpopulation of 
inclusion-containing cells. This analysis showed that R6/2 cells have larger nuclei 
compared with WT cells. It is not known why R6/2 nuclei would be larger than those in 
WT cells but this could be linked to the aggregation of the HTT protein. Nuclear 
aggregates could result in an increased size to accommodate the aggregation of mHTT 
protein. However, when the R6/2 cells were separated into inclusion-containing and 
inclusion-free cells it appeared that this size increase was mostly driven by those cells 
below the inclusion threshold. This opposes the theory of aggregation expanding the 
nuclei. It is possible that cells that were not above the required S830+ threshold contained 
inclusions that were too diffuse to detect but that they had more numerous inclusions, as 
seen previously with super resolution microscopy. These diffuse but numerous aggregates 
could increase nuclear size and, once the inclusions become very large in the nucleus, the 
nucleus might retract. Those cells captured with the larger inclusions retained the diffuse 
staining in the nucleus but too few were captured to probe if this was always the case or 
if the change in volume was related to their quantity.  
The biological processes that govern the morphology of nuclei are complex and not fully 
understood. Indeed, little is known about how the nucleus is formed, what determines its 
shape and what defines its size (Webster et al., 2009, Edens et al., 2013). It is known that 
nuclear shape can change during aging or in diseases such as cancer (Zink et al., 2004, 
Webster et al., 2009) in which enlarged nuclei almost always represent more aggressive 
metastatic disease. The nuclear envelopes ability to change size and shape is a key part 
of the process of mitosis. It is not surprising that it would be able to perform similar 
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adaptations in response to abnormal protein folding and aggregate formation. Why this 
size of the nucleus does change is not known.  
 
4.20.5 Aggregation in the R6/2 cultures only after adapted differentiation protocol. 
When the differentiation protocol was changed to maintain cultures on laminin, the 
aggregation phenotype was observed in the R6/2 lines. Why this change resulted in the 
emergence of the aggregation phenotype is not known. One theory would be that this 
subset of R6/2 cells are predisposed to aggregation and are liable to other phenotypes 
such as an inability to attach to uncoated plastic without a substrate to bind to, and so 
were lost in the media when it was changed. Evidence exists that levels of neural cell 
adhesion molecule (PSA-NCAM) are reduced in the hippocampus and piriform cortex of 
the R6/1 and R6/2 mouse models (van der Borght and Brundin, 2007). In other HD knock-
in mouse models, irregular synaptic and structural plasticity is observed in different brain 
areas, including the hippocampus and the cortex (Usdin et al., 1999, Cummings et al., 
2006, Spires et al., 2004, Gil et al., 2005), both of which can be regulated by NCAM. 
Potentially, cells that will be prone to aggregation might struggle to adhere to uncoated 
plastic and therefore be the most readily lost over that period of culture. Unattached cells 
were present in the media; however, because a large number of cells were still attached 
this was not thought a problem. Whether these cells are those that would eventually show 
aggregation could be studied by collecting the media and plating it onto laminin which 
should allow for the previously floating cells to adhere. These cells could then be 
differentiated to examine their potential for aggregation.  
The substrate used to coat plastic and encourage monolayer growth and attachment was 
laminin, which cells interact with via integrin signalling. Integrins are often found on the 
end of cellular filopodia, cellular membrane protrusions which act as sensors, probing 
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their microenvironment and regulating cell protrusion and cell migration in response to 
extracellular cues (Galbraith et al., 2007, Vasioukhin et al., 2000). Gene expression data 
from post-mortem HD brain highlighted the role of Rho family of GTPase signalling 
proteins in HD pathology (Tourette et al., 2014). Members of this Rho GTPase family, in 
particular ROCK1 and RAC1, are known HTT interactors (Bauer et al., 2009). They are 
also involved in BAIAP2-induced filopodia formation which is known to be interfered 
by the expression of mHTT in cell models (Shao et al., 2008). A reduced interaction of 
cellular adhesion components using the integrin signalling could result in decreased 
attachment of cells with mHTT expression. 
Another explanation could be that the process of removing cells from their adhesion to 
the plastic once they had been induced to start differentiating could be lethal to the subset 
of cells that would differentiate with inclusions. In the original Spiliotopoulos and 
colleagues (2009) protocol, this replating took place at day 3 of the protocol. This once 
again would suggest that cells that are post-mitotic are more sensitive to the stress of 
being passaged. Some groups have reported an increase in vulnerability to apoptotic 
stimuli, in cell lines transiently transfected with expanded polyglutamine-containing 
proteins (Hackam et al., 1998, Cooper et al., 1998). This theory could be tested by 
inducing a stress to the culture to measure whether those cells with aggregates were more 
prone to being affected.  
Another observation about the R6/2 cells that had nuclear aggregates was that they were 
more prone to be isolated and away from the clumps of cells that formed throughout the 
cultures.  This is not to say all aggregating cell were isolated but that those that were made 
up the majority. NCAM has been implicated as having a role in cell–cell adhesion 
(Rutishauser et al., 1988) and levels have been shown to be reduced in HD mouse models. 
NCAM is strongly associated with brain plasticity and also interacts with BDNF (Kiss et 
al., 2001), which is known to also be reduced in HD. If the levels of NCAM were also 
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reduced in the cells cultured here that contained aggregates, then this could also contribute 
to why cells with aggregation were less prone to appear in the clumps with other cells in 
the culture. If this was the case it would suggest a very early phenotype in these cells, 
which would proceed the detected aggregation observed so far.  
4.20.6 Subpopulation differences in the R6/2 cultures 
The presence of a sub-population of R6/2 cells with inclusions is intriguing and suggests 
that those cells that develop detectable aggregation within the first 28 days might have 
been predisposed to do so before they were extracted from the foetal brain. In the brains 
of patients with HD and HD mouse models, the number of cells with inclusions increase 
over time suggesting that certain populations are prone to aggregation more than others. 
Why this is the case is not known and could be due to many different factors. In this 
thesis, little difference was observed with the different microscopy techniques, between 
those R6/2 cells with and without detectable aggregation. Use of the Operetta highlighted 
little difference in nuclear morphology between the cells with and without inclusions.  
Use of super resolution microscopy allowed a nucleus from cells of each population to be 
captured within one region of interest. Only a couple of these images were captured, due 
to the long time taken to capture and process the super resolution images and the rarity of 
cells of each subpopulation being close enough to capture in a single frame. Therefore, 
definitive differences cannot be draw from these data. However, the cells without the 
levels of aggregation that would separate them into the non-aggregated subgroups did 
appear to have some speckles of S830 staining. This finding suggests that the mHTT 
aggregation process could be just beginning to be detectable within those cells, and that 
this process would eventually produce more inclusions with enough time in culture. 
It would be interesting if cells from each R6/2 subgroup population could be isolated and 
differences between cells of each subgroup, with and without detectable inclusions, 
analysed. RNA-Seq would be a valuable tool to look at levels of gene expression between 
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these populations. This analysis would require the isolation of cells into their sub-
populations based on aggregation. Cell sorting methods such as fluorescence-activated 
cell sorting (FACS) are ideal to sort cells based on cell surface protein expression. 
However, the issue with the application of this method is that the only marker that 
distinguishes the sub-populations of R6/2 cells for ICC is the antibody S830, which 
targets the inclusions within the cells. The detectable inclusions appear to be mostly 
nuclear and so, for the antibody to penetrate through to the aggregations, the ICC 
techniques require lysis of cell and nuclear membranes. This lysis is not an issue with 
fixed cells while assessing protein levels using ICC but this could affect the quality and 
quantity of any RNA obtained after FACS. It would also destroy each cell and so prevent 
the ability to culture the isolated populations further. If cell surface markers were 
identified it would be possible to use FACS, however no such markers are known at 
present that could successfully identify these populations.  
One potential way to tackle this problem this would be to exploit the fact that the sub-
population with detectable inclusions does not show markers of differentiation. Those 
cells that do show neuronal and astrocytic markers could be sorted from the population 
sequentially (Feldmann et al., 2014). However, the resulting sorted population would not 





The establishment of cell lines with HD-like phenotypes to allow researchers to examine 
the disease mechanism are greatly needed. The R6/2 NPCs established here exhibited a 
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detectable nuclear aggregation, visualised using immunohistochemistry from 14 days of 
differentiation in 5% of R6/2 cell nuclei, rising to 20% by 28 days, recapitulating an HD-
like phenotype found in vivo. Detection of detergent insoluble mHTT-aggregated protein 
was also validated via western blotting. Super high resolution cell imaging showed 
aggregation of mHTT also occurs in the cytoplasm. High-content imaging analysis 
system was performed using the Operetta system to explore morphological differences 
between WT and R6/2 cultures, as well as within the subset of cells with detectable 
aggregation. R6/2 nuclei were found to be larger than those of WT cells. The aggregation 
detected in these NPCs in combination with the ability to monitor the formation across 








Chapter 5 Results 3: Application of novel compounds to cells while 
assessing phenotypic changes 
5.1 Introduction 
The NPCs created and probed in the previous chapters can be used with high content 
analysis systems to monitor the aggregation phenotype exhibited by the R6/2 cultures in 
addition to assessment of nuclear morphology. The application of potential disease 
modifying treatments to these cells monitored on this platform would allow in-depth 
assessment of how these treatments affect the R6/2 and WT cultures. 
Six compounds were supplied to us from professor Erich Wanker’s laboratory (Berlin, 
Germany). These particular compounds were provided because they have shown promise 
in affecting aggregation of misfolded proteins in models of neurodegeneration. As such, 
these six compounds were applied to the R6/2 and WT NPC lines developed in this thesis 
to determine whether they had similar effects on HTT aggregation in these cells. 
 
5.2 Chapter aim: 
The aim of the experiments performed in this chapter was to: 
 examine the toxicity and then test the effects of novel compounds supplied from 
our collaborators on the R6/2 neural progenitor cell lines developed and 





A description of each compound follows: 
5.3.1 O4 
O4 is an orcein-related small molecule which has been shown to help promote the 
fibrillarisation of amyloid-β (Aβ) polypeptides (Bieschke et al., 2012). The non-fibrillar 
forms of Aβ can form as soluble oligomers or protofibrils that instigate the neuronal 
dysfunction and memory impairments of Alzheimer's disease. This process of Aβ 
formation as β-sheets is similar to that observed in the aggregated polyQ sequences in 
HD (Takahashi et al., 2008, Perutz, 1996, Bieschke et al., 2012). Potentially O4 could 
have similar effects on mHTT aggregates as it does on amyloid aggregation in AD that 
form with similar β-sheet–rich oligomers and protofibrils.   
5.3.2 Β-lapachone 
-lapachone is as a naturally occurring quinone that has been shown to help reduce polyQ 
toxicity by stimulating autophagy clearance of Exon 1 aggregation (Shin et al., 2013). 
This effect is mediated through increase in activity of SIRT-1, a mammalian orthologue 
of the yeast Sir2 protein (Hwang et al., 2009, Lee et al., 2012b). SIRT-1 is reduced in the 
brains of R6/2 and HdhQ150 mice (Tulino et al., 2016) and increasing expression of 
SIRT-1 diminished neurodegeneration and improved motor function in N171-82Q and 
BACHD mice (Jiang et al., 2012) and reduced brain atrophy and mutant HTT aggregation 
in R6/2 mice without lengthening lifespan (Jeong et al., 2012). -lapachone has also 
shown some inhibitory effects in a FRET-based HTT exon 1 aggregation assay (personal 
correspondence, Wanker lab). -lapachone inhibits indoleamine-pyrrole 2,3-dioxygenase 
in human immune pathways at an IC50 of 0.44 M and is useful in cancer research where 
it helps prevent tumour cells to avoid immune responses (Uyttenhove et al., 2003).  
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5.3.3 Quinidine 
Quinidine has long been used as an antiarrhythmic pharmaceutical agent in the heart, 
which acts by blocking the fast inward sodium current (Noujaim et al., 2011). It is also 
currently used as a combination treatment with dextromethorphan hydrobromide to treat 
the pseudobulbar affect in amyotrophic lateral sclerosis (Brooks et al., 2004) In HTT 
aggregate clearance assays quinidine has a substantially reduces the number of HTT Exon 
1 aggregates in SH-EP (human neuroblastoma cell line) (Reddy et al., 1991) cells as 
counted by automated microscopy (personal correspondence, Wanker lab). In further 
analysis, using a HD fly model, quinidine reduced HTT aggregates in treated fly brains 
(Personal correspondence, Wanker lab). When used for its sodium channel blocking 
qualities the IC50 of Quinidine has be calculated to around 1.37 M (Ballestero et al., 
2005). 
5.3.4 Hydrazone #6 and #9 
Hydrazones are a group of organic compounds related to aldehydes and ketones. They 
have been shown to function as uncoupling agents in ATP synthesis (Heytler and 
Prichard, 1962). In a study of the effects of 120 hydrazones on HTTEx1Q49 using a filter 
retardation assay, two were identified to be effective in inhibiting aggregation. These two 
were labelled as hydrazones #6 and #9. Their anti-aggregation effect was confirmed using 
atomic force microscopy, kinetic analysis of HTT Exon 1-Q49 aggregation via filter 
retardation assay, AGERA (agarose gel electrophoresis for resolving aggregates), native 
dot blot assays (using the antibody MW8) and native PAGE (personal correspondence, 
Wanker lab). The IC50 of Hydrozone #6 has been calculated to around 218 M with 
Hydrozone #9 being slightly less potent.  
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5.3.5 Guanabenz 
Guanabenz has been identified as an inhibitor of protein stress in the endoplasmic 
reticulum by helping protect against the build-up of toxic misfolded proteins (Tsaytler et 
al., 2011). In HTT aggregate clearance assays guanabenz reduces the amount of HTT 
Exon 1 aggregates in SH-EP cells, as counted by automated microscopy (personal 
correspondence, Wanker lab).  In further analysis, using a HD fly model, quinidine 
reduced HTT aggregates in treated fly brain, which was confirmed using native dot-blot 
assays (personal correspondence, Wanker lab). Guanabenz is an agonist of the alpha-2 
adrenergic receptor and prescribed as an antihypertensive drug (Holmes et al., 1983). 
Evidence also suggests guanabenz has potential anti-prion activity (Tribouillard-Tanvier 
et al., 2008). The IC50 is around 8.6 M as alpha 2-adrenoceptor agonists (Vago et al., 
1985). 
5.4 Toxicity 
The potential toxicity of these compounds in differentiated NPCs had not previously been 
assessed. To determine the lethal dose to 50% of cells (LD50) for each compound, one 
R6/2 and one WT Dl neural progenitor cell line previously passaged to p15 were 
differentiated on laminin in 96-well plates for 7 days in the presence of 4 concentrations 
of each compound (Table 5-1), and the proportion of surviving cells was visually 
assessed. Culture media was half-refreshed at least every 48 hours and fresh media was 
additionally applied as required by the differentiation protocol. Brightfield images were 
captured after 1, 3, and 7 days of differentiation to visually monitor the cultures (Figure 
5-1&2). The compounds’ effects were measured by comparison of cell number with cells 
differentiated in media containing no compound (NC), as had been optimised in chapters 
3 and 4 of this thesis. Five brightfield images were captured per condition and the number 
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of cells present were counted. LD50 values were then calculated for each compound that 
showed toxicity.  
 
 
Table 5-1. Properties of the novel compounds supplied from collaborators. 
The compounds were stored as stock solutions at 10mM in DMSO. After dilution with 
water, the final percentage of DMSO in the compound solutions is shown in Table 5-2. 
To control for any effect caused by the residual DMSO, differentiation media was applied 
with DMSO at a concentration equal to what would be present at the highest compound 
concentration (Table 5-2). 
 
Table 5-2. DMSO concentration in media depending on the compound concentration used. 














O4- (TimTec) Black 4℃ 429,38 4.29mg 10mM 1ml 2, 5, 10, 20
βLapachone Orange RT 242,27 2.42mg 10mM 1ml 0.5, 1, 2, 5
Quinidine White RT 324,42 3.24mg 10mM 1ml 2, 5, 10, 20
Hydrazon #6 Brown 4℃ 370,14 3.70mg 10mM 1ml 2, 5, 10, 20
Hydrazon #9 Dark Brown 4℃ 289,24 2.89mg 10mM 1ml 2, 5, 10, 20














O4 is an example of a compound that did not affect cell survival (Figure 5-1). With the 
application of differentiation media containing O4, the WT and R6/2 cultures were 
transformed from the proliferative to a differentiated state with elongated morphology 
and process extension. The resulting morphology was similar to that previously observed 
within the adapted differentiation protocol, indicating these cells differentiated in the 
presence of O4. Little change in cell density was observed between normal culture 
conditions compared with those containing all concentrations of O4, suggesting little cell 
death and limited toxicity was associated with its application. 
Hydrazon #9 is an example of a compound that did show some toxicity (Figure 5-2). The 
WT and R6/2 cultures showed visual signs of differentiation at day one. At higher 
concentrations of hydrazon #9 the number of surviving cells was significantly reduced. 
Treatment with 10 M and 20 M hydrazon #9 resulted in a decrease in the number of 
surviving cells observed in both WT and R6/2 lines after 7 days. Within the time frame 
studied here, the 10 M and 20 M concentrations were considered toxic to 
differentiating NPC lines and were not used in the subsequent compound studies (Table 
5-4). 
The LD50 for each compound was calculated based on the number of cells surviving the 
compound treatments. The estimated concentration which would cause 50% cell death 
was calculated (Table 5-3). The number of cells lost between day 0 and day 7 in the 
presence of the increasing concentration of each compound. Cell death was plotted on a 
graph against concentration and the linear line of best fit was applied. This equation 
allowed for an estimation of the concentration which would be toxic to 50% of cells and 
is called the LD50. 
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Table 5-3. Summary of compound toxicity after 7 days via LD50 estimations. Cell counts 
were carried out on images take at day0 and after 7 days in differentiation media containing 
compounds at increasing concentration. From the number of cells lost between these cell counts 
the linear equation for toxicity was calculated and an estimation of the concentration for toxicity 
to 50% of  the cells was estimated (LD50).  
 
On the basis of these toxicity data, the compound concentrations were modified to avoid 
cell death in cells cultured for a longer duration. 
  
Compound O4 B-lapachone Quinidine Hydrazone #6 Hydrazone #9 Guanabenz
Day 0 599 660 519 606 542 660
NC 534 581 497 554 521 612
0.5 µM - 564 - - - -
1 µM - 622 - - - -
2 µM 550 523 497 356 368 583
5 µM 529 522 306 344 531
10µM 525 - 493 56 175 320
20 µM 529 - 450 26 115 220
Linear LD50 
toxicity equation
NA NA NA y = 19.063x + 243.67 y = 14.793x + 154.67 y = 20.768x + 54.392
Estimated LD50 >20 µM >5 µM >20 µM 3.1 µM 7.9 µM 13.3 µM
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Figure 5-1. Effects of addition of compound O4 to growth media for R6/2 and WT cells. 
R6/2 and WT Dl lines were differentiated in standardised differentiation media containing O4 for 
7 days to assess the survival of cells. (A,B) Normal differentiation media with the protocol 
optimised in previous chapters with (A) WT cells and (B) R6/2 cells. Normal differentiation 
media with DMSO (0.2%) added to the same concentration as the highest O4 concentration for 
(C) WT and (D) R6/2 cultures. Addition of O4 to differentiation media at a concentration of 20 
M for (E) WT cells and (F) R6/2 cells; 10 M O4 (G) WT cells and (H) R6/2 cells; 5 M O4 (I) 
WT cells and (J) R6/2 cells; and 2 M O4 (K) WT cells and (L) R6/2 cells. WT=wildtype. Scale 





Figure 5-2 Effects of addition of Hydrazon #9 to growth media for R6/2 and WT cells. R6/2 
and WT Dl lines were differentiated in standardised differentiation media containing compound 
Hydrazon #9 for 7 days to assess the toxicity to cells. Normal differentiation media with the 
protocol optimised in previous chapters with (A) WT cells (B) and applied to R6/2 cultures. 
Normal differentiation media with DMSO (0.2%) added to the same concentration as the highest 
Hydrazon #9 concentration for (C) WT and (D) R6/2 cultures. Addition of Hydrazon #9 to 
differentiation media at a concentration of 20 M for (E) WT cells and (F) R6/2 cells; 10 M O4 
(G) WT cells and (H) R6/2 cells; 5 M O4 (I) WT cells and (J) R6/2 cells; and 2 M O4 (K) WT 






5.5 Assessment of the effect of compounds on nuclear morphology and HTT 
aggregation in differentiated neural progenitor cells 
The concentrations of each compound were modified to avoid toxicity in longer term 
cultures (Table 5-4). This adapted concentration range for each compound was applied to 
three R6/2 lines and one WT Dl line, for which the differentiation protocol was initiated 
at p15. The effects on nuclear morphology and aggregation were assessed. The 
differentiation media used was as optimised in Chapter 4, with either no compound (NC), 
DMSO control (Table 5-2), or containing the appropriate compound concentration. Cells 
were grown for 21 days with half the media refreshed ever 48 hours before fixation in 
PFA and staining by ICC. To perform a non-biased and high throughput analysis of the 
effect of each compound, the Operetta system was used. Cultures were grown on laminin 
coated 96-well plates as indicated in Figure 5-3. A design flaw of the Operetta is that at 
x40 magnification the outside wells of a 96-well plate cannot be captured. As such, the 
experiments were designed without using the outside wells (Figure 5-3). The data were 
pooled for the three biological replicates for the three R6/2 lines. Statistical analysis was 
performed using SPSS (IBM) with Student t-tests set to 95% confidence. 
 





Figure 5-3 Layout of 96-well plates for compound application. R6/2 and WT Dl lines were 
differentiated in the 96-well plates for analysis with the Operetta. Cells were plated in columns 
and the compounds were applied in rows as shown. The outermost wells were not used because 
they were outside the operetta image capture range at higher magnifications. WT=wildtype. 
 
5.6 Assessment of compound affects to nuclear morphology 
The compounds were applied to cultures to investigate the effects on nuclear morphology 
and size in the WT and R6/2 differentiated NPC lines. 
The total number of cells in cultures after differentiation for 21 days was affected by all 
compounds. In the case of O4 (Table 5-6, Figure 5-4), quinidine (Table 5-8, Figure 5-6), 
and guanabenz (Table 5-11 ,Figure 5-9), this reduction in cells compared with the NC 
condition was also seen in the DMSO control, suggesting this effect might not be 
compound related. The hydrazones (Table 5-9, Table 5-10, Figure 5-7, Figure 5-8) also 
caused a reduction in cell number and to a much larger extent. Both hydrazone 
compounds, at their highest concentrations, resulted in a considerable degree of cell 
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death, suggesting their toxicity was more extensive over the longer culture period than in 
the initial toxicity experiment (Table 5-3). Treatment with β-lapachone (Table 5-7 
Summary , Figure 5-5) had the opposite effect and resulted in an increase in cell numbers 
in the culture, while a reduction in cell number was still seen in the DMSO controls. 
The mean area of the WT and R6/2 nuclei was unaffected by treatment with the 
compounds apart from with the hydrazones, which both slightly reduced the nuclear area 
at their highest concentrations. This result must be taken in the context of the great 
reduction in cell number that resulted from hydrazone treatment, as the surviving cells 
could be adversely affected by the toxic environment. Nuclear roundness was affected by 
O4, β-lapachone, and guanabenz. O4 and guanabenz resulted in slightly rounder WT 
nuclei when applied at all concentrations, while DMSO reduced the roundness. Treatment 
with O4 or guanabenz did not affect the roundness of the R6/2 cells. A similar effect was 
observed by β-lapachone on the WT cells, with an increase in roundness by application 
at 2 M. It is unlikely that this effect observed at only one lower concentration can be 
used as an important readout. A reduction in roundness was caused by the DMSO control. 
The length of WT nuclei, as measured by the thickness through the centre of its longest 
point, was slightly reduced by O4 and guanabenz. No effect was seen on the thickness of 
the R6/2 nuclei by the application of these compounds, nor by the other compounds in 
the WT cells. The width of nuclei, as measured by the thickness through the centre 
perpendicular to the longest point, was reduced by the highest concentration of both 
hydrazones. This effect once again might be adversely affected due to the low number of 
cells surviving in these cultures. The ratio of length:width was affected by treatment with 
O4, β-lapachone, guanabenz, and the hydrazones. The ratio was increased in the WT cells 
by the highest concentrations of O4, β-lapachone, and guanabenz, and decreased by the 
hydrazones. R6/2 nuclei ratios were slightly increased by lower concentrations of β-
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lapachone but no effect was observed with treatment with the other compounds. The 
overall effects are summarised in Table 5-5. 
 
 
Table 5-5. Summary of compound effects on nuclear morphology and size in the WT and 








⬆ Roundness (2 µM) 
⬆ Ratio





















Table 5-6 Summary of morphological changes induced in 21-day differentiated NPCs by 
compound O4 measured by the Operetta. Statistical analysis performed as one-way ANOVA 
with bonferroni post-hoc test. Difference between WT and R6/2  at each condition represented as 
*p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 
for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, NC=no compound 
Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-4. Operetta analysis of WT and R6/2 cells after 21 days of O4 application. 
Automated analysis with the Operetta was used to assess R6/2 and WT cultures differentiated for 
21 days in media containing increasing concentrations of the compound O4. (A) Total cells were 
counted based on DAPI nuclear staining. Analysis of cell morphology for (B) mean size, (C) 
roundness, (D) length, (E) width, and (F) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Difference 
between WT and R6/2 at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. 
Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, 
§§§p≤0.001 for R6/2. WT=wildtype, NC=no compound 
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5.6.2 β-Lapachone  
 
Table 5-7 Summary of morphological changes induced in 21-day differentiated NPCs by 
compound β-Lapachone measured by the Operetta. Statistical analysis performed as one-way 
ANOVA with bonferroni post-hoc test. Difference between WT and R6/2 at each condition 
represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, 
##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, 
NC=no compound Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-5 Operetta analysis of WT and R6/2 cells after 21 days of β-Lapachone application.  
Automated analysis with the Operetta was used to assess R6/2 and WT cultures differentiated for 
21 days in media containing increasing concentrations of the compound β-Lapachone. (A) Total 
cells were counted based on DAPI nuclear staining. Analysis of cell morphology for (B) mean 
size, (C) roundness, (D) length, (E) width, and (F) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Difference 
between WT and R6/2 at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. 
Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, 





Table 5-8. Summary of morphological changes in 21-day differentiated NPCs induced by 
compound Quinidine measured by the Operetta. Statistical analysis performed as one-way 
ANOVA with bonferroni post-hoc test. Difference between NC and WT at each condition 
represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, 
##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, 
NC=no compound Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-6 Operetta analysis of WT and R6/2 cells after 21 days of Quinidine application. 
Automated analysis with the Operetta was used to assess R6/2 and WT cultures differentiated for 
21 days in media containing increasing concentrations of the compound Quinidine. (A) Total cells 
were counted based on DAPI nuclear staining. Analysis of cell morphology for (B) mean size, 
(C) roundness, (D) length, (E) width, and (F) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Difference 
between WT and R6/2 at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. 
Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, 
§§§p≤0.001 for R6/2. WT=wildtype, NC=no compound. 
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5.6.4 Hydrazone #6 
 
Table 5-9. Summary of morphological changes in 21-day differentiated NPCs induced by 
compound Hydrazone #6 measured by the Operetta. Statistical analysis performed as one-
way ANOVA with bonferroni post-hoc test. Difference between WT and R6/2 at each condition 
represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, 
##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, 
NC=no compound Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-7 Operetta analysis of WT and R6/2 cells after 21 days of Hydrazone #6 
application. Automated analysis with the Operetta was used to assess R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound 
Hydrazone #6. (A) Total cells were counted based on DAPI nuclear staining. Analysis of cell 
morphology for (B) mean size, (C) roundness, (D) length, (E) width, and (F) length:width. Error 
bars for standard deviation. Statistical analysis carried out using ANOVA with bonferroni post 
hoc correction. Difference between WT and R6/2 at each condition represented as *p≤0.05 
**p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT 
and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, NC=no compound 
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5.6.5 Hydrazone #9 
 
Table 5-10. Summary of morphological changes in 21-day differentiaed NPCs induced by 
compound Hydrazone #9 measured by the Operetta. Statistical analysis performed as one-
way ANOVA with bonferroni post-hoc test. Difference between WT and R6/2 at each condition 
represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, 
##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, 
NC=no compound Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-8 Operetta analysis of WT and R6/2 cells after 21 days of Hydrazone #9 
application. Automated analysis with the Operetta was used to assess R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound 
Hydrazone #9. (A) Total cells were counted based on DAPI nuclear staining. Analysis of cell 
morphology for (B) mean size, (C) roundness, (D) length, (E) width, and (F) length:width. Error 
bars for standard deviation. Statistical analysis carried out using ANOVA with bonferroni post 
hoc correction. Difference between WT and R6/2 at each condition represented as *p≤0.05 
**p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT 





Table 5-11. Summary of morphological changes in 21-day differentiated NPCs induced by 
compound Guanabenz measured by the Operetta. Statistical analysis performed as one-way 
ANOVA with bonferroni post-hoc test. Difference between WT and R6/2 at each condition 
represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as #p≤0.05, 
##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2. WT=wildtype, 
NC=no compound Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Figure 5-9 Operetta analysis of WT and R6/2 cells after 21 days of Guanabenz application. 
Automated analysis with the Operetta was used to assess R6/2 and WT cultures differentiated for 
21 days in media containing increasing concentrations of the compound Guanabenz. (A) Total 
cells were counted based on DAPI nuclear staining. Analysis of cell morphology for (B) mean 
size, (C) roundness, (D) length, (E) width, and (F) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Difference 
between WT and R6/2 at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. 
Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for-WT and §p≤0.05, §§p≤0.01, 
§§§p≤0.001 for R6/2. WT=wildtype, NC=no compound 
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5.7 Effects on aggregation. 
mHTT aggregation was detected within the nucleus of all cells by S830 ICC, and the R6/2 
populations were separated into S830- and S830+ sub-populations based on the S830 
threshold, defined in the previous chapter. Within the S830+ population, the number of 
individual spots per nucleus was calculated. The number of nuclei that reached this S830+ 
threshold was minimal for the WT cell lines, as expected, and remained so with the 
application of compounds. 
No effect was observed on the number or percentage of S830+ R6/2 cells in the presence 
O4 (Table 5-13, Figure 5-10) and β-Lapachone (Table 5-15, Figure 5-11). Treatment with 
both hydrazones (Table 5-19, Figure 5-13, Table 5-21, Figure 5-14) resulted in S830+ 
R6/2 cell number reduction, to the extent where S830+ R6/2 cells were no longer 
significantly more abundant than the WT background. However, this was due to the 
toxicity of the hydrazons rather than any anti-aggregation effect. Quinidine application 
(Table 5-17, Figure 5-12) also resulted in the number of S830+ R6/2 cells no longer being 
significantly higher than the WT background. This effect was also observed in the DMSO 
only control, and so cannot be attributed to the compound alone. Treatment with 
guanabenz (Table 5-23, Figure 5-15), at its highest concentration, also resulted in the 
number of S830+ R6/2 cells no longer being significantly higher than the WT 
background. The percentage of cells this encompassed per culture was not affected, 
suggesting that an increase in noise in both the WT and R6/2 signal might be behind this 
alteration. The number of spots of S830 signal within the S830+ nuclei was unaffected 
by the application of any of the compounds. 
Morphological changes to the nuclei between the WT and S830 subgroups were analysed. 
Nuclear area was only affected by the hydrazons and not the other compounds. The 
application of the hydrazon compounds also reduced the roundness and width of subgroup 
205 
nuclei compared with WT lines, however due to the low number of cells, these data must 
not be over-interpreted. The roundness of nuclei was unaffected by the other compounds, 
as was the nuclear length. The width of the S830 subgroup nuclei was significantly 
increased compared with the WT cells with the application of 2 M guanabenz. The 
opposite effect was observed between the S830+ and S830- subgroups with the 
application of 5 M quinidine, however the effect was also seen in the DMSO control, 
albeit at a higher DMSO concentration than the affected quinidine conditions. 
The ratio of length:width was affected by the compounds O4, quinidine, and guanabenz. 
At their lower concentrations these compounds decreased the length:width ratio when 
comparing the S830 aggregated nuclei with the S830- and WT cells. This suggests a 
potential elongation of these nuclei. Other differences measured were consistent with 
either the NC or DMSO controls in those plates and so not considered to be caused by the 
compounds. The effects of the compounds on aggregation and the morphology of the 
R6/2 subgroups is summarised in Table 5-12 
 
Table 5-12. Summary of compound effects on nuclear morphology and size in the WT and 
S830+/- subpopulations differentiated NPC lines after 21 days.  
Compound Effect
O4 ⬆ Ratio (S830+)
β-lapachone ⬆ Length (2 µM) 
⬆ Length (2 µM) 











⬇ Roundness (2 µM)









Table 5-13. Summary of nuclear S830 aggregation signal with compound O4 measured by 
the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, ***p≤0.001. 
WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-14 Summary of morphological changes induced by compound O4 measured by the 
Operetta between WT and the S830-/+ subgroups. Statistical analysis carried out using 
ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 subgroups at 
each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as 
#p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 







Figure 5-10 Operetta analysis of S830 signal in WT and R6/2 cells after 21 days of O4 
application. Automated analysis using the operetta was applied to R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound O4 (A) 
Number of nuclei with a S830 mean intensity above the applied threshold were counted and (B) 
displayed as a percentage of the total cells analysed. (C) Number of individual intensity spots was 
calculated and displayed at each time point for three R6/2 lines. The population of S830- and 
S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) roundness, (F) length, (G) 
width, and (H) length:width. Error bars for standard deviation. Statistical analysis carried out 
using ANOVA with bonferroni post hoc correction. Statistical difference between WT and R6/2 
subgroups at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC 
denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 





5.7.2 β -Lapachone 
 
Table 5-15. Summary of nuclear S830 aggregation signal with compound β-Lapachone 
measured by the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, 
***p≤0.001. WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-16 Summary of morphological changes induced by compound β-Lapachone 
measured by the Operetta between WT and the S830-/+ subgroups. Statistical analysis carried 
out using ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 
subgroups at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC 
denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 
for R6/2 S830+. WT=wildtype, NC=no compound Std.D=standard deviation, Sig=statistical 




Figure 5-11 Operetta analysis of S830 signal in WT and R6/2 cells after 21days of β-
Lapachone application. The automated analysis using the operetta were applied R6/2 and WT 
cultures differentiated for 21 days in media containing increasing concentrations of the compound 
β-Lapachone (A) The number of nuclei with a S830 mean intensity above the applied threshold 
were counted and (B) displayed as a percentage of the total cells analysed. (C) The number of 
individual intensity spots was calculated and displayed at each time point for 3 three R6/2 lines. 
The population of S830- and S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) 
roundness, (F) length, (G) width, and (H) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Statistical 
difference between WT and R6/2 subgroups at each condition represented as *p≤0.05 **p≤0.01 
***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and 





Table 5-17. Summary of nuclear S830 aggregation signal with compound Quinidine 
measured by the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, 
***p≤0.001. WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-18. Summary of morphological changes induced by compound Quinidine measured 
by the Operetta between WT and the S830-/+ subgroups. Statistical analysis carried out using 
ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 subgroups at 
each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC denoted as 
#p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 






Figure 5-12 Operetta analysis of S830 signal in WT and R6/2 cells after 21days of Quinidine 
application. The automated analysis using the operetta were applied R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound 
Quinidine (A) The number of nuclei with a S830 mean intensity above the applied threshold were 
counted and (B) displayed as a percentage of the total cells analysed. (C) The number of individual 
intensity spots was calculated and displayed at each time point for 3 three R6/2 lines. The 
population of S830- and S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) 
roundness, (F) length, (G) width, and (H) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Statistical 
difference between WT and R6/2 subgroups at each condition represented as *p≤0.05 **p≤0.01 
***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and 
§p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 S830+. WT=wildtype, NC=no compound. 
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5.7.4 Hydrazone #6 
 
Table 5-19. Summary of nuclear S830 aggregation signal with compound Hydrazone #6 
measured by the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, 
***p≤0.001. WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-20. Summary of morphological changes induced by compound Hydrazone #6 
measured by the Operetta between WT and the S830-/+ subgroups. Statistical analysis carried 
out using ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 
subgroups at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC 
denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 
for R6/2 S830+. WT=wildtype, NC=no compound Std.D=standard deviation, Sig=statistical 





Figure 5-13 Operetta analysis of S830 signal in WT and R6/2 cells after 21days of Hydrazone 
#6 application. The automated analysis using the operetta were applied R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound 
Hydrazone #6. (A) The number of nuclei with a S830 mean intensity above the applied threshold 
were counted and (B) displayed as a percentage of the total cells analysed. (C) The number of 
individual intensity spots was calculated and displayed at each time point for 3 three R6/2 lines. 
The population of S830- and S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) 
roundness, (F) length, (G) width, and (H) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Statistical 
difference between WT and R6/2 subgroups at each condition represented as *p≤0.05 **p≤0.01 
***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and 
§p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 S830+. WT=wildtype, NC=no compound. 
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5.7.5 Hydrazone #9 
 
Table 5-21. Summary of nuclear S830 aggregation signal with compound Hydrazone #9 
measured by the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, 
***p≤0.001. WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-22. Summary of morphological changes induced by compound Hydrazone #9 
measured by the Operetta between WT and the S830-/+ subgroups. Statistical analysis carried 
out using ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 
subgroups at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC 
denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 
for R6/2 S830+. WT=wildtype, NC=no compound Std.D=standard deviation, Sig=statistical 





Figure 5-14 Operetta analysis of S830 signal in WT and R6/2 cells after 21days of Hydrazone 
#9 application. The automated analysis using the operetta were applied R6/2 and WT cultures 
differentiated for 21 days in media containing increasing concentrations of the compound 
Hydrazone #9. (A) The number of nuclei with a S830 mean intensity above the applied threshold 
were counted and (B) displayed as a percentage of the total cells analysed. (C) The number of 
individual intensity spots was calculated and displayed at each time point for 3 three R6/2 lines. 
The population of S830- and S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) 
roundness, (F) length, (G) width, and (H) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Statistical 
difference between WT and R6/2 subgroups at each condition represented as *p≤0.05 **p≤0.01 
***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and 
§p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 S830+. WT=wildtype, NC=no compound. 
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5.7.6 Guanabenz  
 
Table 5-23. Summary of nuclear S830 aggregation signal with compound Guanabenz 
measured by the Operetta. Statistical analysis performed as Students t-test: *p≤0.05, **p≤0.01, 
***p≤0.001. WT=wildtype, Std.D=standard deviation, Sig=statistical significance of p-value. 
 
 
Table 5-24. Summary of morphological changes induced by compound Guanabenz 
measured by the Operetta between WT and the S830-/+ subgroups. Statistical analysis carried 
out using ANOVA with bonferroni post hoc correction. Difference between WT and R6/2 
subgroups at each condition represented as *p≤0.05 **p≤0.01 ***p≤0.001. Difference from NC 
denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and §p≤0.05, §§p≤0.01, §§§p≤0.001 
for R6/2 S830+. WT=wildtype, NC=no compound Std.D=standard deviation, Sig=statistical 






Figure 5-15 Operetta analysis of S830 signal in WT and R6/2 cells after 21days of 
Guanabenz application. The automated analysis using the operetta were applied R6/2 and WT 
cultures differentiated for 21 days in media containing increasing concentrations of the compound 
Guanabenz. (A) The number of nuclei with a S830 mean intensity above the applied threshold 
were counted and (B) displayed as a percentage of the total cells analysed. (C) The number of 
individual intensity spots was calculated and displayed at each time point for 3 three R6/2 lines. 
The population of S830- and S830+ R6/2 nuclei compared with WT cells for (D) mean size, (E) 
roundness, (F) length, (G) width, and (H) length:width. Error bars for standard deviation. 
Statistical analysis carried out using ANOVA with bonferroni post hoc correction. Statistical 
difference between WT and R6/2 subgroups at each condition represented as *p≤0.05 **p≤0.01 
***p≤0.001. Difference from NC denoted as #p≤0.05, ##p≤0.01, ###p≤0.001 for R6/2 S830- and 
§p≤0.05, §§p≤0.01, §§§p≤0.001 for R6/2 S830+. WT=wildtype, NC=no compound. 
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5.8 Chapter discussion 
5.8.1 Compound effects 
The were compounds applied to the NSCs and the effect on the cells screened using the 
automated operetta machine. The total number of cells in cultures after differentiation 
was affected by all compounds. O4, quinidine, and guanabenz reduction in cells 
compared with the NC condition was also seen in the DMSO control, suggesting this 
effect might not be purely compound related. The hydrazones caused a reduction in cell 
number to a much larger extent. Both hydrazone compounds, at their highest 
concentrations, resulted in a considerable degree of cell death, suggesting their toxicity 
was more extensive over the longer culture period than in the initial toxicity experiment. 
β-lapachone had the opposite effect and resulted in an increase in cell numbers in the 
culture, while a reduction in cell number was still seen in the DMSO controls.  
The mean area of the WT and R6/2 nuclei was unaffected by treatment with the 
compounds apart from with the hydrazones, which must be taken in the context of the 
great reduction in cell number that resulted from hydrazone treatment.  Nuclear roundness 
was affected by O4, β-lapachone, and guanabenz. A similar effect was observed by β-
lapachone on the WT cells, with an increase in roundness. The length of WT nuclei, as 
measured by the thickness through the centre of its longest point, was slightly reduced by 
O4 and guanabenz. No effect was seen on the thickness of the R6/2 nuclei by the 
application of these compounds, nor by the other compounds in the WT cells. The width 
of nuclei, as measured by the thickness through the centre perpendicular to the longest 
point, was reduced by the highest concentration of both hydrazones. This effect once 
again might be adversely affected due to the low number of cells surviving in these 
cultures. The ratio of length:width was affected by treatment with O4, β-lapachone, 
guanabenz, and the hydrazones.  
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Nuclear area in the presence of S830 was only affected by the hydrazons and not the other 
compounds. This was one of the main findings that mHTT had on cell morphology and 
it was an indication that little therapeutic affect was seen by any compounds. The 
roundness of nuclei was unaffected by the other compounds, as was the nuclear length. 
The ratio of length:width was affected by the compounds O4, quinidine, and guanabenz. 
At their lower concentrations these compounds decreased the length:width ratio when 
comparing the S830 aggregated nuclei with the S830- and WT cells. This suggests a 
potential elongation of these nuclei.  
 
5.8.2 Using neural progenitor cells for screening  
Analysis of cultured cells from mouse models of HD is an ideal complement to the work 
done in vivo using HD mouse models, for mechanistic studies at the cellular level. NPCs 
can be maintained in as mitotic progenitors or differentiated in to mature adult neurons 
and glia making them useful to mimic and study phenotypes found during development 
and disease onset. Cell culture models with reliable, measurable, phenotypes such as the 
aggregation found in the R6/2 cultures developed in this thesis would make idea models 
for drug and compound screens.  
The use of in vitro cultured cells is a necessary intermediate step between drug discovery 
of HTT interacting and altering compounds and applying these to whole animal systems. 
The use of high content analysis can allow multiple conditions to be interrogated at the 
same time in many wells and plates of cells; and automation of data capture and analysis 
can be performed in a non-biased way. As a proof of principle of the potential of the NPC 
cultures developed in this thesis, six novel compound from Erich Wanker’s lab in Berlin, 
which had shown HTT alteration effects in aggregation models, were tested on the R6/2 
lines. Most of the data is yet to be published and had been performed using synthetic 
assays. Unfortunately, the amount of compound supplied was finite and so the 
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experimental design and application was also limited. In hindsight better planning could 
have optimised the use of compounds. 
The potential toxicity of each compound was unknown so as an initial screen the 
compounds were applied to cell lines at the recommended concentration rages suggested 
by the Wanker lab. This screen was carried out over 7 days, which in hindsight was too 
short a period to properly assess compound toxicity and should have been performed for 
longer. The subsequent testing of the compounds’ effects on nuclear morphology and 
aggregation profile was carried out over a 21-day period with concentrations adapted to 
suit the findings of the short toxicity screen. Four of the compounds reduced the number 
of total cells in culture suggesting their true toxicity had been underestimated in the 
shorter toxicity experiment. This toxicity hampered the testing of the compounds effects 
on morphology and aggregation, especially in the experiments using the hydrazones, 
which had only a few surviving cells at the highest concentration.  
Another oversight was that at higher magnifications the operetta cannot capture and 
analyse the outside wells of a 96 well plate, therefore essentially reducing them to 60 well 
plates. This limits the number of lines and conditions that can be included in a single 
plate. Ideally more wells would have been used for a larger number of conditions or more 
replicates. Three separate R6/2 lines were used which was an ample number of biological 
repeats, however this left room on the plate for only a single WT line as a control. To 
design similar experiments in the future, power calculations should be performed to check 
the number of biological and technical replicates is high enough to obtain meaningful 
results. Preliminary experiments and longer assessments of toxicity will require larger 
quantities of compound, the amount of which was limited in this thesis.  
The data captured here were not ideal for the reasons stated but the goal of testing whether 
the high throughput platform could be applied to measure the effects of compounds on 
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HD-related phenotypes in the cell lines was achieved. With further optimisation and 
additional resources, greater degree of statistical power could be achieved. 
High-content/high-throughput imaging is based on the phenotypic assessment of a variety 
of physical measures and biological activities. The use of imaging platforms with ability 
to asses ICC in four fluorescent channels allows for correlation between captured signals 
of multiple proteins. These data in this chapter have only utilised two or those channels, 
with Dapi nuclei signal assessed along with S830 mHTT antibody. This leaves scope for 
two other proteins of interest to be investigated in any follow up use of these cells.  
 
5.9 Summary 
The compounds supplied from our collaborators were applied to cultures of WT and R6/2 
during differentiation of the cells over a 21-day period. The initial toxicity screen was 
performed over a 7-day period and showed the need to reduce the concentrations of three 
of the six compounds. Despite reducing their concentration after the initial toxicity screen, 
some compounds were still toxic at the lower applied concentrations when the cells were 
treated for a longer period. The effects of the compounds were marginal on the 
morphology and aggregation within the cells. As a proof of principle, the use of the 










Chapter 6 General Discussion 
In this thesis novel neural progenitor cell lines were created from the brains of foetal R6/2 
and WT mice. This process of harvesting NPCs from foetal brains builds mainly upon the 
work of the Reynolds and Weiss in the 1990s and the Catteneo lab in the 2000s. This 
principle was applied to R6/2 mice to establish cell models of HD carrying the human 
HTT gene alongside WT litter mates. These lines were maintained as adherent 
proliferative monolayer cultures over many passages and banked at regular intervals 
without affects to karyotype or CAG repeat length. Cultures could be readily 
differentiated into mixed glia and neuronal populations via modifications to a growth 
factor free media. Evidence for potential functional neuronal networks was observed with 
synaptic proteins present at neurite junctions. R6/2 cultures expressed a HTT aggregation 
phenotype from day 14 of differentiation in a subset of cells. Aggregated detergent 
insoluble mHTT was detectable by western blot analysis, and observable by ICC as 
nuclear inclusions, similar to those observed in the R6/2 mouse brain (Davies et al., 1997). 
The Operetta high throughput analysis system was used to explore morphological 
difference between WT and R6/2 cultures, as well as within the subset of cells with 
detectable aggregation. R6/2 nuclei were found to be larger than those of WT cells. This 
automated analysis system was used as readout to test the effects of aggregation 
modifying compounds on the R6/2 cell inclusion phenotype after prolonged exposure in 
differentiation media. 
The cell lines created within this thesis advance the HD research field because they form 
mHTT aggregation without the need for outside influence, such as viral, mechanical or 
chemical induction. Cell lines with HD-like phenotypes to allow researchers to examine 
the disease mechanism are greatly needed.  To my knowledge, the lines produced in this 
thesis are the first developed from NPCs dissected from foetal mouse brains that have 
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successfully been used to model aggregation in neurodegerative disease. Aggregation of 
mutant or modified protein is observed in a variety of neurodegenerative diseases 
including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis, as 
well as many others. Based on the approach taken within this thesis, similar methods 
could be used within these research fields to model disease mechanisms. The usefulness 
of these lines was demonstrated using a high throughput compound screen. Experiments 
using the cells produced here with their aggregation phenotype will help researchers to 
understand how the aggregation of mHTT begins and how it relates to HD symptoms and 
neuropathology.   
6.1 Future Directions 
The ability for the cell lines developed here to be used in high content microscopy 
analysis makes them ideal for the testing of aggregation altering compounds. Further 
optimisation of the high throughput systems to detect other useful measures of cell 
morphology and aspects of the aggregation phenotype detected would be useful. The 
Operetta system and its software (Harmony) have many algorithms that were not used in 
the analysis performed in this thesis. These further advanced algorithms could potentially 
allow new novel measures and HD-like phenotypes to be uncovered, such as morphology 
of the total cell area, beyond the nuclear measures, or neuronal neurite length along with 
further analysis of the aggregated inclusions.  
Primary experiments using the cell lines developed in this thesis have now been carried 
out using a time-lapse imaging system called PhaseFocus. This technology uses high-
fidelity quantitative imaging and microscopy to capture brightfield images and to refocus 
post-capture if required. Using these images, cells can be tracked over time and 
information on their number, confluence, proliferation, thickness, volume, and dry mass 
all obtained. Further work using this system will allow differences between the WT and 
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R6/2 cultures to be measured while the cells are still mitotic. Cells could then be 
differentiated and their fates could be traced back to investigate whether single parent 
cells spawn similar daughter cells with the same fate potential. The PhaseFocus system 
could also be used to determine whether the sub-population that have detectable 
aggregation are descended from a single population of parents cells. 
Low neurogenic potential limits the study of the molecular effects of HD on neurons, 
even when detectable aggregation is not present. It would be interesting to use 
electrophysiology on the neurons in these cultures to both establish their maturity and to 
probe for rudimental in vitro phenotypes recorded in vivo with HD mouse models. This 
would require further development and optimisation of the differentiation protocol and 
media to attempt to increase the number of neurons or to isolate them using sorting 
techniques.  
In the HD brain and HD mouse models, aggregation is most readily but not exclusively 
found in neurons (Tong et al., 2014, Shin et al., 2005, Jansen et al., 2016). It cannot be 
presumed that the population of cells that have limited marker expression are of either a 
neuronal or glia cell type. Without a method to identify the fates of these cells, 
experiments to assess the effects of aggregation on mature cell activity such as trafficking 
in dendrites will be limited. Unless other markers can be found, the isolation of definable 
populations might be the approach required study these cells.  
The R6/2 cell lines developed in this thesis will be fragment models of HD, akin to the 
R6/2 line, which models the incomplete mRNA splicing that results in an exon 1 HTT 
protein. The presence of this incomplete splicing event has been found in the human HD 
brain as well as HD mouse models and could be important in the pathology of the disease. 
The R6/2 lines developed could be useful in investigating how this splicing contributes 
to the disease mechanism. 
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The R6/2 mouse model is a fragment model of HD expressing the first HTT exon to 
replicate HD. Other mouse models exist using different approaches, such as the knock in 
lines with endogenous mouse Htt expanded to a pathogenic length, exhibit similar HD-
like phenotypes but at a slower progression. It would be interesting to develop NSC lines 
from these other mouse models to examine if aggregation could be detected in vitro. 
Depending on the CAG length within the knock in line, it can take months before 
phenotypes can be detected. This may hamper the ability to detect aggregation within a 
reasonable time frame that cells can be cultured and maintained. If this was to be achieved 
it would give an excellent insight into how aggregation forms in the cells and if it follows 
a similar pattern to that observed in this thesis.  
The nature of the culture environment appears to limit how long cells can survive once 
differentiated. To probe the aggregation phenotype further, longer culture conditions 
would be ideal. In the R6/2 mouse brain the aggregation process is progressive. Not all 
cells develop inclusions in the same time frame, and indeed, it is not until the later stages 
of the 16-week lifespan that the majority of neurons in the striatum and cortex display a 
detectable phenotype. Ageing the differentiated R6/2 cells would allow an investigation 
into if this was also the case in vitro. 
6.2 Final conclusions 
This thesis presents a series of progressive experiments that have allowed new NPC lines 
to be established from the R6/2 mouse model of HD. These lines exhibit a measurable 
progressive aggregation phenotype similar to that seen in vivo. There has been a gap in 
the research field for in vitro cellular models that exhibit such a phenotype to complement 
the work done using the mouse model. The NPC model will allow further investigation 
into the mechanisms that underlie preferential HTT aggregation in some cells over others.  
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The expression of the aggregation phenotype was measurable using high-content imaging 
systems and so is ideal as a model for screening aggregation modifying compounds. The 
cell lines were probed in a proof of principle experiment with 6 compounds which have 
shown effects on aggregation in other experimental systems. Although the effects on 
aggregation were limited on this platform, the potential for further investigation remains. 
These cell lines will help the HD research community further work towards 
understanding, and hopefully one-day developing disease-modifying treatments for HD. 
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